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ABSTRACT 
 
Nan Wang 
 
VIRAL MODULATION OF MHC CLASS II-MEDIATED ANTIGEN 
PRESENTATION 
 
Vaccinia virus (VV) has been used as a vaccine, yet safety concerns remain due to its 
viral immunoevasive properties. Among these, VV infection of antigen presentation cells 
(APC) perturbs MHC class II-mediated antigen (Ag) presentation. The goals of this 
project include: 1) to define mechanisms by which VV disrupts class II presentation; and 
2) to examine whether disruption of the class II pathway by VV alters T cell responses in 
vitro and in vivo. A significant reduction in the expression of the class II chaperone, 
invariant chain (Ii), was observed during the late stage of VV infection. Yet surface 
expression of MHC class II molecules was maintained along with cell viability. To 
examine whether VV acts solely to disrupt host protein synthesis, B cells were treated 
with an inhibitor of translation-cycloheximide (CHX). Like VV, CHX negatively 
regulated Ii protein expression and class II presentation. Ii proteolysis also contributed in 
part to reduce Ii expression in VV infected and CHX treated APC. Yet only VV infection 
altered lysosomal protease expression, potentially influencing Ii degradation. Over-
expression or ectopic-expression of Ii partially protected cells from VV-induced class II 
dysfunction. These studies suggest VV destabilizes class II molecules by disrupting Ii 
expression. To examine the presentation of viral Ags by class II, CD4 T cells from VV-
primed mice were used. Viral proteins were presented by class II shortly after APC 
exposure to low concentrations of VV. The presentation of VV Ags correlated temporally 
with reductions in exogenous peptide presentation. At higher MOI (≥ 1), class II 
presentation of VV Ags was reduced. To examine the in vivo effects of VV on Ag 
presentation, a mouse model of ovalbumin-induced airway hypersensitivity was used. 
Th2 cytokine production was reduced, while a novel inflammatory cytokine Interleukin-
17 (IL-17) production was enhanced in asthmatic VV-infected mice. In health mice, 
repeated VV infections lead to enhanced CD8 T cell production of Interferon-γ (IFN-γ) 
and IL-17. Finally, antibodies to a viral protein H3 were generated and shown to preserve 
 vi
class II presentation. Together these studies suggest VV disruption of the class II pathway 
may blunt T cell responses to VV.   
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INTRODUCTION 
 
Vaccinia virus (VV), an enveloped virus, belongs to the poxviridae family of complex 
DNA viruses that replicate in the cytoplasm of host cells. VV has a linear, double-
stranded DNA genome (about 200 kb) encoding more than 200 proteins. VV falls in the 
chordopoxvirinae subfamily and orthopoxvirus genera which include 3 genetically and 
antigenically related members: variola virus (smallpox), cowpox (the first vaccine for 
smallpox), and VV. Because of this homology, VV had been used as the vaccine to 
eradicate smallpox [1]. More recently, VV has been proposed as a vector to express 
foreign genes to generate potent vaccines for infectious agents and tumors. While VV is 
highly effective in inducing long-lasting protective immunity in a majority of healthy 
individuals, potentially serious complications following VV infection have limited 
enthusiasm for this virus as a universal vaccine reagent in immune deficient as well as 
hypersensitive individuals, the elderly and children [2-5]. Thus, investigation of the 
mechanisms by which VV perturbs host immunity remains important in terms of 
designing attenuated VV-based vaccines. Here, basic concepts of host immunity, the 
immune-evasion properties of VV, and VV vaccine development are reviewed.  
 
1. Introduction to the host immune system 
 
Host immunity is comprised of two parts - innate immunity and adaptive immunity. 
Innate immunity is quick acting and not specific for a pathogen or Ag. Adaptive 
immunity is induced later, is Ag specific and leads to the development of immunological 
memory. Detailed discussion of both innate and adaptive immunity is offered here.  
 
1.1 Innate immunity 
 
Innate immunity is the first line of defense promoting host protection against infection 
independent of the Ag or pathogen trigger. Many types of immune cells (i.e. phagocytes, 
neutrophils and natural killer (NK) cells etc.) and soluble factors (cytokines, chemokines, 
and complement) have evolved to protect the host from pathogen infection via pattern 
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recognition and other mechanisms. For example, after an epithelia barrier has been 
breached, the repeating patterns of molecular structures on the surface of a pathogen 
(termed pathogen-associated molecular patterns, PAMPs) such as bacterial 
lipopolysaccharide (LPS) are recognized by cell surface pattern recognition receptors 
(PRRs) such as Toll-like receptor-4 (TLR4) on surveying immune cells as well as 
epithelial cells. The ten TLRs identified in humans and mice detect PAMPs on most 
pathogens. Activated TLRs then induce pro-inflammatory cytokine and chemokine 
production to recruit and activate phagocytes and NK cells. TLR activation can also up-
regulate co-stimulatory molecule expression on APCs to promote adaptive immunity. 
Other PRRs like the mannose-binding lectin (MBL) increase phagocytosis and activate 
complement to destroy pathogens [6, 7]. Soluble innate mediators including complement 
components, cytokines, and chemokines, also facilitate the activation of cellular or 
adaptive immunity.  
 
1.2 Adaptive immunity 
 
Adaptive or acquired immunity is characterized by clonal expansion of Ag-specific 
lymphocytes including T and B cells. The development of CD4 and CD8 T cells as well 
as Ag-specific antibody (Ab) producing B cells is critical for host elimination of 
pathogens and the induction of long-lasting immunological memory. The activation of T 
cells is dependent upon engagement with antigen presenting cells (APCs) such as 
dendritic cells (DCs), B cells, and macrophages. These professional APCs are 
characterized by their expression of detectable surface major histocompatibility complex 
(MHC) class I and class II as well as co-stimulatory molecules. APCs survey the host to 
internalize pathogens and antigens (Ags) such as proteins, lipids, nucleic acids and 
sugars. Protein Ags are processed within APCs by a variety of pathways, leading to the 
generation of antigenic peptides which bind MHC class I and class II proteins. The 
resulting peptide-class I or II complexes are recognized by T cell receptors (TCR) along 
with engagement of adhesion and co-stimulatory molecules to promote T cell activation. 
After being activated by peptide-class II complexes, CD4 T cells can be differentiated 
into 4 effector subsets, i.e. Th1, Th2, T regulatory (Tr)1 and Th17 cells, depending on 
 3
their profile of transcription factor controlled cytokine and chemokine expression in 
response to stimulation by APCs. Th1 cells predominantly produce IL-2 and IFN-γ to 
activate macrophages and induce localized inflammation. Th2 cells make IL-4, IL-13, 
and IL-5 and stimulate B cells to produce Ab. Th17 cells secrete IL-17 to help recruit 
granulocytes including neutrophils to sites of infection or inflammation. Tr1 produce 
TGF-β and IL-10 to suppress or down-regulate immune responses [8]. CD8 T cells are 
activated by MHC class I-peptide complexes on APCs. These cells frequently produce 
cytokines and express proteins promoting killing or cytolytic function, thus they are 
named cytotoxic T lymphocytes (CTL). CD8 CTL can induce apoptosis of infected or 
target cells. CD8 T cells producing IFN-γ and IL-4 are termed as Tc1 and Tc2 
respectively [9], while CD8 T cells secreting IL-17 are known as Tc17 [10]. The 
differentiation of Th and CTL cells has been summarized in Fig. 1.  
 
 
 
 
 
 
 
 
 
B cells which display surface immunoglobulins (Igs), with or without Th2 cell help, are 
activated and mature to plasma cells which secrete Abs. Abs neutralize pathogens or tag 
infectious agents for clearance and destruction by phagocytes [6, 8, 11, 12]. As 
professional APCs, B cells also display MHC molecules and present Ag. B cells have 
specific Ag receptors or Igs on their surface. B cells uptake soluble proteins and solid Ag 
by pinocytosis and specific receptors respectively. Although B cells constitutively 
express MHC class II molecules, they need activation by Th cells to significantly increase 
co-stimulatory molecule expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Differentiation of Th and Tc cells. See details in the text. 
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1.3 Ag processing and presentation 
 
Ag presentation leads to the generation and display of TCR ligands, and thus regulates 
adaptive immunity. There are two pathways, i.e. MHC class I and class II which activate 
CD8 and CD4 T cells respectively. These molecules bind and display peptides or 
epitopes from protein antigens for recognition by T cells. By contrast, CD1 and 
specifically CD1d proteins bind glycolipids and display these to NKT cells. NKT cells 
also express CD4 and CD8 surface markers. The basic concepts of these pathways are 
reviewed here. 
 
1.3.1 MHC class I-mediated Ag presentation  
 
MHC class I molecules typically present endogenous Ag including protein products of 
cytosolic replicating viruses and bacteria, as well as the incorrectly translated host 
proteins or peptides known as defective ribosomal products (DRiPs). Cytosolic Ags are 
processed by a multi-catalytic protease complex called the constitutive proteasome. 
During infection, the immunoproteasome can be induced upon cellular exposure to IFN-
γ, α and β [13]. Proteasome processing of Ags leads to the formation of short peptides 
which are transferred to the ER by the transporter associated with antigen processing 
(TAP1/TAP2). Within the ER, newly synthesized MHC class I molecules are folded, 
chaperoned and retained in the ER by a series of proteins (calnexin, calreticulin, Erp 57 
and tapasin). Peptides delivered into the ER by TAP are loaded onto class I molecules, 
and these MHC class I-peptide complexes are exported to the cell surface for display to 
CD8 T cells. In some APCs including macrophages and DCs, cross-presentation of 
exogenous Ags by class I molecules also occurs. For example, a virus infected cell is 
phagocytosed by a DC. The viral Ags are retrotransported into the cytosol of the DCs, 
processed and delivered to the ER for binding to class I molecules. Cross-presentation 
pathways appear to be essential for priming naïve CD8 T cells [14].  
 
In addition to classical class I molecules encoded within the MHC gene complex, there 
are MHC class I-like molecules called CD1. CD1 molecules present lipid Ag to NKT 
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cells, which have both NK and T cell surface markers. Although CD1 molecules are 
structurally similar to MHC class I molecules, they behave like MHC class II molecules 
by transporting through the endosome-lysosomal pathway. The five human CD1 gene 
products are divided into 3 groups – group 1 including CD1a, CD1b and CD1c; group 2 
containing CD1d and the intermediate group comprised of CD1e. Group 1 molecules 
present microbially derived lipids to diverse NKT cells while group 2 molecules present 
self lipids to invariant NKT cells with same TCR chain (Vα24-Jα18 in humans) [14]. 
Activated NKT cells secrete both Th1 and Th2 cytokines.  
 
1.3.2 MHC class II-restricted Ag presentation  
 
MHC class II molecules typically acquire exogenous Ags after endocytic or phagocytic 
uptake by professional APCs including B cells, DCs and macrophages. While Ag can be 
delivered into APCs by fluid phase uptake, receptors on APCs can enhance Ag 
internalization by 100-1000 fold to enhance Ag presentation. Ag processing can begin in 
endosomes and may increase upon delivery to lysosomes. Acidic proteases in these 
organelles such as cathepsins (Cat) S, L, B and D and asparagine endopeptidase (AEP) 
have been shown to differentially cleave Ags to yield smaller peptides. Endogenous Ags 
can also be transported to lysosomes by autophagy [14]. In addition, reductases such as 
the IFN-γ induced lysosomal thiol reductase (GILT) also facilitate Ag unfolding and 
proteolytic processing to peptides [15]. 
 
MHC class II molecules consist of αβ dimers which pair with the chaperone protein Ii in 
the ER. These αβIi complexes transit to the Golgi for glycosylation, and then they are 
targeted to the endosomal network where Ii is degraded by AEP, Cat S and Cat L [16-18].  
Another MHC-encoded dimer complex, HLA-DM binds class II α and β to release 
residual Ii fragments from the class II ligand binding groove. This permits peptide 
fragments from processed Ags to bind to class II molecules. In some APCs including B 
cells and DCs, there is another class II like dimer termed DO which can physically bind 
to DM to partially inhibit DM’s function [19]. The regulation of DM and DO binding 
may depend upon an acid pH environment. Newly formed peptide-class II complexes 
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rapidly transit to the surface of APCs for display to CD4 T cells. Thus, the intracellular 
maturation and trafficking of class II molecules are key to their acquisition of function.  
 
1.3.3 Regulation of MHC class II function by Ii 
 
Among the components of the class II pathway, Ii plays an essential role by stabilizing 
class II dimers, targeting class II to endosome-lysosomal vesicles, and preventing 
premature peptide binding to class II [14]. The importance of Ii in class II presentation 
has been demonstrated by studies using cell lines and animals with altered Ii expression. 
Ii loss induced either by antisense oligodeoxynucleotides or CHX significantly reduces 
MHC class II mediated Ag presentation, while enhancement of Ii expression by either 
transfection or knock-in improves class II function [20-22]. Ii reduction in APCs may 
have pathogenic implications. For example, in human diabetic cells impaired class II 
function is coupled with decrease Ii expression while correction of Ii expression by a 
vector rescues class II-mediated presentation [23].  
 
The gene for Ii is located on chromosome 5 in humans and chromosome 18 in mice. Both 
human and mouse Ii genes are encoded outside the MHC gene loci on chromosome 6 and 
17 respectively [14]. The Ii gene gives rise to a family of 4 protein isoforms, i.e. p33, 
p35, p41 and p43, dependent on the use of different translational initiation sites and 
alternative splicing [24, 25]. Newly synthesized Ii forms trimers, with each of the 4 
isoforms potentially incorporated into homotrimers and heterotrimers. The predominant Ii 
isoforms found in APCs, are p33 homotrimers and p33/p35 heterotrimers. Each subunit 
of the Ii trimer binds noncovalently to MHC class II αβ heterodimer with help from the 
chaperone calnexin in the endoplasmic reticulum (ER). Following the formation of these 
nonamers, (αβIi)3 complexes are directed to the Golgi and then endosomal network 
through targeting sequences locating in the cytoplasmic domain of Ii. Along the ER-
Golgi-endosome pathway, post-translation modifications of Ii such as glycosylation, 
lipidation and phosphorylation also take place [26-28].   
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Throughout the endocytic pathway, Ii is degraded successively into 3 intermediates: 1) 
leupeptin-induced proteins (LIP); 2) small leupeptin-induced proteins (SLIP); and 3) 
class II-associated invariant chain peptide (CLIP) [29]. A leupeptin-insensitive protease(s) 
initiates the cleavage of Ii to produce LIP, studies suggest this maybe an aspartyl protease 
[30] or AEP [16, 31].  In B cells and DCs, the protease responsible for the later stages of 
Ii proteolysis steps is Cat S. By contrast, in cortical thymic epithelial cells Cat L plays 
this role in terminal Ii processing. In macrophages, however, both Cat S and Cat L as 
well as another cysteine protease- Cat F may be involved [32, 33]. As Ii processing 
progresses in the acidic late endosome-lysosomal organelles or MHC class II containing 
compartments (MIICs), CLIP, a terminal Ii peptide, is removed from the class II ligand 
binding groove by DM and replaced by processed antigenic peptides.  
 
Ii assists with the folding, assembly, transport, and peptide occupancy of class II 
molecules. Without Ii, class II molecules may bind misfolded proteins or other 
chaperones and remain tethered in the ER. Indeed, for some class II alleles the absence of 
Ii hinders their folding and exiting from the ER. The absence of Ii could also alter the 
terminal glycosylation of class II in the Golgi, or result in mis-sorting of class II 
molecules and pre-mature degradation [34]. Some MHC class II molecules form high 
molecular mass aggregating in the absence of Ii [35]. Studies suggest that B cell 
development is negatively affected in Ii deficient mice. There are more mechanisms 
responsible for this besides the impaired Ag presentation [35-38]. Notably, CD4 T cell 
development and selection are defective in Ii knockout mice. Defects in T cell selection 
are likely due to the absence of Ii in thymic epithelial cells [39, 40]. This results in altered 
display of peptides by these class II molecules which escape the ER for surface 
presentation. 
 
Ii also serves to chaperone DM to endosomal compartments where DM regulates peptide 
binding to class II molecules. DM functions to remove the Ii fragment CLIP from class 
II. DM also serves as a peptide editor. Thus, DM modifies the peptide repertoire for class 
II by increasing the formation and stability of high affinity class II-ligand complexes [35, 
41]. Ii also protects DM from proteolysis and may help coordinate the coupling of DM 
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with class II by targeting DM to endosomal compartments such as MIIC [35, 42, 43]. By 
chaperoning both class II and DM, Ii plays an essential role in class II mediated Ag 
presentation. 
 
1.3.4 Host protein synthesis and MHC class II pathway 
 
It is well established that host protein synthesis is important for the function of the class 
II pathway for Ag presentation. Native protein Ag processing and presentation by class II 
molecules in B cells is disrupted by the protein synthesis inhibitor-cycloheximide (CHX) 
and a protein export inhibitor-brefeldin A (BFA) [44]. BFA may perturb intracellular Ag 
processing and/or peptide-MHC class II complex formation [45]. CHX was postulated to 
disrupt class II mediated-Ag presentation by reducing the pool of functional Ii in B cells 
[22]. Most of cell surface class II molecules are synthesized de novo, while a small 
number of class II may come from the recycled pool which transfers between the cell 
surface and the endosomal pathway [46]. CHX and BFA only inhibit production of newly 
synthesized but not the recycled class II molecules. Thus, the sensitivity of Ag 
presentation to CHX or BFA is dependent on the ratio of these two parts of class II 
molecules.  Emetine, an irreversible inhibitor of protein synthesis, reduces intracellular 
class II protein levels but not cell surface class II [47]. This result may be consistent with 
a loss of Ii which stabilizes intracellular class II. Together, these studies suggest a step or 
steps in the class II pathway are sensitive to changes in host protein synthesis. Results 
from the current study support a loss of class II function when protein synthesis is 
disrupted and Ii levels decrease.  
 
2. Pathogenesis of VV 
 
The natural pathogenesis of smallpox is revealed by two associated incidences of viremia 
in infected individuals. The primary viremia occurs after variola virus moves from local 
respiratory lymphatics to spleen, liver and bone marrow. Following virus multiplication 
in these reticuloendothelial organs, secondary viremia is seen as virus traffics to distant 
sites like the skin [48]. By contrast, vaccinia inoculation in skin results only in local 
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lesion without systemic illness in immunocompetent individuals. Yet in 
immunocompromised patients, severe dissemination of VV occurs after vaccination.  To 
mimic the physiological and pathological conditions induced after VV infection of 
humans, several murine models of VV infection utilizing intranasal (i.n.), intraperitoneal 
(i.p.), intracranial (i.c.), and intradermal (i.d.) virus delivery routes have been developed 
and applied [49]. While the i.n. model and the i.d. model are more physiologically 
relevant to natural infection and inoculation respectively, the i.p. model mimics the 
systemic viremia observed with the virus, and the i.c. model mirrors post-infection 
neurovirulence in some humans. Studies with these models provides evidence that viral 
evasion of both innate and adaptive immunity is important in VV pathogenesis.  
 
2.1 Innate immune evasion properties of VV 
 
Complications associated with VV inoculation such as: progressive vaccinia in patients 
with defects in cellular immunity; eczema vaccinatum in atopic patients; generalized 
vaccinia; postvaccination encephalomyelitis; and carditis, as well as research directed 
towards attenuating VV, have led to the discovery of multiple viral proteins which disrupt 
host immune responses [1, 48, 50]. Innate immunity is typically the first barrier to 
infectious agents and also an important target for VV. VV evades the host’s innate 
immune system by several mechanisms. Specifically, VV produces factors which: 1) 
directly bind complement, cytokines or chemokines; 2) serve as decoy receptors for these 
innate pathways; 3) disrupt IFN (α, β, and γ) gene expression at the transcriptional and 
translational levels; 4) block infected cells from undergoing apoptosis; 5) perturb TLRs 
and their signaling pathways; and 6) promote the synthesis of steroids to suppress 
inflammation. Viral gene products linked to disrupting innate immunity and 
consequently, influencing adaptive immunity are listed in Table 1. 
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Table 1 Established mechanisms of VV evasion of innate immunity 
VV protein  Mechanism  of  action  Reference 
VV complement  
control   protein  
Binds  and inactivates C4B and C3B [51] 
B8 Acts as a soluble receptor to bind and antagonize IFN-γ [52] 
B18 Acts as a soluble receptor to bind and antagonize IFN-α/β [53] 
B15 Acts as a soluble receptor to bind and antagonize IL-1β [54] 
C12 Acts as a soluble receptor to bind and antagonize IL-18 [55] 
A53 Acts as a soluble receptor to bind and antagonize TNF [56] 
35Kd protein Binds and antagonizes CC chemokines [57] 
A39 Acts as a soluble receptor to bind and antagonize semaphorin [58] 
E3 Acts as a ds-RNA binding protein to prevent the activation of dsRNA-
dependent protein kinase (PKR) and 2’-5’ oligoadenylate synthetase 
(OAS); inhibits  ds-RNA induced apoptosis 
[59-61] 
K3 Acts as a pseudo-substrate of PKR; prevents the activation of eIF-2a 
by PKR 
[62] 
B13 or 
CrmA/Spi-2 
protein 
Inhibits the IL-1β-converting enzyme; blocks caspase 8 activity by 
closing the permeability transition pore of mitochondria 
[63, 64] 
F1 Inhibits apoptosis by stabilizing mitochondrial membranes and by 
binding and inactivating a proapoptotic molecule - Bak 
[65, 66] 
A46 Disrupts IL-1 induced nuclear factor (NF) κB activation; mimics the 
toll-interleukin 1 receptor (TIR); inhibits myeloid differentiation factor 
88 (MyD88), TIR domain–containing adaptor inducing IFN-β (TRIF) 
and related adaptors to block mitogen-activated protein (MAP) kinases 
and NF κB as well as interferon regulatory factor 3 (IRF3) signaling  
[67, 68] 
A52 Inhibits IL-1 and TLR4 mediated NF-κB activation; serves as a 
dominant-negative version of  MyD88 on IL-1, TLR4, and IL-18 
signaling; inhibits TLR3 induced NF-κB activation by binding with 
interleukin 1 receptor–associated kinase 2 (IRAK2) and tumor necrosis 
factor receptor–associated factor 6 (TRAF6); activates TLR-induced 
p38 and c-Jun amino N-terminal kinase (JNK) to induce IL-10 
production 
[67, 69, 
70] 
N1 Inactivates NF-κB by inhibiting TIRs and TNF receptors, adapters 
such as TRAF, I-kappa B kinase-α, and I-kappa B kinase -β signaling; 
disrupts IRF3 signaling. 
[71] 
K1 Inhibits IκBα degradation to prevent NF-κB activation  [72] 
A44 Induces steroid production to suppress inflammation [73] 
 
2.2 Viral Ag presentation by class I and class II molecules 
 
VV vaccination induces both cellular and humoral immunity. Studies have shown that 
virus specific CD4 and CD8 T cells as well as Abs are detected in humans several months 
to years after immunization [74-77]. After vaccination, virus specific memory T and B 
cells persist in healthy individuals providing protection from variola infection for 50-70 
years. The detection of both CD8 and CD4 T cells in humans and animals after exposure 
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to VV, suggest VV Ags are processed and presented by both MHC class I and class II 
molecules for T cell recognition.  
 
VV enters host cells by at least two routes including direct fusion at the plasma 
membrane and by delivery into the acidic endosomal pathway with subsequent 
membrane fusion to the cytoplasm [78, 79]. Delivery of VV into the cytoplasm results in 
virus uncoating and the synthesis of new viral proteins in the cytoplasm. Studies suggest 
early viral Ags are processed likely by infected cells, yielding peptides which bind MHC 
class I molecules (Fig. 2A). These viral peptide-class I complexes transit to the cell 
surface for detection by CD8 T cells [80-82]. By contrast, studies to define viral peptides 
recognized by CD4 T cells in the context of class II molecules, suggest these peptides are 
derived from late viral structural Ags. This would be consistent with virus entry into cells 
by endocytosis or minimally, the delivery of late viral membrane proteins into cells via 
the endosomal network. Ags delivered into cells by endocytosis are denatured and 
proteolytically processed by endosomal and lysosomal proteases. The resulting antigenic 
peptides can bind class II molecules which reside and transit through endosomes to the 
cell surface (Fig. 2B). Thus, CD4 T cells may recognize peptides from VV late Ags 
bound to class II molecules after viral infection of professional APCs. Or alternatively, 
late viral Ags released during the lysis of infected cells may be endocytosed by APCs and 
processed for class II presentation to T cells. CD4 T cells are essential for the 
development of anti - viral CD8 T cells as well as the induction of virus - specific Ab. 
The observations of the long lasting VV specific CD4 T cells and Ab in vaccinees, as 
well as enhanced lethality of VV in mice with decreased CD4 or MHC class II expression 
highlights the importance of MHC class II presentation in VV-induced immune responses 
[75, 83]. Thus, studies to understand VV Ag presentation are important and may lead to 
new approaches to enhance immunity using VV-based vaccines.  
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Fig. 2 Models for VV Ag presentation. A. Presentation of VV by class I pathway. 
B. Class II-mediated VV presentation.  
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2.3 Disruption of Ag presentation by VV 
 
While VV infection and vaccination with live virus can elicit the activation of virus 
specific T cells, studies also suggest the virus has evolved mechanisms to thwart or 
dampen Ag presentation and T cell activation. Here, studies demonstrating VV-related 
defects in MHC class I presentation to CD8 T cells as well as alterations on CD1d and 
MHC class II presentation are discussed.  
 
Selective inhibition of MHC class I presentation has been observed upon VV infection of 
fibroblasts. Using VV as a vector to express different cDNAs for different influenza Ags, 
it was observed that VV perturbed the presentation of some of influenza viral peptides by 
class I molecules.  During late stage of VV infection, influenza haemagglutinin (HA) 
presentation to CTL was inhibited [84]. VV disruption of class I mediated-presentation of 
two influenza nuclear protein (NP) epitopes further supported selective disruption of the 
class I pathway. Here disruption occurred at both early and late stages of VV infection, 
although the severity of the inhibition was greater as viral infection progressed. VV 
induced class I dysfunction could be rescued by rapidly promoting the degradation of Ag 
by either Ag ubiquitination or deletion of NH2-terminal signal sequence of the Ag, thus 
suggesting VV may disturb Ag processing [85]. VV infection also disturbed class I 
presentation of other influenza Ags including non-structural 1 (NS1) Ag [86]. Reduced 
surface class I expression has been observed during in vivo VV infection, perhaps 
partially explaining virus induced class I dysfunction [87]. 
 
CD1d molecules present lipid Ag to NKT cells. Studies by Brutkiewicz and colleagues 
showed that CD1d mediated-lipid Ag presentation is also perturbed by VV. The 
perturbation is mediated through the p38 pathway and is negatively regulated by ERK1/2. 
Intracellular CD1d trafficking appears to be altered by in vitro VV infection of fibroblasts. 
Murine splenic DC and macrophage expression of surface CD1 is reduced several days 
after in vivo VV infection [88, 89]. Two viral genes B1R (encoding a kinase) and H5R 
(encoding one substrate of the B1R gene product) appear to play important roles in 
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mediating VV induced CD1 dysfunction [90]. Yet, the precise mechanism(s) by which 
viral gene products alter CD1d function and Ag presentation remains unknown.  
 
CD4 T cells play a critical role in the clearance of infectious VV [91]. The majority of 
CD4 T cells in humans and rodents, recognize peptides complexed to MHC class II 
molecules displayed on APCs. Thus, VV may target the class II pathway for Ag 
presentation as a means of immune evasion or modulation. A very early and transient 
reduction in CD4 T cell responses to several Ags after VV vaccination of humans, led to 
the suggestion of diminished APC function in vivo following exposure to VV [92]. 
Resting murine and human T cells are not readily infected by VV, although low levels of 
infection are observed with activated human T cells exposed to virus in vitro [93, 94]. By 
contrast, APCs are highly susceptible to VV infection in vitro and in vivo as shown by 
others and in this thesis [94-96]. In vivo and in vitro studies have shown that VV disrupts 
MHC class II mediated Ag presentation by professional (macrophages, DCs and B cells) 
and non-professional APCs (fibroblasts) [96, 97]. Thus, MHC class II molecules 
represent a likely target for viral evasion of host immunity, yet specific mechanism(s) by 
which VV disrupts APC function and the class II pathway remains to be elucidated.  
 
Disruption of class II mediated Ag presentation by VV is a relatively general 
phenomenon. As shown in our previous study [97], VV perturbed the exogenous Ag 
(human serum albumin (HSA)), endogenous Ag (glutamate decarboxylase (GAD)) and 
peptide (GAD273–285, hen egg lysozyme (HEL)74–88,  HSA64–76, and IgG I188–203) 
presentation by both newly synthesized and recycled class II molecules.  VV inhibited 
class II function in both professional and non-professional APCs without changing total 
or surface class II expression levels up to 24 h of in vitro infection. This inhibition 
affected both cell lines (such as B cell and macrophage cell lines) and primary cells (such 
as DCs). Class II function in both human and murine cells could be disrupted. The 
inhibition was dependent on the duration and dose of VV while independent of virus 
replication level. Over-expression of endogenous Ag-GAD or provision of external co-
stimulation could not rescue the class II function. However, VV infection disturbed the 
binding of peptide to class II molecules. In a latter study, we showed that in vivo VV 
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infection decreased class II function and expression in DCs. The mRNA of class II 
dropped much earlier than the protein did [96]. We saw the reduced class II protein 
expression level in the latter study instead of the earlier one may be due to the fact that 
we extended the observation time from 24 h ( in the earlier paper) to 48 h (in the latter 
paper) post VV infection. The long half-life of class II protein, i.e. 36 h, may cause this 
difference.   
 
2.4 VV modulation APC function 
 
Whether VV disruption of MHC class I, class II and CD1d presentation is linked or via 
viral inactivation of common pathways in APCs remains unclear. In addition to alteration 
in Ag presentation, VV infection can perturb host protein synthesis, cell maturation or 
differentiation as well as secretion of soluble messengers such as cytokines. Here, a brief 
description of VV infection on each of these pathways is offered.  
 
2.4.1 Inhibition of host protein synthesis and APC function 
 
In mouse L cell fibroblasts, VV infection dramatically decreased host protein synthesis, 
presumably by hijacking cellular resources to assemble infectious virions [98]. Multiple 
viral components may regulate host protein expression including proteins present in 
infectious virions [99-101] as well as viral gene products transcribed after infection [102]. 
Studies with epithelial and fibroblast cells suggest VV may use multiple methods to 
block host DNA, RNA and protein synthesis. These include disruption of host nuclear 
DNA replication by viral encoded deoxyribonucleases [103]; interference with cellular 
RNA synthesis and processing by viral reduction of RNA polymerase II activity [104]; 
and enhancement of cellular mRNA degradation [105]. Despite loss of these key cellular 
functions, viral gene transcription remains active during the early and late stages of 
infection. Notably, not all host gene expression is blocked with VV infection, as the virus 
exploits host proteins to survive and replicate.  
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Few studies have examined the effects of VV disruption of host protein synthesis on APC 
function. Disruption of class II presentation was observed 1-2 h after VV infection [97]. 
In epithelia and some tumor cells, host protein synthesis was inhibited by VV within 1-2 
h of infection [106]. Prior studies established that inhibition of host protein synthesis can 
diminish class II presentation using the well characterized protein synthesis inhibitor, 
cycloheximide (CHX) [22, 44]. CHX interrupts both the initiation and elongation of de 
novo protein synthesis by blocking: 1) binding of deacylated tRNA to reticulocyte 
ribosomes; 2) activation of transferase II; 3) release of tRNA from the donor site of 
ribosomes; and 4) aggregation of polysomes [107, 108]. However, few studies have 
specifically investigated whether VV perturbs the expression of host proteins critical for 
immune recognition. Yet, a recent analysis of changes in dendritic cell (DC) gene 
expression during attenuated VV infection did suggest alterations in the levels of some 
components of antigen presentation pathways [109]. While inhibition of host protein 
synthesis was postulated as one potential explanation for virus inhibition of class II 
presentation [110], we demonstrated sustained surface expression of class II proteins in 
APCs up to 24 h after in vitro VV exposure [97]. However, surface class II expression on 
DCs is reduced 48 h after  in vivo infection [96]. Investigating how VV infection 
influences the expression of class II molecules and other factors required for APC 
function, is one of the important goals of this thesis. 
 
2.4.2 Changes in APC maturation with virus infection 
 
DCs serve as potent APCs bridging the innate and adaptive immune response. After 
capturing Ags, immature DCs migrate from peripheral tissues to secondary lymphoid 
organs and undergo a programmed maturation.  These matured DCs express high levels 
of surface MHC class I, class II, and co-stimulatory molecules and secrete cytokines such 
as type I interferons, interleukins, and TNF-α which modulate host immune responses. 
VV infection can subvert DC function in part by blocking the function of some of these 
cytokines as summarized in Table 1. In vitro VV infection of DCs decreased the 
maturation of these cells in response to monocyte-conditioned medium, LPS or 
PGE2/TNF-α [111]. By contrast, surface MHC class I, class II, CD40 and co-stimulatory 
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molecules such as CD86 expression on DCs is initially up-regulated upon in vivo VV 
infection [96]. One study has suggested in vivo VV acts to stimulate the maturation of 
DCs by triggering TLR2 activation [112]. Yet as shown by another study, while VV 
infection in vivo can promote increased surface marker expression consistent with DC 
maturation, these APCs display defects in class II Ag presentation [96]. Perturbation of 
normal DC maturation may contribute to VV disruption of Ag presentation pathways. 
 
2.4.3 Alteration in APC cytokine production by VV 
 
Using a murine epidermis-derived dendritic cell line, it was demonstrated that upon in 
vitro VV infection, normal production of various cytokines (TNF-α, IL-1β, IL-6, IL-10, 
IL-12, IFN-α and IFN-γ) was disrupted. Even after pre-activation with LPS or poly(I:C), 
TNF- α and IL-6 production is inhibited by VV in vitro. This inhibition is mediated by 
viral protein E3 and K1 through blocking the NF-κB pathway [113]. In vivo VV 
infection, on the other hand, increases primary splenic DC secretion of  IL-10, IL-12, IL-
6, IL-1β and TNF-α [96]. Comparison of these studies is complicated as DCs from 
different tissues as well as in vitro vs. in vivo infection were employed. Yet, changes in 
APC cytokine production with VV infection very likely influence host immunity and 
possibly APC function. 
 
3. Development of VV-based vaccines  
 
Cowpox was the 1st vaccine used to prevent smallpox transmission. VV, is a less virulent 
but closely related virus, which has been used to successfully eradicate smallpox 
worldwide. Currently, due to concerns of virus weaponization and cross-species infection 
by other more virulent poxviruses such as monkeypox virus, the effectiveness and safety 
of vaccinia virus have been re-evaluated. VV is a relatively safe vaccine with overall 
complication rate at 4 per 100,000 vaccinees [114]. It can protect vaccinees from variola 
infection for 50-70 years. However, the severity of complications lead to the generation 
of an attenuated strain-Modified Vaccinia Ankara (MVA) which has defects in 
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replication and virulence [115]. Both VV and MVA are effective in inducing immunity 
against a few poxviruses including monkeypox [116].  
 
Besides being a poxvirus vaccine, VV continues to be proposed as a vector to selectively 
express Ags from infectious agents or tumors. By replacing VV nonessential genes such 
as thymidine kinase (TK) via homologous DNA recombination, foreign genes derived 
from infectious pathogens or tumors could be expressed in host cells by VV. VV displays 
many properties which make it desirable as a vaccine vector. These properties include: 
the easy generation and purification of recombinant VV; the virus’s large insertion 
capacity; the virus’s wide host range; high levels and precision-controlled expression 
driven by the virus; and the virus’s lack of host genomic integration [1, 117]. However, 
the serious complications (heart, brain, and skin inflammation) after VV inoculation in 
immune-deficient patients and healthy individuals can not be ignored. Contraindications 
of VV vaccination include eczema or atopic dermatitis, human immunodeficiency virus 
(HIV) positive patients, and transplant or chemotherapy receiving patients. In other 
conditions such as asthma, the effects of VV vaccination are unknown. These 
complications have led to the design of attenuated VV vaccines for use in humans. Here, 
the development of VV and attenuated VV derived vaccines is reviewed. 
 
3.1 Usage of VV as a vector to express genes derived from pathogens  
 
VV has been widely used as a vector to express pathogen-derived genes for study and to 
induce host immunity against various infections. Recombinant VV expressing 
heterologous viral genes such as human immunodeficiency virus (HIV) gp160 induces 
both  humoral and cellular immunity against HIV [118]. VV expressing hepatitis B virus 
surface Ag (HBVsAg) [119]; rabies glycoprotein [120]; influenza virus hemagglutinin 
[121]; respiratory syncytial virus (RSV) G or F glycoprotein [122, 123]; and RSV 
nucleocapsid (N) protein [124] provoke neutralizing primary and memory Abs against 
these corresponding viruses.  VV driven expression of nonstructural immediate-early 
protein pp89 of murine cytomegalovirus (MCMV) [125]; lymphocytic choriomeningitis 
virus (LCMV) nucleoprotein or glycoprotein [126]; friend murine leukemia helper virus 
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(F-MuLV) envelope protein [127]; and RSV M2 protein [128] stimulate CTL responses 
in mice.  F-MuLV gag protein encoded by VV, on the other hand, induces CD4  T cell 
expansion in vivo [129].  Mucosal immunity or IgA secretion which is important for 
fighting respiratory tract infection could be achieved by either i.n. delivery of a 
recombinant VV containing the H1 gene of influenza [130] or enteric inoculation of 
recombinant VV expressing RSV F glycoprotein or the influenza virus hemagglutinin 
[131, 132]. A VV recombinant vaccine can also exert antiviral function by encoding pro-
inflammatory cytokine such as IL-5 and IL-6, which helped to increase IgA production 
[133, 134].  
 
VV-based vaccines for infection are not limited to viral pathogens, as recombinant VV 
encoding bacterial and parasitic vaccines have also been developed. For example a 
nonamer CTL epitope from the listeriolysin O  protein expressed in a VV vector 
stimulates the expansion of protective CTL responses against bacterium Listeria 
monocytogenes [135]. A recombinant VV encoding the surface protein of Neospora 
caninum tachyzoite, NcSAG1 or NcSRS2, induces both humoral and cellular immunity 
against this parasite [136].  
 
3.2 Tumor Immunization using VV vectors 
 
A cause of cancer malignancies is that the host is tolerant of the tumor and host immunity 
is not activated.  Thus, two immunological tools being tested against cancer are: 1) 
enhancement of tumor immunogenicity; and 2) disruption of inhibitory factors that lead 
to immune tolerance. High expression of tumor-associated Ags (TAA) is a major method 
being used to increase immunogenicity. Recombinant TAAs such as rat neu oncogene-
encoded transmembrane glycoprotein p185 [137], carcinoembryonic antigen (CEA)  
[138] and  human melanoma-associated glycoprotein p97 [139] induce humoral and/or 
cellular immunity against tumors. Expression of genes from tumorigenic viruses  such as 
polyoma virus [140] or F-MuLV [127] using VV based vectors, can help promote host 
immune responses to lyse these tumors. Encoding other adjuvant pro-immunity 
molecules within the VV genome also helps increase anti-tumor immune response upon 
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in vivo infection. Co-expression of TAA together with co-stimulatory molecules (B7-1 
and B7-2) using VV vectors was found to enhance tumor-fighting effects [141]. Insertion 
of pro-inflammatory cytokines such as IL-2 and IL-12 into VV vectors further 
strengthens the anti-tumor effects of these cytokines [142]. VV encoding granulocyte-
macrophage colony-stimulating factor (GM-CSF) also effectively increases 
immunogenicity of an originally poorly immunogenic murine colon adenocarcinoma cell 
line, MC-38 [143]. As a pathogen itself, VV infection alone stimulates oncolysis of 
melanoma and metastatic breast, kidney, and colon carcinoma [144]. Besides TAA and 
immuno-modulators, VV can be used to express tumor suppressing genes to enhance 
tumor deterioration. For example, VV expression of wild-type p53 inhibits human (U-
373MG, U-87MG, LN-Z308) and rat glioma cell (9L, C6) growth and mediates tumor 
apoptosis [145]. 
 
3.3 Development of attenuated VV-based vaccines for poxviruses, other infectious 
agents and cancer  
 
Various strains of VV including Dryvax and Lister were used as vaccines to annihilate 
smallpox transmission. However, severe complications after VV vaccination in some 
individuals led to the design of less virulent VV-based vaccines. Those attenuated 
vaccine strains have lost virulent genes following multiple passages in cell culture, or via 
selective deletions of virulence genes, and/or insertions of pro-inflammatory cytokines by 
genetic engineering.  Examples of live attenuated strains include LC16m8 with a B5R 
mutation which was derived from Lister [146],  CVI-78 or the New York City Board of 
Health (NYCBOH) strain which has proven effective in eczema patients [147], and 
replication defective Modified Vaccinia Ankara (MVA) which lacks many 
immunoregulatory genes existing in the parent Ankara strain and does not replicate in 
mammalian cells [148]. NYVAC is derived from the Copenhagen strain by deleting 18 
open reading frames (ORFs) of virulent genes. These include many immune evasive 
genes such as B13R, K1L and N1L [149]. Encoding pro-inflammatory cytokines in VV 
can in some cases help to decrease VV virulence. For instance, both IL-2 and IL-15 
expressing recombinant VV reduce viral evasion of host immunity [150, 151]. These 
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attenuated vaccines are effective and safe to be administrated in immune-deficient 
subjects [149-153]. Yet VV encoding IL-4 or IL-17 have proven to have deleterious 
effects as vaccines [154, 155]. Thus engineering modified VV-based vaccines is an on-
going effort.  
 
Besides being used as vaccines for poxviruses, modified VV strains may also be used as 
vectors to express foreign genes from other infectious agents or cancer. Virus replication 
in MVA is blocked at a late stage of morphogenesis in mammalian cells, yet viral protein 
synthesis remains intact. Thus, MVA may potentially be used as an expression vector 
with a higher degree of safety. Indeed, recombinant MVA (rMVA) is highly 
immunogenic and effective in protecting animals from influenza, parainfluenza, measles 
virus, flaviviruses, CMV, severe acute respiratory syndrome (SARS) coronavirus, simian 
immunodeficiency virus (SIV), and HIV infections [117, 156-159]. Vaccines based on 
rMVA have been tested for bacteria such as Mycobacterium tuberculosis and for 
parasites such as plasmodium [160-162].  
 
rMVA vectors encoding cancer related viral Ags such as Epstein-Barr virus-associated 
nasopharyngeal carcinoma Ag and human papillomavirus (HPV) E2 Ag have been tested 
as vaccines [163-165]. Recombinant MVA encoding TAAs- CEA; oncofetal antigen 5T4; 
and mucin (MUC)-1 together with host immunity enhancement treatments appear 
effective in treating various cancers [166-168]. To improve vaccine immunogenicity, 
both the enhancement of immune-stimulatory factors and the reduction of immune 
inhibitory factors have been tested. For example, co-expression of multiple co-
stimulatory molecules and/or pro-inflammatory cytokines such as IL-2 has been 
employed to boost vaccine immune stimulation, or alternatively blockade of cytotoxic T-
lymphocyte antigen 4 (CTLA-4) [169]. Activation of APCs is another way to break 
tumor tolerance. Increased anti-melanoma responses by transfer autologous CD34+ cell-
derived DCs transduced ex vivo with a rMVA encoding the human tyrosinase gene has 
been studied [170]. Notably, intralesional infection with MVA alone induces anti-
melanoma immunity [171].  
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Besides being used individually, MVA could also be used together with a DNA vaccine 
to increase antigenicity. Primary immunization with the DNA plasmid followed with a 
booster immunization using recombinant MVA (rMVA) encoding the same or a related 
pathogenic proteins induces immune responses against several infections. For instance, 
studies have tested a DNA vaccine expressing SIV Gag, Pol, Vif, Vpx, Vpr, and HIV-1 
Env, Tat, and Rev genes followed with the rMVA booster encoding SIV Gag, Pol, and 
HIV-1 Env genes [172]; combinations of DNA and rMVA both encoding plasmodium 
falciparum multiple epitope (ME) - thrombospondin-related adhesion protein (TRAP) 
[173], and combination of the classical bacille Calmette-Guérin DNA vaccine with 
rMVA expressing Mycobacterium tuberculosis antigen 85A [174] greatly enhances host 
immunity against SHIV (an SIV and HIV chimera), malaria and tuberculosis 
respectively.  
 
Other attenuated VV strains are also useful as vectors to express foreign genes. For 
example, NYVAC engineered to express the Japanese encephalitis virus (JEV) prM, E, 
and NS1 genes, protects pigs from JEV viremia [175]. 
 
4. Summary and Objectives 
APCs appear to be highly susceptible to VV infection in vitro and potentially in vivo 
leading to alterations in the function of these cells. In this thesis, the efficiency of VV 
infection in vitro and in vivo was quantified using a recombinant virus encoding EGFP. 
To extend our previous observation that VV perturbs MHC class II mediated Ag 
presentation, the effect of this virus on class II-restricted Ag presentation was tested using 
immortalized and primary human or murine APCs. The ability of VV to destabilize class 
II ligand binding was investigated along with the role of cellular transformation on viral 
disruption of the class II pathway. The effects of heat inactivation and genetic 
manipulation of VV on Ag presentation were also studied to elucidate VV-derived factors 
that could affect class II function.  
Previous studies had suggested that in some cases, disruption of class II protein function 
was linked to alterations in host protein synthesis. Because VV infection can perturb the 
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expression of some host proteins, studies were carried out to test for change in the 
expression of class II molecules and their cofactors during VV infection of APCs. While 
no change in class II protein levels were detected with virus infection at 24 h, a marked 
reduction in Ii cellular abundance was noted. Studies were carried out to determine 
mechanistically whether VV infection of APCs altered Ii synthesis and/or degradation. 
Parallel studies were carried out using a chemical inhibitor of protein expression.  
To establish the relative contribution of Ii loss in class II dysfunction, studies were 
carried out using cell lines lacking or expressing Ii. Biochemical and functional assays 
were used to compare the effect of variable Ii expression on VV disruption of the class II 
presentation.  
Ii protein levels dropped only during the late stages of VV infection. Yet, studies 
suggested an earlier loss of class II function due to VV infection. The competition 
between VV and other Ags for class II presentation could at early time be responsible for 
class II disruption. Studies were carried out to look at virus Ag presentation using wild 
type or modified virus. CD4 T cell responses to virus infected cells were monitored by T 
cell proliferation assay to detect IL-2 and ELISA to check other cytokines. Recall CD4 
and CD8 responses after rechallenge in vivo with virus were also studied. To study the 
effect of VV on in vivo Ag presentation, ovalbumin (OVA)-induced asthmatic mice were 
infected by VV. Histological analysis and cytokine production was assessed. Finally, the 
ability of an H3 (a viral envelope protein) epitope specific Ab in blocking VV infection 
and protecting class II function was investigated.  
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MATERIALS AND METHODS 
 
Viruses 
 
VV, Western Reserve (WR) strain was grown, cultured, gradient purified, and titered as 
previous described in CV-1 (African green monkey kidney) cells [97]. To culture VV, 
CV-1 cells were infected with VV at MOI 0.1 for 30 m followed by culturing for 
additional 2-3 d until all cells were round. To harvest and purify VV, infected CV-1 cells 
were centrifuged, resuspended in 10 mM Tris HCl (pH 9.0), homogenized on ice, and 
centrifuged again to remove nuclei. The supernatants were sonicated, underlaid with an 
equal volume of 36% sucrose in 10 mM Tris HCl (pH 9.0), and centrifuged at 33000 g 
for 80 m at 4˚C. Pellets resuspended in 1 mM Tris HCl (pH 9.0), were aliquoted, and 
stored at -80˚C. To titer VV, CV-1 cells were infected with serially diluted VV for 30 m 
followed by incubation for additional 3 d, then stained with 0.1% crystal violet in 20% 
ethanol. The numbers of the plaques formed in cells infected with VV at the highest 
dilution (i.e. the most diluted VV) were averaged to determine the titer (pfu/ml). To heat 
inactivate VV,  undiluted, purified VV was incubated at 60˚C for 1 h to yield HI-VV 
[176]. To generate replication deficient virus,  purified VV was exposed to UV light (254 
nm) for 20 m to generate UV-VV [97]. The B1R and H5R temperature-sensitive viruses, 
were obtained originally from Drs. R. Condit (University of Florida, Gainesville, FL) and 
P. Traktman (Medical College of Wisconsin, Milwaukee, WI) respectively [90]. BSSH 
(VV expressing soluble truncated D8L gene product) was obtained from Dr. E. Niles 
(State University of New York, NY) [177]. CD4-VV (recombinant VV (rVV) encoding 
the human CD4 molecule); mIi-VV, rVV encoding murine Ii; EGFP-VV, rVV encoding 
Enhanced Green Fluorescent Proteins (EGFP)  [178] were obtained from Dr. R. 
Brutkiewicz (Indiana University School of Medicine (IUSM), Indianapolis, IN) or  Dr. J. 
Yewdell (National Institutes of Health, Bethesda, MD). VSC, rVV encoding E. coli β-
galactosidase (β-Gal) behind an engineered high expression early late promoter [179], 
was obtained from Dr. G. Alkhatib (IUSM, Indianapolis, IN). All viruses were 
propagated and purified by the Poxvirus Core Facility at IUSM.  
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Cell lines 
 
CV-1 (African green monkey kidney cells); TK-143B (human osteosarcoma cells); 
M1DR4, a human fibroblast cell line transformed with SV-40 [180, 181] and retrovirally 
transduced with human MHC class II molecules HLA-DR4; M1DR4Ii, M1DR4 cells co-
transfected with a plasmid encoding human Ii; L1DR4, a murine fibroblast cell line [182] 
retrovirally transduced with DR4; L1DR4Ii, L1DR4 cells co-transfected with a plamid 
encoding human Ii were cultured in DMEM (Invitrogen Life Technologies) with 10% 
fetal bovine serum (FBS), 2 mM L-glutamine, 50 U/ml penicillin, and 50 µg/ml 
streptomycin. Priess, a human B lymphoblastoid cell line (B-LCL) expressing DR4; 
PriessGAD, Priess cells retrovirally transduced for constitutive expression of the 65-kD 
form of human glutamic acid decarboxylase (GAD); Frev, another B-LCL; Frev/SMA, 
Frev cells transfected with a mutated form of the human immunoglobulin (Ig) κ chain or 
SMA [183]; Raji, a B-LCL; 7C3DR4, the human B-LCL Swei transfected with murine 
class II molecules I-Ab [184] and retrovirally transduced for constitutive expression of 
DR4; T2DR4DM, a mutant human B-LCL retrovirally transduced with DR4 and 
transfected with plasmids encoding DM α and β [185-187]; and the murine B cell tumor 
TA3  (expressing two alleles of murine class II molecules or I-A k×d) [188] were cultured 
in IMDM (Invitrogen Life Technologies) with 10% heat-inactivated calf serum, 50 U/ml 
penicillin, and 50 µg/ml streptomycin.  
 
Murine T cell hybridomas recognizing DR4 including: 33.1 specific for GAD273–285, 17.9 
specific for human serum albumin (HSA)64–72 and 1.21 specific for Ig κ145-159; actin 15.10 
specific for actin and I-Ab [189]; B04 specific for HEL74–88 and I-Ab; TS2.1 recognizing 
influenza hemagglutinin (HA)126-138 and I-Ad [190]; as well as the mouse B cell tumor 
line 1153 (expressing I-Ab) were cultured in RPMI 1640 (Invitrogen Life Technologies) 
with 10% FBS, 50 U/ml penicillin, 50 µg/ml streptomycin, 2 mM L-glutamine, and 50 
µM beta-mercaptoethanol (2-ME). HT-2, an IL-2 dependent T cell line was grown in 
RPMI 1640 media with 10% FBS, 50 U/ml penicillin, 50 µg/ml streptomycin, 50 µM 2-
ME and 20% T stim (BD Biosciences). For quantification of IL-2 using HT-2 cells, T 
stim was omitted from the culture media. 
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Isolation of primary APCs from human peripheral blood mononuclear cells (PBMCs) 
and murine primary splenocytes  
 
Human PBMCs were isolated from buffy coats (Indiana Blood Center) using Ficoll-
Paque PLUS (GE Healthcare) and centrifugation. T cells were depleted from these 
PBMCs with anti-CD3 Ab coated microbeads (Miltenyi Biotec). To isolate murine APCs, 
spleens of C57BL/6 mice were harvested, homogenized and red blood cells (RBC) were 
lysed with RBC lysis buffer (0.15M NH4CL, 10mM KHCO3, 0.1mM Na2EDTA in H2O, 
pH 7.4). T cells were removed with anti-CD4 and anti-CD8 Ab coated microbeads 
(Miltenyi Biotec) to obtain monocytes, B cells, DCs along with lesser numbers of 
granulocytes. When required, splenic cells were fractionated using HISTOPAQUE-1083 
(Sigma) to remove dead cells. In some studies APCs were pre-activated with 1µg/ml LPS 
(Sigma) for 24 h. To separate individual APC populations, microbeads coated with Abs 
to CD11c, CD11b or B220 (Miltenyi Biotec) were used sequentially for positive selection 
of murine DCs, macrophages or B cells. All studies using mice were reviewed and 
approved by the Laboratory Animal Resource Center (LARC) at IUSM prior to initiation.      
 
Peptides and Ags 
 
GAD273–285 (IAFTSEHSHFSLK), HEL74–88 (NLCNIPCSALLSSDI), HSA64–76 
(VKLVNEVTEFAKTK), HA126-138 wild type (HNTNGVTAACSHE), HA126-138 mutation 
T128V (HNVNGVTAASSHE) [190] and AENK (an inhibitor for AEP) [16] were 
produced using F-moc technology and HPLC to a purity of >90%. VV viral peptides 
which bind class II molecules were provided by Dr. Alessandro Sette (La Jolla Institute 
for Allergy and Immunology, San Diego, CA). HSA protein (protease free preparation) 
was obtained from Sigma.  
 
Antigen presentation or T cell assay 
 
APCs were cultured in the absence or presence of VV for 2-14 h to permit virus 
infection. APCs were then washed, and fixed with 0.5% paraformaldehyde for 10 m at 
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4˚C, followed by co-culture with T cell hybridomas for 24 h. In some assays, Ag or 
peptide was added to cells during virus infection, prior to washing, fixation and co-
culture to detect T cell activation as described below. VV infection was observed in 
>90% of the treated B cell as detected by viral Ag expression [97]. To monitor the effect 
of virus replication on GAD presentation, PriessGAD cells were treated with VV +/- the 
viral DNA polymerase inhibitor – arabinosylcytosine (AraC, 10 µM, from Sigma) for 14 
h before GAD specific T cell addition. To investigate the effect of protein synthesis 
inhibition on endogenous Ag presentation, PriessGAD or FrevSMA cells were treated 
with 10 µg/ml CHX (Sigma) for 0-6 h. To study the effect of CHX on exogenous Ag or 
peptide presentation, Priess cells were incubated with 0-10 µM HSA protein; HSA 
peptide; Ig κ II peptide; or GAD peptide +/- CHX (10 µg/ml) for 6 h. After CHX 
treatment, APCs were washed, fixed and co-cultured with Ag-specific T cells. To 
compare the effects of CHX and VV on exogenous Ag presentation, APCs were treated 
with 1-10 µM HSA protein with or without (+/-) 10 µg/ml CHX for 6 h or +/- VV 
(MOI=10) for 14 h, paraformaldehyde fixed and co-cultured with HSA-specific T cells. 
To determine the effects of CHX or VV on peptide presentation, Priess cells were co-
incubated with 1-10 µM HSA64–76 or GAD273–285 peptide +/- CHX or VV, washed, fixed 
and co-cultured with peptide-specific T cells. APC viability was assessed by trypan blue 
exclusion during exposure to virus or CHX, and conditions optimized to ensure little to 
no decrease in cell viability during these treatments.  
 
To test the effect of increased intracellular Ii expression on class II presentation, 
fibroblast cells lacking Ii (M1DR4 and L1DR4) and M1DR4 and L1DR4 engineered to 
express Ii (M1DR4Ii and L1DR4Ii) were incubated with GAD peptide (up to 10 µM) +/- 
VV (MOI up to 10) for 6 h prior to fixation and addition of GAD specific T cells. Similar 
comparison analysis was carried out with human B cells expressing normal levels of Ii 
(7C3DR4) and T2DR4DM cells which contain 4 copies of genomic Ii. To investigate the 
effects of recombinant VV which encode Ii, PriessGAD cells were infected with mIi-VV 
(rVV encoding murine Ii); CD4-VV (rVV encoding human CD4) or wild type VV at 
MOI=10 for up to 24 h, then fixed and co-cultured with GAD specific T cells.  
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T cell activation was quantified by IL-2 production using the IL-2-dependent 
proliferation of HT-2 cells [191] in hybridoma assays. All assays were performed in 
triplicate, and the relative mean proliferation and standard deviations expressed as cpm. 
 
Immunoblot or Western Blot analysis 
 
Cells infected with VV (MOI = 10) +/- AraC or treated with CHX (10 µg/ml) for 
different times, were harvested and lysed in buffer (10mM Trizma Base, 150mM NaCl 
and 1% Triton-X 100 with 1% protease inhibitors: Nα-tosyl-lysine-chloromethylketone 
and phenylmethylsulphonyl fluoride). Cell lysates were centrifuged to remove nuclei 
prior to the addition of SDS sample buffer. Samples of 40 µg or 400 µg (the latter for 
cathepsin analysis only) of total cell proteins were fractionated by SDS-PAGE followed 
by transfer to nitrocellulose membranes. Membranes were probed for: DRα monomer 
expression using the monoclonal antibody (mAb) DA6.147; DRαβ dimer using mAb 
L243; MHC I heavy chain using mAb 3B10.7; GAD using a polyclonal Ab (Sigma-
Aldrich); Ii using mAb Pin 1.1; Cat S using Cat S Ab (Biovision); Cat B using Cat B 
mAb (Calbiochem); Cat D using Cat D mAb (Calbiochem); Cat L using the mAb CPLH 
36.1 [192]; DMβ using a rabbit Ab to DMβ peptide (TPLPGSNYSEGWIS); and GILT 
using a rabbit Ab to GILT.  Cellular actin was detected using the mAb-Pan Actin Ab-5 
(Lab Vision). VV Ags were detected with a rabbit polyclonal VV specific Ab (Cortex 
Biochem) to demonstrate cellular VV infection. Viral proteins D8 and H3 were detected 
with corresponding specific rabbit Abs-C8 (immunogen: soluble D8 protein)  and anti-H3 
Ab (immunogen: full length H3 protein) respectively [193, 194]. Densitometric analysis 
of Western blots was carried out with software ImageJ (NIH website) using cellular actin 
or GAPDH expression as a relative internal standard. 
 
To monitor the effects of VV on Ii maturation and processing, PriessGAD cells were 
cultured with VV (MOI=10) for 2 h to permit infection, followed by incubation with 
agents to disrupt Ii transport or proteolysis. Thus, cells were incubated with Brefeldin A 
(BFA, 50 ng/ml, Calbiochem) to block protein transit from ER to Golgi; Leupeptin (Leu, 
500 μM, Sigma) to block lysosomal cysteine proteases; monensin (Mon, 1 μM, 
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Calbiochem) to block protein exit from the Golgi; chloroquine (Chl, 0.3 mM, Sigma) to 
block endosome and lysosome acidification; Phenylmethyl-sulphonylfluoride (PMSF, 50 
µM, Sigma) to block cellular serine proteases; lactacystin (LAC, 250 nM, Sigma) to 
block the proteasome; epoxomicin (EPO, 200 nM, Sigma), a proteasome inhibitor; E64 
(0.5mM, Sigma), an irreversible cysteine protease inhibitor; and AENK (1 mg/ml) to 
block AEP for an additional 12 h before cell harvesting and cell protein analysis by 
Western Blotting. In the 2×Leu group, Leu was added again at 6 h before cell harvesting 
to ensure protease inhibition during the course of infection. To study the effects of CHX 
on Ii processing, PriessGAD cells were cultured with proteolysis inhibitors for 1h, then 
CHX (10 μg/ml) was added to the media for an additional 4 h followed by 
immunoblotting of cell lysates and protein quantification by densitometry.  The working 
concentrations of drugs used in these studies were derived from literature [195, 196]. The 
incubation periods used were selected after pilot studies to optimize cell viability, 
inhibitor action and detection of target proteins in uninfected cells. Cell viability of >80% 
after each treatment was confirmed by trypan blue staining. 
 
Immunoprecipitation 
 
PriessGAD cells treated +/-VV or CHX were harvested, lysed and pre-cleared by 
incubation with 50 μl of protein G coupled beads/sample for 30 m. Protein G coupled 
beads were spun down and the cell supernatant was collected. The anti DRα mAb 
DA6.147 was added to the pre-cleared cell lysates and incubated at 4˚C overnight. 100 
μL of Protein G coupled beads were added to each sample and incubated for an additional 
1 h in the cold. DR molecules bound to protein G coupled beads were eluted by addition 
of reducing SDS buffer and boiling for 5 m. Eluates were resolved on SDS-PAGE and 
Western analysis was performed using specific Abs (e.g. Pin 1.1 for Ii). 
 
Quantification of protein synthesis 
 
To monitor total new protein synthesis, APCs were culture with l-lysine [4,5-3H] and l-
leucine [3,4,5-3H] (ICN Biomedicals Inc) in lysine- and leucine-deficient minimum 
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essential media (Sigma) with increasing concentrations of CHX (up to 50 µg/ml) for 6 h. 
Cellular proteins were filter captured to quantify radiolabeled- amino acid incorporation. 
At the concentration of 10 µg/ml, CHX efficiently decreased cellular protein synthesis 
(about 85%) with minimal loss of cell viability (>90%). During analysis of Ii processing 
and expression, PriessGAD cells were incubated with BFA (50 ng/ml) or Leu (500 µM) 
+/- CHX (10 µg/ml) in the [3H]-amino acid containing media for 6 h before harvesting 
and quantification of radiolabel incorporation to ensure BFA or Leu treatments did not 
alter inhibition of host protein synthesis by CHX. 
 
[35-S] methionine incorporation and pulse-chase assay  
 
To assess the effects of VV on host protein synthesis, PriessGAD cells (1×107/sample) 
were infected with VV (MOI=10) for 0, 2, 6, and 14 h before addition of 0.5 mCi of 
[35S]-methionine (specific activity: 1175 Ci/mmol, MP Biomedicals) in 0.5ml cold 
methionine free RPMI media /sample for 1 h. Cells were harvested, lysed and 
immunoprecipitated with Pin 1.1 for Ii and DA6.147 for DR. The precipitated samples 
were resolved on the SDS-PAGE followed by Coomassie Blue gel staining and 
autoradiography. Coomassie Blue staining was performed to ensure equal sample loading. 
For pulse-chase assays, PriessGAD cells were starved in methionine free RPMI media for 
1 h and labeled with 0.5 mCi of [35S]-methionine (specific activity: 1175 Ci/mmol) for 
another hour. Samples were chased in media containing excess methionine +/- VV 
(MOI=10) and/or E64 (500 μM) for 0, 2, 6, and 14 h. Samples were immunoprecipitated, 
subjected to SDS-PAGE and analyzed by autoradiography of SDS-PAGE. 
 
Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and 
quantitative real time PCR 
 
PriessGAD cells were treated +/- VV (MOI = 10) for up to 14 h. Total RNA was 
extracted from these cells with an RNEasy Mini kit (Qiagen) following the 
manufacturer’s instructions. cDNA was generated from RNA using an Advantage RT for 
PCR kit from BD Biosciences.  Primers for PCR amplification were designed using the 
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Custom Primers - OligoPerfect™ Designer software (Invitrogen). The primers used for 
human Ii (CD74) were 5'-GCT GTC GGG AAG ATC AGA AG-3'  (sense) and 5'-GCC 
ATA CTT GGT GGC ATT CT-3' (antisense); for DRα (HLA-DRA) 5'-CAA AGA AGG 
AGA CGG TCT GG-3' (sense) and 5'-AGC ATC AAA CTC CCA GTG CT-3' 
(antisense); for human Cat S (CTSS) 5'-GGA TCA CCA CTG GCA TCT CT-3' (sense) 
and 5'-CCA GCT TTC CTG TTT TCA GC-3' (antisense); for human Cat B (CTSB) 5'-
GCT ATC CTG CTG AAG CTT GG-3' (sense) and 5'-CAT TGT CAC CCC AGT CAG 
TG-3' (antisense);  for human Cat D (CTSD) 5'-AGC TGG TGG ACC AGA ACA TC-3' 
(sense) and 5'-CTC TGG GGA CAG CTT GTA GC-3' (antisense);  for human Cat L 
(CTSL) 5'-TGT GGT TCT TGT TGG GCT TT-3' (sense) and 5'-CAG GCC TCC ATT 
ATC CTG AA-3' (antisense); for human actin (ACTA1) 5'-AGA AAA TCT GGC ACC 
ACA CC-3' (sense) and 5'-CCA TCT CTT GCT CGA AGT CC-3' (antisense); for human 
Early Endosome Antigen1 (EEA1) 5’-GAA GAA AAG GAG CAG CAT GG-3’ (sense) 
and 5’-GGT CCT TAT CGC CAA TTT GA (antisense); for human AEP (LGMN) 5’-
GAA ACG CAA AGC CAG TTC TC-3’ (sense) and 5’-GCA AGG AGA CGA TCT 
TAC GC-3’ (antisense); and for human HSC70 (HSPA10) 5'- AGC TGT AAG ACG 
CCT CCG TA -3' (sense) and 5'- GTG ACA TCC AAG AGC AGC AA -3' (antisense); 
for viral E3L 5'-CGC AGA GAT TGT GTG TGA GG-3' (sense) and 5'-AAC GGT GAC 
AGG GTT AGC AC-3' (antisense); for viral D8L 5’-CAA ATC GGA CAA CCA TCT 
CA-3’ (sense) and 5’-CCA TTA GAT CCG CCA ATA CG-3’ (antisense); for viral H3L 
5’-GCG GCC GCC ATG GCG GCG GCG AAA ACT CC-3’ (sense) and 5’-GCG GCC 
GCC TTA GAT AAA TGC GGT AAC G-3’ (antisense). GAPDH primers were obtained 
from the Advantage RT for PCR kit. Amplification reactions were performed using 
1.1×ReddyMixTM PCR Master Mix (ABgene) with different cycle times in a MJ 
Research thermal cycler. The number of amplification cycles for semiquantitative 
analysis was 28 cycles except for HSC70, Cat S, Cat B and Cat D (32 cycles); and Cat L 
(40 cycles).  The cycling  parameters used were: 95˚C, 15 sec; 50˚C, 30 sec; and 68˚C, 1 
m. PCR products (10 µl) were electrophoresed on 1% agarose gels, stained with SYBR® 
safe DNA gel stain (Invitrogen), and detected with UV transillumination using 
ChemiDocTM XRS (Bio-Rad). mRNAs for early viral gene product E3L and late gene 
product D8L were monitored as evidence of VV infection. Host cell HSC70 (HSPA10) 
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mRNA was used as a control for sample loading. Similar procedures were used to detect 
relative mRNA abundance after CHX treatment. Ii (CD74) mRNA expression levels in 
CHX treated samples were evaluated and averaged from three independent experiments 
with the standard deviation indicated.   
 
To detect human Ii (CD74), DRα (HLA-DRA) and HSC70 (HSPA10) mRNA levels by 
quantitative real time PCR, RNA isolation and cDNA synthesis were performed as above. 
TaqMan® Gene Expression Assays with specific primers and probes (Hs00269961_m1 
for CD74; Hs00219575_m1 for HLA-DRA and Hs00852842_gH for HSPA10) were 
incubated with TaqMan® Fast Universal PCR Master Mix and cDNA templates. Samples 
were amplified 40 cycles using a 7500 Real-Time PCR System (Applied Biosystems) 
with the following parameters: 95˚C, 15 sec; and 60˚C, 1 m. HSPA10 was used as the 
endogenous reference while 0 h relative quantification of CD74 or HLA-DRA mRNA 
was used as the calibrator. 
 
To detect murine mRNAs by semi-quantitative and realtime PCR, the following specific 
primers were used: for I-Ab (H2-Ab1) were 5'-CTG TCT GGA TGC TTC CTG AGT TT-
3' (sense) and 5'- CAG CTA TGT TTT CAG TCC ACC-3' (antisense); for murine Ii 
(Cd74)  5'- AGA GAG CCA GAA AGG TGC AG -3' (sense) and 5'- ATC TTC CAG 
TTC ACG CCA TC -3' (antisense); for murine Cat L (Ctsl) 5'- CTG CTT GGG AAC 
AGC CTT AG -3' (sense) and 5'- TGA GCG TGA GAA CAG TCC AC -3' (antisense); 
for murine Cat S (Ctss) 5'- CCA TTG GGA TCT CTG GAA GA -3' (sense) and 5'- AGC 
CCT TCT CTC TCC AGT CC -3' (antisense); and for GAPDH (Gapdh) 5'- CCA GGT 
TGT CTC CTG CGA CGA CT -3' (sense) and 5'- ATA CCA GGA AAT GAG CTT 
GAC AAA GT -3' (antisense). Semi-quantitative PCR was performed as described above. 
For real time PCR, SYBRgreen master mix (Applied Biosystems), primers for specific 
genes and cDNA templates were mixed before running with 7500 Real-Time PCR 
System for 40 cycles. 
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DNA sequencing 
 
To confirm the identity of  the PCR product amplified using primers specific for human 
Cat L (CTSL) , PriessGAD cells were cultured +/- VV (MOI = 10) for 14 h followed by 
mRNA isolation and cDNA synthesis. After amplification of cellular mRNA using the 
CTSL primers, the reaction products from each sample were separated on a 1% agarose 
gel, and the amplified cDNA bands were excised and extracted using a QIAquick gel 
extraction kit (Qiagen) according to the manufacturer’s instructions. The cDNAs were 
sequenced by the DNA Sequencing Core Facility at IUSM using a Perkin Elmer / 
Applied Biosystems 3100 Genetic Analyzer and Big Dye Terminator chemistry v3.1. 
CTSL cDNA amplified from uninfected PriessGAD cells was sequenced, and this cDNA 
sequence was compared with the sequence from VV infected PriessGAD cells using 
ClustalW software from the European Bioinformatics Institute. To prove the identity of 
these amplified cDNA sequences as CTSL, nucleotide-nucleotide BLAST software from 
the National Center for Biotechnology Information was used. Proteins translated from 
these cDNA sequences were predicted using Expasy software from the Swiss Institute of 
Bioinformatics. 
 
Flow cytometry and cell sorting 
 
Cells (5×105) were incubated with a primary Ab or appropriate isotype Ab for 30 m on 
ice followed by washing and treatment with a fluorescence labeled secondary Ab (e.g. 
phycoerythrin (PE)-conjugated rabbit anti-mouse IgG  or cyanine 2 (Cy2) conjugated 
donkey anti-rat IgG (Jackson ImmunoResearch) at 1:1000 dilution for additional 30 m 
followed by extensive washing. In some cases, direct fluorescein isothiocyanate (FITC) 
or PE conjugated Abs such as FITC Mouse Anti-Human CLIP Ab (BD bioscience) or 
FITC conjugated anti-human CD74 (Ii) (eBioscience) were used directly without the 
addition of a labeled secondary Ab. To detect intracellular molecules (such as HLA-DM), 
cells were permeabilized with 0.05% saponin in PBS (200µl/sample) for 15 m at 37˚C. 
Subsequent steps for treating cells were all using 0.05% saponin added to the wash-
staining buffer (1% BSA in PBS). When using the EGFP expression virus, cells were co-
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stained with PE-labeled Abs to avoid fluorescence overlap that would be expected using 
FITC. EGFP occupies fluorescent channel 1 as FITC does. Thus, to study the infection of 
different APC populations, murine splenic APCs treated +/- the EGFP-VV were co-
stained with PE labeled Abs to distinguish cell types. Cell surface expression of CD11c 
was used to detect DCs, CD11b for macrophages, and B220 as a marker for B cells 
(Miltenyi Biotec). Samples were analyzed by flow cytometry using Cell Quest software. 
For sorting EGFP positive cells, cells (2×107/sample) infected with EGFP-VV (MOI=10) 
for 14 h were harvested, fixed in 1% paraformaldehyde for 20 m on ice. The cells were 
washed and resuspended in 2 ml media /sample. Sorting was done by Flow Cytometry 
Resource Facility at IUSM. 
 
Generation of recombinant VV  
 
The procedure to generate recombinant virus was modified from the method described 
previously [97, 197].  Briefly, full length cDNA of human Ii genes (CD74, named here as 
hIi) isoform b cloned from PriessGAD cells was inserted into a transfer vector-zero 
pCR®-Blunt vector (Invitrogen) to engineer flanking restriction sites of EcoRI (New 
England Biolabs). This hIi cDNA was then ligated into the EcoRI site of the recombinant 
plasmid pSC59 to yield pSC59-hIi. pSC59 is a plasmid containing engineered 
overlapping early and late VV promoters designed for higher expression of inserted genes 
compared with the natural promoter containing plasmid [198]. The hIi insertion in 
pSC59-hIi was flanked by VV TK sequences, which provide sites for homologous 
recombination with VV. The uncut and HindIII (New England Biolabs) cut pSC59-hIi 
were electrophoresed on 1% agarose gels, stained with SYBR® safe DNA gel stain, and 
detected with UV transillumination to confirm the appropriate insertion fragment. 
Plasmid orientation of the hIi insert and the sequence of hIi was confirmed by DNA 
sequencing. To recombine the pSC59-hIi with VV, VV (MOI=0.05) infected TK-143B 
cells (confluence: 85%) were transfected with pSC59-hIi (20 µg) by lipofectamine 
(Invitrogen).  Virus particles were harvested after 2 days with 3 freeze-thaw cycles and 
used to infect 143 TK- cells in presence of 5-bromodeoxyuridine (BUdR, 25 ug/ml). The 
basis of this selection is that the insertion in pSC 59 disrupts the TK gene of VV by 
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homologous recombination. Only viruses without an active TK gene can survive in the 
presence of BUdR and form plaques. Three rounds of this selection and amplification 
were performed before the final harvest of the recombinant VV containing hIi (hIi-VV). 
hIi-VV was titered in CV1 cells. hIi expression was also tested in CV1 cells infected by 
hIi-VV (MOI=10) with Western analysis using VSC or β-Gal-VV (recombinant VV 
encoding β-Gal also derived from pSC59) as the insertion vector control . The mIi-VV 
used in the Western analysis and following functional assays was provided by Poxvirus 
Core Facility using pSC11 as the recombinant vector. pSC11 contains both early and late 
VV promoters [199, 200].   
    
CD4 T cell proliferation/cytokine production assay following in vivo exposure to virus or 
viral Ags 
 
C57BL/6 mice were infected with WR VV (i.p. 106 pfu/mouse) at day 0 and housed for 
1, 2, 7 d prior to termination during primary infection assays. Similarly, mice were i.p. 
infected for 7 days with same dose of modified or mutant VV [e.g. UV irradiated VV, 
heat inactivated VV, or BSSH (VV with truncated D8L)] prior to sacrifice and analysis. 
To examine T cell memory or recall responses to virus, in some studies animals were i.p. 
infected with 106 pfu/animal WR VV at day 0, housed for 21 days which time the animal 
was re-infected by i.p.. After 4 days these mice were terminated and analyzed. Control 
studies using uninfected mice were carried out in parallel. To harvest immune cells from 
these animals for analysis, superficial and mesenteric lymph nodes as well as spleens 
from infected mice were harvested, homogenized and positively selected with anti-CD4 
Ab coated microbeads (Miltenyi Biotec) to capture CD4+ T cells. The CD4 T cells were 
cultured with in vitro VV infected or viral peptide added APCs (1153 or primary splenic 
APCs).  The APCs were inactivated by either fixation with 0.5% paraformaldehyde (for 
1153) or irradiation (1000 rad, for splenic cells). The cell number and ratio of CD4 T 
cells to APCs were optimized according to pilot assays. For example, 105 cells of each 
cell type (or a ratio 1:1 for CD4 T cells to APCs) were placed in each well of a 96-well 
plate for T cell proliferation assay. 106 cells of each cell type (1:1 for CD4 T cells to 
APCs) were placed in a well on a 24-well plate for cytokine analysis. In all cases, CD4 T 
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cells were co-cultured with APCs for 72 h. CD4 T cell proliferation was monitored by 
[3H]-thymidine incorporation. Cytokines (IL-2, IFN-γ, IL-4, TNF-α and IL-17 etc) 
produced by CD4 T cells were assayed with a conventional ELISA and multi-analyte 
ELISArrary analysis (see following).  
 
Enzyme linked immunosorbent assay (ELISA) 
 
To detect cytokines produced by T cells after re-stimulation, capturing Abs (for IL-2, 
IFN-γ, IL-17, IL-4 and TNF-α; BD Bioscience) were coated on 96-well EIA/RIA plates 
(Corning Incorporated) at 4˚C overnight. Cell media from APC-T cell co-culture assays 
were incubated at 4˚C overnight with plates coated with Abs to cytokines. To detect Ab 
captured cytokines, Biotin labeled Abs specific for cytokines (BD Bioscience) followed 
by Streptavidin-HRP (Thermo Scientific) were used. To detect Abs binding to viral 
protein, purified viral recombinant proteins such as H3 were used to coat the plates. 
Then, rabbit Abs eH3 or eH3c were added to H3 protein coated plate at 4˚C overnight 
followed by addition of goat anti-rabbit IgG Fc-HRP (Jackson ImmunoResearch 
Laboratories). Finally, HRP activity was measured using ABTS (BioFX). 
 
Multi-analyte ELISArray kits for mouse Th1 / Th2 / Th17 cytokines (SA Biosciences) 
were used according to the manufacturers’ instruction. Briefly, conditioned media from 
T-APC cultures (50 μl/well) as well as negative (no addition) and positive controls 
(recombinant cytokines) were added to microtiter plates coated with Abs to specific 
cytokines for 2 h at room temperature. Next, Biotin labeled Abs specific for cytokines 
were added, followed by Avidin-HRP and HRP-substrate. A total of 12 cytokines were 
analyzed, i.e. IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IL-23, IFNγ, TNFα and 
TGFβ-1 during this approach.  
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Cytokine production by memory CD8 and CD4 T cells upon restimulation with a mitogen 
PMA and ionosphere iononmycin 
 
CD8/CD4 T cells were isolated from C57BL/6 mice after two injections with WR VV 
(see CD4 T cell proliferation/cytokine production assay) using anti-CD8/CD4 Ab coated 
microbeads (Miltenyi Biotec). These cells were restimulated with 50 ng/ml phorbol 
myristate acetate (PMA, Sigma) and 500 ng/ml ionomycin (Sigma) in the presence of 
GolgiPlug (BD Biosciences) for 4 h to induce cytokine production and accumulation in 
the Golgi. Surface CD4 and CD8 molecules were detected by incubating cells with the 
corresponding fluorescently conjugated Abs (eBioscience) for 30 m at 4˚C.  After 
fixation with 1% formaldehyde, cells were washed twice with the wash-staining buffer 
(1% BSA in PBS) containing 0.05% saponin followed by intracellular staining for IL-17, 
IFN-γ, and granzyme B using fluorescently conjugated specific Abs (eBioscience) for 30 
m at 4˚C.  Flow cytometric analysis was performed as mentioned above. In vitro 
restimulation and cell staining for these assays were done by Norman Yeh from Dr. Mark 
Kaplan’s laboratory at IUSM.  
 
In vitro IL-17 polarization assay 
 
Isolated splenic CD4 or CD8 T cells from untreated C57BL/6 mice were activated with 
soluble anti-CD3 Ab (2 µg/ml; BD Pharmingen) and anti-CD28 Ab (1 µg/ml; BD 
Pharmingen) in the presence of various splenic APC populations (total APCs, DCs, B 
cells and macrophages) or lymph node derived APCs under conditions favoring the 
development of IL-17 producing T cells.  In these studies, T cell IL-17 polarization was 
induced by adding anti-IFN-γ (10 µg/ml; BD Pharmingen), anti-IL-4 (10 µg/ml; BD 
Pharmingen), TGF-β1 (1 ng/ml; R&D Systems), IL-6 (100 ng/ml; Peprotech), and IL-1β 
(10 ng/ml; eBioscience) in culture media at 37˚C [201]. On day three, fresh media 
containing IL-2 (20 U/ml; Roche) was added to these cells.  Cells were cultured for 2 
additional days prior to intracellular IL-17 staining and analyzed by flow cytometry. The 
in vitro polarization, cell staining and flow cytometric analysis were done by Norman 
Yeh. 
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Ovalbumin (OVA)-induced asthma model 
 
To study the effects of virus infection on Ag driven inflammation in the mouse, an OVA 
induced asthma model was used. At day 0, Balb/c mice (five per group) were randomly 
divided into 4 groups including: 1) no asthma and no infection or control; 2) asthma only; 
3) VV infection only; and 4) asthma + VV infection. The mice in the asthma alone (group 
2) or asthma + VV (group 4) groups were i.p. injected with 20 µg OVA (Sigma-Aldrich) 
with 2mg Imject Alum (Pierce) twice at days 0 and 7 respectively. From day 14 to 19 
each OVA primed mouse was i.n. sensitized with 50 µg OVA/day for six consecutive 
days. The sensitization of mice using OVA to induce asthma was carried out by Dr. 
Sarita Sehra at Dr. Mark Kaplan’s laboratory.  Three days after the i.n. sensitization (day 
22), the mice in VV alone (group 3) or asthma + VV (group 4) groups were intra-tracheal 
(i.t.) infected with VV (103 pfu/mouse) by Dr. Robert Presson, Department of Medicine, 
IUSM. Four days after VV infection (day 26), the lungs and splenocytes from these mice 
were harvested for histology and cytokine production assays respectively by Dr. 
Gourapura Renukaradhya, Jeremy Eltz and Beau Champ of  the Poxvirus Core Facility 
under the direction of Dr. Randy Brutkiewicz, IUSM.  
 
For histology, lungs were perfused with PBS and fixed in 10% formalin overnight.  The 
next morning the tissues were transferred to 70% ethanol prior to paraffin embedding by 
Dr. Keith Condon, IUSM. Tissue samples were sectioned and haematoxylin and eosin 
(HE) and periodic acid-Schiff (PAS) stained to detect inflammatory cell migration into 
the lungs as well as mucous production. Tissue sample histology and mucous production 
quantification were assessed by Dr. David Wilkes, Department of Medicine, IUSM. 
  
For cytokine production assays, 1.5 x 106 splenocytes from each mouse were cultured in 
24 well plates +/- 100 µg/ml OVA for 72 h before analysis by ELISA using IL-5, IL-13, 
IL-17, and IFN-γ specific Abs. Samples were assayed in triplicate and the mean and 
standard deviation determined. These assays were carried out by Dr. Gourapura 
Renukaradhya.  
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Synthesis of viral D8 and H3 recombinant proteins using an E coli protein expression 
system  
 
Truncated VV proteins D8 and H3 lacking their transmembrane domains were expressed 
in DE3 E. coli cells using plasmids provided by Dr. W. Chang (Academia Sinica, 
Taiwan). The recombinant viral proteins were tagged with tandem histidine residues and 
purified with the QIAexpressionist kit (Qiagen) according to the instructions from the 
manufacturer. To optimize the production of the histidine conjugated viral D8 and H3 
proteins, cells were cultured +/- isopropyl β-D-1-thiogalactopyranoside or IPTG (Qiagen, 
0.4 mM for H3 and 0.8 mM for D8) to monitor recombinant protein expression. Lysates 
from these cells were fractionated by SDS-PAGE, transferred to nitrocellulose 
membranes and probed with either D8 and H3 specific Abs or rabbit anti-6-His-HRP Ab 
(His-Ab, Bethyl). The purified H3 protein was used to test the binding specificity and 
affinity of the eH3 or eH3c Abs by ELISA.    
 
Protective H3 Ab analysis 
 
Individual rabbits were immunized with either the keyhole limpet hemocyanin (KHL) 
conjugated peptides H344-61 (CPEKRNVVVVKDDPDHYKD) or the peptide H3244-259 
(CVAEHRFENMKPNFWSR) to induce the eH3 Ab (to H344-61) and the eH3c Ab (to 
H3244-259) respectively. Both pre-immune and immunized sera were harvested from each 
rabbit. Ab titers and the specificity of these Abs were verified by Western analysis and 
ELISA using purified VV and H3 protein respectively. Infection efficiency of PriessGAD 
cells by EGFP-VV (MOI=10, 6 h) in the absence or presence of the eH3/eH3c Abs was 
tested using flow cytometry with human vaccinia immune globulin (VIG) as a positive 
control which blocks VV infection. Pre-immune sera were used as the negative control. 
Presentation of endogenous GAD by PriessGAD cells upon VV (MOI=10, 6 h) infection 
in the presence or absence of the eH3/ eH3c Abs was monitored using an Ag presentation 
assay. For both flow cytometry and Ag presentation assays, 1 volume of VV (MOI=10) 
was pre-incubated with 3 volumes of various Abs for 40 m at 37˚C. To rule out non-
specific Fc receptor binding to Abs, cells were first treated with FcR blocker (2µl/1×106 
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cells, Miltenyi Biotec) prior to the addition of virus +/- virus-specific Abs. When FcR 
blocker was present, cells were pre-incubated with this reagent at 37˚C for 30 m before 
the addition of virus. 
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RESULTS 
 
Chapter 1 VV infection of APCs and disruption of class II mediated-Ag 
presentation  
 
Although T cells are resistant to VV entry, APCs (such as DCs and macrophages) are 
susceptible to VV infection in vitro and in vivo [94-96]. APC dysfunction after in vivo 
and in vitro exposure to VV has been established [92, 96, 97]. Specifically, VV perturbs 
MHC class II mediated Ag presentation by both professional and non-professional APCs 
[96, 97]. Here, to confirm the susceptibility of B cells, macrophages and DCs to VV 
infection, the infection efficiency of immortalized B cells and primary APCs was 
compared both in vitro and in vivo after VV inoculation. To validate VV-induced 
disruption of class II function, Ag presentation was tested in several human and murine B 
cell lines as well as murine primary APCs upon VV infection. VV disruption of class II 
presentation was rapid, occurring in <1 h of virus infection. Class II Ag presentation was 
disrupted by live VV as well as replication deficient virus [97]. Although inhibition of 
host protein synthesis had been postulated, specific mechanism(s) for viral disruption of 
the class II pathway remained to be elucidated [110]. Thus, the effect of virus on the 
expression of key components of the class II pathway was investigated using human B 
lymphoblasts. To explore the viral factors contribute to disruption of class II function, T 
cell assays were carried out using VV +/- the virus specific DNA polymerase inhibitor 
arabinofuranosylcytosine (AraC). This inhibitor also blocks the synthesis of virus late 
gene products [202]. Heat inactivated VV and viruses lacking specific genes reported to 
regulate other pathways for Ag presentation were also tested for their effects on the class 
II pathway. Thus, these initial studies began to probe how virus infection influences class 
II presentation.  
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1.1 Efficiency of APC infection by VV 
 
Previous studies have shown that APCs are susceptible to VV infection while T cells are 
more resistant to virus entry [94-96]. To investigate the in vitro infection efficiency of 
APCs, a human B cell line-PriessGAD, murine splenic APCs (depleted of T cells by 
microbeads coated with Abs to CD4 and CD8) and T cells (cells positively selected using 
microbeads coated with Abs to CD4 and CD8) were infected with EGFP-VV (MOI=10) 
for 24 h. The EGFP-VV is a recombinant VV encoding enhanced green fluorescent 
protein (EGFP) under the control of virus early-late gene promoter [178]. Cells 
expressing EGFP were detected by flow cytometry. To further analyze the efficiency of 
infection for primary APCs, these cells were further identified using PE labeled Abs 
specific for phenotypic surface markers, i.e. B220 for B cells, CD11c for DCs and CD11b 
for macrophages. Using murine splenic cells, pilot experiments showed that the relative 
abundance of each APC population within the spleen remained constant after 24 h of in 
vitro VV infection. Thus, we did not observe the loss of discrete cell types during this in 
vitro infection analysis. As listed in Table 2, PriessGAD cells were the most susceptible 
cell type with more than 80% cells infected after 24 h of incubation with VV. By 
contrast, the infection efficacy for mixed population of murine primary APCs was much 
lower with only 20% of cells containing EGFP-VV. However, higher infection was 
observed for specific populations of splenic APCs. Potent APCs such as DCs, the 
efficiency of virus infection was 72%. Macrophages also had a high efficiency of 
infection at 51%. Since the majority of the primary APCs in the spleen are B cells with an 
infection efficiency of about 20%, the overall efficiency for the mixed splenic population 
of APCs was close to this number. DCs and macrophages are also known to be more 
endocytic and they can take up more material by phagocytosis [203], thus these higher 
efficiencies of infection might be expected compared to murine B cells. T cells, on the 
contrary, displayed only limited infection, i.e. 8% EGFP+ 24 h post VV infection. The in 
vivo infection efficiency for different APCs was also studied. C57BL/6 mice were i.p. 
infected with 2.5×108 pfu of EGFP-VV/mouse for 24 h. Animal spleens were then 
harvested, homogenized and depleted of T cells by microbeads coated with Abs to 
CD4/CD8. The remaining splenic cells were then stained with different PE-conjugated 
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Abs to detect different APC populations (B cells, DCs and macrophages) and analyzed by 
flow cytometry. Although less than observed with in vitro virus exposure, in vivo 
inoculation of mice also resulted in virus EGFP detected in individual APC populations 
at about 10-30% (Table 2). The data on infection efficiencies for individual APC 
populations was normalized relative to the abundance of each cell type in the spleen. 
Thus, as previous studies have demonstrated [94-96], APCs but not T cells could be 
effectively infected by VV. 
                 Table 2  Infection efficiencies after 24 h VV inoculation 
Cell type Infection route Virus EGFP + cells (%) 
PriessGAD (human B-LCL) In vitro 81 
In vitro 72 
Primary murine DCs 
In vivo 30 
In vitro 51 Primary murine macrophages 
In vivo 27 
In vitro 24 Primary murine B cells 
In vivo 10 
In vitro 25 Primary murine APCs (mixed 
population of splenic APCs) In vivo 17 
Primary murine T cells In vitro 8 
For in vitro infection, human B-LCL or isolated primary cell populations were infected 
with EGFP-VV (MOI=10) for 24 h. For in vivo infection, cells were harvested from 
EGFP-VV (2.5×108 pfu) infected C57BL/6 mice. APC populations were distinguished 
with PE-conjugated Abs, and the relative abundance of each cell type in the spleen, i.e. 
75% B cells, 18% macrophages and 7% DCs was used to calculate the percent infected 
cells.  
 
1.2 Disruption of class II-mediated Ag presentation by VV  
 
Our studies showed that VV perturbs MHC class II-mediated Ag presentation by both 
professional and non-professional APCs [97]. To extend these results, endogenous GAD 
Ag presentation by PriessGAD cells upon VV infection was tested using T cell assays. 
As shown in Fig. 3A and B, VV infection of PriessGAD reduced MHC class II 
presentation of GAD in a manner dependent on viral MOI and duration of infection. 
PriessGAD cells were infected with VV and then treated with paraformaldehyde to 
inactivate the virus prior to co-culture of these APCs with T cells. Exposure of APCs to 
VV at an MOI of 10 resulted in a dramatic inhibition of class II Ag presentation with 
little or no change in cell viability. VV induced class II dysfunction not only in human 
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but also in a murine cell line. Presentation of a naturally processed Ag, actin by the 
murine B cell tumor 1153 diminished in a dose dependent manner when 1153 was 
exposed to VV (Fig. 3C).  The effects of virus on class II presentation by primary murine 
spleen cells were also investigated. Murine splenic cells depleted of T cells, were infected 
with EGFP-VV (MOI=10) or under mock conditions for 14 h. The virus infected cells 
were fixed and sorted by FACS to ensure analysis of only cells expressing viral EGFP. 
HEL peptide presentation by murine spleen cells mock infected or isolated based on 
EGFP expression was analyzed. The EGFP-VV positive cells failed to present HEL 
peptide while the non-infected spleen cells efficiently presented HEL (Fig. 3D). Thus, 
100% VV infected APCs lost their Ag presentation ability completely. Therefore, cell 
infection correlated with the loss of Ag presentation in vitro. Similar to human B-LCL, 
little to no change in cell viability was observed during virus infection of these murine 
cell lines and primary APCs.  
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1.3 Viral early-late gene products in disruption of class II presentation 
 
The efficacy of VV inhibition of class II presentation may be influenced by both virus 
associated factors and/or a cellular component from the host. To further investigate the 
role of virus-derived products, the following functional assays were undertaken. Our 
previous study showed that replication of VV is dispensable for the inhibitory effect on 
endogenous GAD presentation using UV and psoralin treated VV  [97]. This treatment 
also blocks virus production of early gene transcripts, and thus the expression of virus 
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Fig. 3 Disruption of class II function by VV infection of established cell lines and 
primary cells. A. Inhibition of class II presentation by VV was dependent on viral MOI. 
PriessGAD cells were infected with VV (MOI 0 to 25) for 6 h, prior to fixation and 
analysis of GAD Ag presentation. B. Temporal progression of VV inhibition of class II 
function. PriessGAD cells were incubated with VV (MOI=10) for 0 to 14 h, then assayed 
for GAD Ag presentation. C. Endogenous actin presentation by murine B cell tumor upon 
VV infection was dependent on MOI. 1153 B cells were infected with VV (MOI up to 10) 
for 6 h and fixed prior to actin-specific T cell addition. D. Loss of class II function 
correlated with VV infection of primary APC. Splenic cells were harvested from 
C57BL/6 mice. Semi-purified APC were obtained by depleting T cells with microbeads 
coated with Abs to CD4 and CD8 molecules. The CD4/CD8- spleen cells were infected 
with EGFP-VV (MOI=10) for 14 h followed by fluorescence activated cell sorting 
(FACS). A parallel sample of these cells was mock infected. EGFP positive cells after 
sorting and non-infected cells were incubated with 10 µM HEL peptide for 6 h prior to 
co-culture with HEL-specific T cells and analysis for T cell activation (see materials and 
methods). 
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early gene protein products. Thus, these results suggest that a viral late gene or host 
product may be involved in disrupting class II presentation. Using 
arabinofuranosylcytosine (AraC) which specifically inhibits viral DNA polymerase, 
similar inhibitions were observed regardless of AraC presence at 6 h. AraC can also 
block the synthesis of virus late gene products [202]. Indeed at longer times of cell 
culture with AraC or untreated VV, we noted less inhibition with the AraC treated 
cultures suggesting a virus late gene may be involved (Fig. 4A). Viral particles contain 
several abundant late proteins which are carried into cells and often promote infection 
[204]. To examine if these virion proteins must be in their native conformation, VV was 
heat treated (60˚C for 1 h).  Heat-inactivated VV has been used as a control for studies 
with live VV [205]. VV that has been heat-inactivated can not form plaques and is 
generally thought to be non-antigenic [206]. As shown in Fig. 4B, heat-inactivated VV 
was less effective in blocking GAD Ag presentation compared to live VV. Thus, the 
native structure and virion infection appear to be important. In subsequent studies, we 
found even heat treated virus enters cells, thus the most likely requirement is virion 
protein conformation or function. 
  
 
 
 
 
 
 
 
 
 
 
CD1-mediated lipid presentation pathway is also disrupted by VV [90]. CD1 molecules 
are structurally similar to class I while behaving like class II molecules by using the 
endosome-lysosomal pathway. The CD1 family is divided into three groups. The group 2 
member CD1d molecules are expressed on hematopoietic cells, hepatocytes and 
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Fig. 4 Viral factors contributing to the inhibitory property of VV. A. Inhibition of 
DNA replication and late gene expression partially preserved class II function. 
PriessGAD cells were treated with VV +/- the viral DNA polymerase inhibitor-
arabinosylcytosine (AraC, 10 µM) for 0, 6 and 14h. T cell assay was performed to 
monitor GAD presentation. B. Heat inactivation of VV ablates the ability of the virus 
to disrupt the class II pathway. VV, untreated or heat inactivated, was incubated with 
PriessGAD cells for 6 h prior to T cell addition and assays for T cell activation.  
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gastrointestinal epithelium [89]. CD1d molecules present lipids to invariant Vα24-Jα18 
TCR containing NKT cells [14], like class II molecules present peptide to CD4 T cells 
(Fig. 5A). Activated NKT cells fulfill their function by secreting Th1 and Th2 cytokines. 
Like the disruption of class II presentation, VV also perturbs CD1d-mediated lipid 
presentation. It has been demonstrated that the products two viral genes, B1R and H5R, 
may be involved in VV-induced CD1d dysfunction [90].  B1R is an early viral gene 
encoding a kinase required for viral replication [207, 208]. The H5R gene product, a 
substrate of B1 kinase, is a transcription factor expressed at both early and late stages and 
is involved in the transcription of VV late genes [209, 210]. We tested if viral B1R and 
H5R genes were necessary for class II perturbation using temperature sensitive (TS) 
mutants. Neither B1 nor H5 proteins were necessary for class II inhibition since at both 
permissive (31˚C) and non-permissive (38˚C) temperatures, GAD Ag presentation was 
equally disrupted using the TS mutant viruses and VV (Fig. 5B). Specifically, about 20% 
GAD presentation remained when PriessGAD cells were infected with viruses (MOI=1) 
and less than 10% remained when cells were infected with higher MOIs independent of 
B1 and H5 protein function. These results were also consistent with our previous study 
showed that VV disrupted class II presentation is independent of viral replication [97].  
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1.4 Inhibition of class II function by VV is not due to EBV-associated genes in B-
LCL 
 
Our studies demonstrated similar losses in class II function upon VV infection of human 
or murine cells. Yet there remained some concerns that the human B-LCL examined in 
our studies expressed Epstein Barr virus (EBV) gene products as result of their 
transformation using this virus. Thus, studies were carried out to examine the effects of 
VV infection using a human B cell tumor line lacking EBV genes. BJAB is a human B 
cell tumor line which does not express hallmark EBV Ags such as EBV nuclear antigen 
(EBNA) associated with EBV transformation [211]. BJAB cells were retrovirally 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 The effect of virus B1 and H5 proteins on class II presentation. A. Ag 
Presentation by class II and CD1d pathway. Processed peptide is presented by class II 
molecules on the surface of APC to CD4 T cells, which express Ag specific TCR.  
Interaction between co-stimulatory molecules is required for CD4 T cell activation 
(Left panel). Lipid Ag is presented by CD1d containing cells to NKT cells expressing 
invariant TCR (Right panel). B. Inhibition of endogenous GAD presentation was 
independent of virus B1R and H5R gene product functional expression. PriessGAD 
cells were infected with VV or temperature sensitive mutant viruses (MOI 0 to 10) for 
6 h at permissive (31˚C) or non-permissive (38˚C) temperature prior to T cell assay. 
Viral mutants with temperature sensitive B1 and H5 proteins were obtained from Dr. 
R. Brutkiewicz, IUSM.  
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transduced with class II DR4 for these studies and surface expression of class II 
molecules was confirmed by flow cytometry. GAD peptide presentation was dramatically 
inhibited by VV infection (MOI=10) of BJAB-DR4 cells (Fig. 6A). Similar to our results 
with EBV transformed B cells, virus inhibition of class II presentation could be partly 
reversed by adding higher concentration of peptide to BJAB-DR4 cells. Inhibition of 
GAD peptide presentation by BJAB-DR4 cells was similar to that observed with EBV+ 
Priess cells (Fig. 6B). Thus, we concluded that EBV transformation did not influence the 
ability of VV to disrupt class II presentation. Notably, as expected, the parent cell line 
BJAB, which lacks the appropriate class II DR4 molecules, failed to present GAD 
peptide even at the highest dose. This result confirms the specificity of our T cell assays 
using these B cell lines. 
 
  
 
   
  
 
 
 
 
 
 
 
 
 
 
1.5 Expression of key components of the class II pathway with VV infection 
 
Inhibition of host protein synthesis and recruitment of host resources to build virions are 
important cytopathic effects of VV. Inhibition of host protein synthesis is typically 
associated with virus early gene expression, and thus might correlate temporally with the 
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Fig. 6 VV inhibition of class II function was not influenced by EBV transformation 
of B cells. A. GAD peptide presentation was not affected by EBV transformation. 
BJAB or BJAB-DR4 cells were incubated with GAD peptide (up to 10 µM) +/- VV 
infection (MOI=10) for 6h before T cell addition and analysis of T cell activation. B. 
VV induced comparable inhibition of GAD presentation by Priess cells and by BJAB-
DR4. Priess and BJAB-DR4 cells were incubated with 0.5 µM or 10 µM GAD peptide 
respectively in the presence or absence of VV (MOI=10) for 6 h prior to T cell addition. 
Higher concentration of GAD peptide was used with BJAB-DR4 cells due to their 
lower expression of class II DR4 allele after retroviral transduction. Samples without 
VV infection were set to 100% for each cell line and relative peptide presentation upon 
VV treatment was measured. 
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loss of class II function in infected APCs. Reduction in components required for the class 
II pathway could be one mechanism by which the virus disrupts this pathway. Studies to 
evaluate the effects of VV on host protein synthesis were historically carried out in Hela 
cells or epithelial cell lines such as BSC [212, 213]. More recent microarrays of host gene 
expression examined Hela cells and DCs upon VV infection [109, 214].   
 
To examine the expression of components of class II pathway upon VV infection, 
Western analysis was applied using specific Abs. Protein levels for both MHC class I and 
class II molecules were assessed during 24 h of VV infection. VV infection did not 
significantly diminish steady state expression of MHC class II DRα monomers or DRαβ 
dimer levels up to 24 h (Fig. 7A and B). Surface class II levels as detected by flow 
cytometry were not altered by VV infection [97]. The constant surface expression of class 
II molecules even after 24 h VV infection was also demonstrated for murine 1153 and 
TA3 B cell lines using flow cytometry (data not shown). The relatively high stability or 
long half-life of assembled class II, for example, class II complexes in human B cells 
display half-life of approximately 36 h [215], may account for the preservation of these 
proteins upon VV infection. Quantification of the data in Fig. 7B confirmed that human 
class II DRα monomer, DRαβ dimer, MHC class I heavy chain and endogenous Ag GAD 
expression remained constant up to 24 hours after VV infection. VV protein expression, 
on the other hand, increased progressively.             
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Fig. 7 Sustained expression of MHC molecules and GAD protein during VV 
infection. A. MHC class I, class II and GAD steady state expression was maintained 
during VV infection. PriessGAD cells were infected with VV (MOI=10). Samples 
were immunoblotted to detect MHC class II DRα; DRαβ complexes; MHC class I; 
GAD; VV late proteins (30-35 KD) and actin. B. Densitometric analysis of protein 
expression.  For samples in panel A, each protein’s abundance at 0 and 24 h was 
calculated relative to actin as a control for loading.  Protein abundance at time 0 h 
was normalized to 100% for comparison with samples exposed to VV for 24 h. 
Standard error in densitometry for replicate studies was ≤ 15%.
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In contrast to host protein abundance, most cellular mRNAs decreased significantly after 
VV infection. For example, as shown in Fig. 8A, HLA-DRA (encoding DRα) mRNA 
abundance was reduced gradually over time following VV infection. mRNA for house 
keeping genes like ACTA1 (encoding actin) and GAPDH (encoding glyceraldehyde-3-
phosphate dehydrogenase or GAPDH) also dropped progressively upon VV infection. As 
expected, mRNA for viral E3L was detected early during infection. Messages for some 
host genes including HSPA10 (encoding heat shock cognate protein 70 or HSC70) did 
not change up to 14 h after infection, therefore the message for this gene was used as a 
loading control in RNA analysis. To more accurately estimate the alteration in HLA-
DRA mRNA, real time PCR was applied. Again, HLA-DRA mRNA levels diminished 
progressively post VV infection using HSPA10 as the endogenous control (Fig. 8B). A 
reduction in mRNA for MHC class II was also confirmed in an in vivo VV infected 
mouse model. C57BL/6 mice were infected with VV (i.p.106 pfu/mouse) up to 2 d. 
Spleen cells from these animals were harvested and used to isolate different APC 
populations. Murine class II gene H2-Ab1 (encoding I-Ab) mRNA decreased in a time 
dependent manner for DCs and B cells. The H2-Ab1 mRNA reduction was not 
significant in macrophages (Fig. 8C). To examine H2-Ab1 mRNA alteration in more 
detail, a shorter time course of in vivo infection was used to assess class II mRNA in DCs 
(Fig. 8D). Again, H2-Ab1 mRNA abundance was reduced progressively after infection. 
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Fig. 8 Reduction in class II mRNA upon in vitro and in vivo VV infection. A. 
Alteration in cellular and viral mRNAs after VV infection. PriessGAD cells were 
infected with VV (MOI=10) for up to 14 h and mRNA was isolated for semi-
quantitative RT-PCR using primers for HLA-DRA, ACTA1, GAPDH, HSPA10, and 
viral early gene E3L. Analysis was carried out with 32 amplified cycles for HSPA10 and 
28 cycles for all other genes. Viral E3L gene transcripts were assessed to confirm virus 
gene expression. Host HSPA10 expression was maintained during infection. B. 
Quantitative real time PCR analysis of HLA-DRA mRNA during VV infection. mRNA 
was isolated from PriessGAD cells infected with VV up to 14 h and converted to cDNA. 
cDNA was amplified with HLA-DRA and HSPA10 specific primers for up to 40 cycles. 
Quantification of HLA-DRA mRNA level was calculated relative to HSPA10 message 
level. 0 h or the non-infected sample was used as the calibrator. The results of three 
individual experiments were averaged. C. Decrease in H2-Ab1 mRNA in APCs after in 
vivo VV infection. Mice infected with VV (1×106 pfu/mouse) for up to 2 d were 
followed by harvesting of spleen cells. DCs, B cells and macrophages were isolated with 
corresponding Ab coated microbeads. Extraction of RNA and synthesis of cDNA was 
preformed prior to realtime PCR analysis. D. Progressive reduction in H2-Ab1 mRNA 
of in vivo infected DC detected by realtime PCR. Mice were infected with 1×106 pfu VV 
up to 24 h before isolation of DCs. For C & D, relative quantification of H2-Ab1 mRNA 
levels was normalized with Gapdh as the endogenous control. H2-Ab1 mRNA from 
non-infected or 0 d/h samples was used as the calibrator for comparison. At each time 
point, values were averaged from three mice in the same group. 
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1.6 Destabilization of peptide-class II complexes by VV 
 
Our previous study showed that VV destabilizes class II at an early stage of infection by 
disrupting peptide binding [97]. Since GAD peptide can directly bind cell surface class II 
without intracellular processing, we first examined the effect of VV on GAD peptide 
presentation. Functional assay showed a reduction in GAD peptide presentation upon VV 
infection (Fig. 9A). These results confirmed that VV may disturb the binding of peptide 
to class II. To further prove the destabilization of peptide-class II complexes by VV, the 
presentation of different influenza hemagglutinin (HA) peptides were tested in the 
absence or presence of VV (Fig. 9B). These HA peptides bind class II with different 
stabilities [190]. VV inhibition of wild type (WT) HA (half-life of peptide:I-Ad 
complexes is 26 h) presentation was more significant (about 50%) than that of the more 
stable HA mutation-T128V (TV) (half life of peptide:I-Ad complexes is 85 h) 
presentation (about 28%). Thus, stability of peptide association with class II molecule 
was another factor affecting VV disruption of class II function. The peptides that can 
form more stable complexes with class II molecules were more resistant to VV inhibition. 
These results proved indirectly that VV may disturb class II function by destabilizing 
class II-peptide complexes.  
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Fig. 9 VV infection of APC disturbed class II-peptide presentation. A. The effect 
of VV on GAD peptide presentation. Priess cells were incubated with GAD peptide 
(up to 10 µM) and VV (MOI=10) for 6 h. Cells were washed, fixed, co-cultured with 
GAD specific T cells and assayed for T cell activation. B. Stable peptide-class II 
complex was relatively resistant to VV infection. TA3 cells were co-incubated with 5 
µM of wild type HA peptide (WT) or T128V mutated HA peptide (TV) and VV 
(MOI=10) for 14 h prior to the addition of HA specific T cells and analysis of the T 
cell activation. Relative T cell responses for each peptide were normalized to no VV 
samples as 100%. 
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Together the data presented in this chapter confirm that APCs but not T cells were 
vulnerable to VV infection. VV disrupted class II mediated peptide and Ag presentation 
by immortalized cell lines and primary APCs, heat treatment destroyed the ability of VV 
to perform this activity. The efficacy of inhibition positively correlated with the level of 
cellular infection. Virus replication and early gene products were not required for 
disrupting class II function. Yet, native virions and possibly viral late gene products 
appear to be important in disrupting class II presentation. EBV transformation did not 
affect the ability of VV to disrupt class II function. VV reduced class II expression at 
mRNA levels but not at protein levels. Destabilization of peptide-class II binding is one 
of the mechanisms VV used to disturb class II -mediated Ag presentation.  
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Chapter 2 Loss of invariant chain (Ii) upon VV infection of APCs 
 
Ii is essential for the class II pathway by chaperoning both class II and DM molecules. Ii 
expression level correlates positively with the class II presentation ability [20-22]. 
Stabilization of class II dimers is one of the most important functions of Ii.  Previously, 
we showed that VV destabilizes peptide-class II complexes. Thus, we explored whether 
VV induces class II destabilization by affecting Ii.  Indeed, consistent with the VV 
induced destabilization results, a significant reduction in Ii at the protein and mRNA 
levels was found. To further demonstrate the adverse effects of disrupting protein 
synthesis on Ii expression and class II function, a classical protein synthesis inhibitor-
cycloheximide (CHX) was used. CHX mimicked the inhibitory effects of VV in term of 
Ii protein level and class II function. Yet, there were significant differences in how VV 
perturbs the class II pathway, suggesting virus infection alters more than host protein 
synthesis. Apparent differences in Ii proteolysis were observed with VV and CHX 
treatment of APCs. Only VV but not CHX altered Ii processing. Virus infection led to 
losses in the expression of specific cathepsins required for Ii and Ag processing, while 
Cathepsin L is induced. Likely, the reduction in Ii expression during VV infection is 
caused by changes in both synthesis and processing. Over-expression of Ii partially 
reversed VV-induced class II dysfunction, further confirming the contribution of Ii loss to 
the disruption of class II function.  
 
2.1 Diminished Ii levels in VV-infected APCs  
 
Upon screening the expression of several components of class II presentation pathway by 
Western analysis, we observed a significant reduction in Ii protein expression. As shown 
in Fig. 10A, the steady state level of cellular Ii decreased in a time dependent manner 
upon VV infection of PriessGAD cells. Ii protein levels were slightly decreased at 2 h of 
infection with an even more significant drop between 8-12 h. Densitometric 
quantification revealed a 15% reduction in cellular Ii expression at 2 h and an 80% 
decrease in Ii levels 12-14 h following VV infection. Since Ii is crucial for class II Ag 
presentation, the loss of Ii may contribute in part to VV disruption of MHC class II-
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mediated Ag presentation, particularly at later stages of viral infection. To further 
examine the correlation between class II dysfunction and Ii reduction upon VV infection, 
the expression of Ii and other components along the Ag presentation pathway was 
compared using VV or UV-irradiated VV. Our previous study had shown that UV-treated 
VV diminished class II function to a level slightly less than untreated VV [97].  As 
shown in Fig. 10B, the reduction in cellular Ii for PriessGAD cells treated with UV-
inactivated VV was less severe compared with cells infected by VV. Again class I and II 
protein levels remained constant. The partial preservation of Ii may possibly explain the 
decreased perturbation of class II mediated Ag presentation by UV-treated VV. Another 
method to block VV replication is to use a viral specific polymerase inhibitor, 
arabinosylcytosine (AraC). AraC treatment of VV also blocks synthesis of viral late 
genes. Similar to the effect of UV treated VV, AraC partially preserved Ii expression 
(Fig. 10C). The effects of AraC were observed post 6 h infection, when virus replication 
and late protein expression occur. Thus, we conclude that loss of cellular Ii at later stages 
of infection appears to be linked to class II dysfunction. 
 
To monitor the synthesis of Ii upon VV infection, a [35S]-methionine incorporation assay 
was performed. Here, PriessGAD cells were infected with VV for up to 14 h with 
radiolabeled methionine added at different times prior to immunoprecipitation of Ii and 
class II proteins. At 6 h, VV infection decreased Ii synthesis significantly yet DR 
synthesis was preserved (Fig. 10D). Even at 14 h, synthesis of new class II is detected but 
little if any Ii could be isolated from infected cells. To determine if the reduction in Ii 
expression was due to a global inhibition of host gene expression by VV, the relative 
abundance of CD74 (encoding Ii) mRNA was measured using semi-quantitative RT-PCR 
analysis. CD74 mRNA levels progressively decreased upon VV infection temporally 
preceding the drop in Ii protein expression (Fig. 10E). By contrast, host HSPA10 
(encoding HSC70) mRNA levels did not change up to 14 h after VV infection. To more 
accurately detect alterations in CD74 mRNA levels after VV infection, real time PCR 
was performed using HSPA10 as the endogenous control. Quantification of CD74 mRNA 
revealed a 65% decrease after 6 h and an 80% drop after 10 h post VV infection (Fig. 
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10F). These results indicate that the diminished expression of host CD74 mRNA 
contributed to the reduced steady state levels of Ii protein during VV infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10 VV infection reduced Ii expression at both the protein and mRNA levels. 
A. VV reduced Ii steady state protein levels during infection of APC. Samples of 
PriessGAD cells infected with VV for up to 14 h were Western blotted for Ii 
expression. Actin was used as the loading control. Densitometric quantification of Ii 
protein expression was calculated relative to actin abundance at each time point after 
VV infection of B cells (averaged from three separate experiments). B. Relative less 
loss of Ii upon cell exposure to  UV-irradiated VV. PriessGAD cells were incubated 
with VV or UV treated VV at MOI 10 for 14 h prior to Western Blot analysis using 
specific Abs to Ii, MHC class II DRα, class II DRαβ dimers, MHC class I, VV and 
actin. Densitometric analysis of protein expression is listed besides the blots.  Each 
protein’s abundance was calculated relative to actin. Treated samples were normalized 
to control, untreated samples which had been set as 100%. C. Inhibition of DNA 
replication and late gene expression partially preserved Ii expression. PriessGAD cells 
were treated with VV +/- the viral DNA polymerase inhibitor –AraC (10 µM) for 0, 6 
and 14h. Western blot analysis was performed to monitor Ii expression. Quantification 
of Ii protein expression was calculated relative to actin abundance at each treatment 
(averaged from three experiments). 
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The observed reduction in cellular Ii upon VV infection was not limited to PriessGAD 
cells. When other human B-LCL such as Raji and Frev were tested, similar decreases in 
Ii expression were observed (Fig. 11A). To further investigate whether Ii reduction is a 
general phenomenon observed in primary cells upon in vitro VV infection, Ii protein and 
mRNA levels were monitored in human PBMCs and murine splenic cells following VV 
infection. To purify these APCs from peripheral blood or tissues, T cells were depleted 
from the total cell population with either microbeads coated with Abs to CD3 (for human 
PBMCs) or CD4 plus CD8 (for murine splenic cells). Similar to what was observed in B-
LCL, Ii expression in human primary APCs dropped remarkably at both the protein and 
mRNA level upon VV infection (Fig. 11B). However, in total murine splenic APCs, Ii 
protein levels remained unchanged upon VV infection (Fig. 11C to E). Several methods 
were used to isolate and treat the murine APCs including: isolating live cells using Ficoll 
or isolation of B cells using microbeads coated with B220 Abs (Fig. 11C) or pre-
activating APCs with LPS, a Toll like receptor ligand, before infection with VV (Fig. 
11E). Notably, Ii protein in murine APCs remained unchanged even following VV 
infection at the highest dose (i.e. MOI=10) and the longest time (i.e. 24 h) as shown in 
Fig. 10 legend (Cont’). D. Exposure of B cells to VV decreased the synthesis of Ii 
protein between 2-6 h. PriessGAD cells were infected with VV for 0 - 14 h, and at 
specific times (0, 2, 6, 14 h) aliquots of cells were labeled with 0.5 mCi of [35S]-
methionine for 1 h. Following this brief radio-labeling, cells were washed and detergent 
lysates prepared. Cell lysates were immunoprecipitated with Abs specific for Ii or class 
II proteins and these immunoprecipitated samples were resolved by SDS-PAGE. 
Electorphoretic gels were fixed, stained with Coomassie Blue and dried prior to 
autoradiography. Proteins loaded in each sample lane were monitored by Coomassie 
Blue staining and as shown here, support equal sample loading. Quantification data of 
relative abundance of Ii or DR normalized to loading controls is listed besides. 0 h 
samples were set equal to 100%. E. VV infection reduced B cell CD74 mRNA levels in 
a time dependent manner. PriessGAD cells were infected with VV (MOI=10), mRNA 
levels for CD74 and HSPA10 were analyzed by RT-PCR. Data shown after mRNA 
amplification for 28 cycles for CD74 and 32 cycles for HSPA10. The relative abundance 
of HSPA10 mRNA was tracked as the loading control. F. Quantitative real time PCR 
analysis of CD74 mRNA during VV infection. mRNA was isolated from PriessGAD 
cells infected with VV for 0-14 h and converted to cDNA for amplification with CD74 
and HSPA10 specific primers for 40 cycles. Quantification of CD74 mRNA levels was 
determined relative to HSPA10 message levels. Data were averaged from three separate 
experiments.  
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Fig. 11D. UV irradiated VV was tested in parallel with VV in each of the studies with 
murine APCs and no alteration in Ii protein was observed (data not shown). The constant 
expression of surface and intracellular Ii in murine splenic APCs after incubation with 
VV or UV irradiated VV was also demonstrated by flow cytometric analysis (data not 
shown). While the half-life of human Ii is about 1-2 h [216, 217], the half-life of murine 
Ii is longer than 2 h [218]. The increased stability of murine Ii protein compared to 
human Ii may account for this discrepancy. Murine Cd74 (encoding Ii) mRNA, however, 
increased after LPS stimulation and was reduced upon VV infection as expected (Fig. 
11E). Thus, it is likely over longer times, Ii protein expression would drop for these 
murine APCs. 
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To examine whether Ii expression was regulated during in vivo VV infection, we assessed 
Ii expression in primary murine APCs isolated from animals that received i.p. VV. 
Following in vivo VV infection (2 d for all APC types or 24 h for DCs only), animal 
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Fig. 11 Loss of Ii in B-LCL, human and murine primary APC with VV infection. 
A. Human B-LCL Raji or Frev cells were infected with VV (MOI=10) for 14 h prior to 
Western Blot analysis with Ii, VV and actin specific Abs. B. Reduction of Ii protein and 
mRNA in human primary APC post VV infection. PBMCs were depleted of T cells 
prior to infected with VV at MOI=5 for 14 h followed with Western Blot analysis (left 
column) or RT-PCR (right column). GAPDH and HSPA10 were used here as the 
loading controls for proteins and mRNAs respectively. C. Ii protein remained constant 
in VV infected total murine primary splenic APC with confirmed viability and B cells. 
Murine splenic cells were depleted of T cells then selected with ficoll reagent (left 
column) or microbeads  coated with B220 Abs (right column) to isolate B cells 
followed with VV (MOI=1) infection and Western Blot analysis. D. The abundance of 
murine Ii protein did not change up to 24 h infection with VV. Splenic cells depleted of 
T cells were infected with VV up to MOI 10 for 24h before Western Blotting analysis. 
E. Ii protein remained constant while Cd74 mRNA altered in LPS pre-activated and VV 
infected splenic cells. Splenic cells without T cells were pre-incubated with LPS (1 
µg/ml) for 24 h prior to addition of VV (MOI=5) for 14 h. Western blot analysis (left 
column) and RT-PCR analysis (right column) were performed for detecting Ii 
expression. Quantification data is listed for Ii expression (protein/mRNA) under 
corresponding panels. Abundance of Ii was normalized to loading controls, i.e. 
actin/GAPDH for protein or HSPA10/Gapdh for mRNA. Abundance of Ii in samples 
without treatment was set equal to 100%. Experiments were repeated for at least three 
times. 
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spleens were harvested and different APC populations were isolated using Ab coated 
microbeads. Cd74 (encoding Ii) mRNA levels following infection were assessed using 
real time PCR.  As shown in Fig. 12A, Cd74 mRNAs decreased in a time dependent 
manner in each of the APC populations. The most significant reduction in Cd74 mRNA 
occurred in B cells and DCs.  Cd74 mRNA also diminished progressively when DCs 
were infected for a shorter time period (Fig. 12B).  These studies are consistent with in 
vitro infection experiments suggesting viral infection decreases Ii expression at mRNA 
levels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The main function of Ii is to chaperone class II molecules along the antigen presentation 
pathway. Since total Ii protein levels decreased significantly upon VV infection of human 
APCs, the amount of functional Ii or class II DR associated Ii, was assessed using an 
immunoprecipitation assay. DR bound Ii, similar to total Ii, was remarkably reduced 
upon VV infection in a time dependent manner. Total class II DR protein, however, 
remained constant (Fig. 11). Reduced DR associated Ii protein following VV infection 
further suggested that diminished Ii might contribute to the disruption of class II function. 
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Fig. 12 Loss of Cd74 mRNA upon in vivo infection of APC. A. Progressive reduction 
of Cd74 mRNAs in different APC after in vivo VV infection. The infection of mice, the 
isolation of APC, the extraction of RNA, and the synthesis of cDNA were same as 
described in Fig 8C. Real time PCR was performed using murine Cd74 and Gapdh 
specific primers. B. Loss of Cd74 mRNA in DC after in vivo VV infection. Mouse 
infection, DC isolation and cDNA preparation were performed as in Fig. 8D. For A & B, 
relative quantification of Cd74 mRNA levels was normalized with Gapdh as the 
endogenous control. Cd74 in non-infected or 0 d/h sample of each APC population was 
used as the calibrator and set up as 1. All other time points were calculated compared 
with the calibrators. In each time point for each population, three mice were included. 
Data shown here are representatives from at least three separate experiments. Cell and 
mRNA samples for this study were prepared by Drs. Yongxue Yao and Ping Li.  
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The residual Ii that existed in cell lysates after DR Ab pulldown also decreased in a time 
dependent manner post VV infection. This may represent Ii associated with class II DP or 
DQ molecules or free Ii. The decrease in this pool of Ii appeared to occur even more 
quickly than the loss of DR-Ii molecules. There was no residual DR protein detected after 
DR Ab pulldown confirming that the precipitation using the DR specific Ab was efficient 
(Fig. 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
A previous study showed that some class II alleles aggregate in the endoplasmic 
reticulum of spleen cells from Ii deficient mice [35]. To investigate whether the reduced 
expression of Ii by VV could result in DR aggregation, PriessGAD cells were infected 
with VV (MOI=10) for up to 14 h. Following infection, DRα and DRαβ protein 
expression was assessed by Western analysis. If aggregation occurs, class II positive 
bands with larger molecule weights will aggregate near the top of SDS-PAGE gel. Under 
these conditions, we failed to detect aggregation of class II molecules. As shown in Fig. 
14A, no aggregation was observed up to 14 h post VV infection. Other studies have 
shown that DM, another important factor along the class II pathway, is also chaperoned 
by Ii [35, 42, 43]. Since VV decreased Ii expression significantly, we tested if VV 
infection could also affect DM expression.  To determine if DM protein levels change 
upon VV infection, PriessGAD cells were infected with VV (MOI=10) for 14 h followed 
VV infection (h)
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Fig. 13 Reduction of functional Ii levels upon VV infection. PriessGAD cells were 
infected with VV (MOI=10) for up to 14 h followed by immunoprecipitation (IP) with 
DR specific Ab-DA6.147. Ii associated with these Ab captured class II were detected 
by Western analysis. Residual Ii represents Ii proteins left in cell lysates after class II 
Ab pulldown. Cell lysates were resolved on SDS-PAGE and immunoblotted (IB) with 
Ii specific Ab Pin1.1 or DR specific Ab DA6.147. The quantification of DR bound Ii 
and residual Ii normalized to DR is list below the graph. 0 h samples were set equal to 
1. Data shown here is representative of five individual experiments.  
 63
by Western analysis and flow cytometry. Both methods failed to detect any alteration of 
DM expression upon VV infection (Fig. 14B and C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thus, in vitro VV infection reduced Ii mRNA and protein expression levels in human B-
LCLs and PBMCs without inducing DR aggregation or reduction in DM protein levels. 
DR associated Ii also diminished upon VV infection. Both in vitro and in vivo VV 
infection led to Cd74 mRNA reduction in primary murine cells. Little loss of murine Ii 
protein was observed using primary murine cells. However there may be a decrease in Ii 
protein expression in a longer period. Other class II pathway components only decreased 
at the mRNA level during VV infection. 
 
VV infection time (h)
0                 14
DM
VV
Actin
BVV infection (h)
0   2    6   8   10  12  14
DR αβ
Actin
DRα
A
10 0 10 1 10 2 10 3 10 4
FL2-Height
Isotype
Cont.
VV (MOI=10) 14 h
Isotype
VV
Cont.
C 
 
 
 
 
 
Fig. 14 No aggregation of class II DR or changes in the expression of DM upon VV 
infection. A. The expression of DR upon VV infection. PriessGAD cells were 
incubated with VV (MOI=10) for 0 to 14 h. Cells were harvested, lysed, samples mixed 
with non-reducing SDS buffer without boiling, and resolved on SDS-PAGE. After 
transfer to nitrocellulose membranes, the blots were probed with DRαβ Ab-L243, actin 
Ab and DRα Ab-DA6.147. DRαβ dimers of approximately 55-60 KD as well as DRα 
monomers (35 KD) were found without protein aggregation. B. DM protein expression 
upon VV infection. PriessGAD cells were cultured +/- VV (MOI=10) for 14 h, cells 
harvested, lysed and protein samples then immunoblotted using DM specific Ab. VV 
proteins were detected as evidence of infection. Actin was used as the loading control. 
C. Intracellular DM protein levels upon VV infection. PriessGAD cells were infected as 
in panel B. Cells were permeabilized with 0.05% saponin containing PBS for 15min. 
Permeabilized cells were then stained with Ab to DM or isotype control Abs for 30 m 
followed by the 2nd PE-conjugated rabbit anti-mouse Ig G at 1:1000 dilution in buffer 
containing 0.05% saponin. Finally flow cytometric analysis were performed. Dash line 
represented the non-infected cells while dark line represented infected cells. The shaded 
histogram represented isotype-matched irrelevant Ab staining of control or infected 
cells. Intracellular DM expression was unchanged after VV infection. At least five 
separate experiments were repeated for each panel. 
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2.2 Inhibition of class II function and reduction of Ii protein expression by CHX 
treatment of APCs 
 
VV inhibition of class II-mediated Ag presentation as well as Ii expression, led us to 
propose that this observed reduction in Ii synthesis may contribute in part to class II 
dysfunction. The protein synthesis inhibitor - CHX was used to further explore the 
relationship between Ii expression and class II function. CHX interrupts both the 
initiation and extension of de novo protein synthesis at the translational stage [107, 108].  
Earlier studies with murine cells showed that CHX  perturbs class II presentation of 
native Ags but not peptides [22, 44]. Thus, here using human cell lines, the effects of 
CHX on class II presentation of exogenous and endogenous Ags as well as peptides were 
tested. In addition, the effect of CHX on the expression of Ii and other components of the 
class II Ag presentation pathway was assessed. First, a [3H]-labeled leucine and lysine 
incorporation assay was used to select the optimal concentration of CHX for treating 
cells. Priess or PriessGAD cells were labeled with [3H] leucine and lysine in media with 
different concentrations of CHX. These studies suggested that as early as 6 h after CHX 
exposure, human B cell protein translation is markedly reduced. At longer times of 
treatment, CHX induced cytopathic effects hence our studies were limited to cells treated 
with CHX for 6 h. Cells were harvested after a 6 h incubation +/- CHX, and protein 
synthesis was quantified as the amount of [3H] labeled amino acid in the cells. CHX 
decreased both Priess and PriessGAD cellular protein synthesis in a dose dependent 
manner (Fig. 15A). At a concentration of 10µg/ml, CHX efficiently decreased cellular 
protein synthesis with minimal effects on cell viability (>90% of cells were viable as 
detected by trypan blue). Thus 10 µg/ml CHX was used as a working concentration in the 
following biochemical and functional experiments. CHX treatment inhibited endogenous 
GAD Ag presentation in a time dependent manner (Fig. 15B). CHX treatment for 30 m 
reduced the presentation of endogenous GAD by about 45% compared to the 0 h group. 
To investigate whether CHX inhibition of the class II pathway is a general phenomenon, 
HSA Ag presentation by class II was investigated. Notably, presentation of the HSA 
peptide was more efficient than that of the full length protein, the latter requires increased 
processing before presentation. Yet, CHX disrupted both HSA peptide and protein 
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presentation significantly, with a higher dose of HSA peptide partially able to 
compensate for this inhibitory effect. The efficacy of CHX inhibition was greater for the 
HSA protein than for the HSA peptide possibly suggesting that protein translation is 
required for Ag processing as well as peptide association with class II (Fig. 15C). The 
presentation of another peptide-GAD was more resistant to CHX inhibition. As shown in 
Fig. 15D, at 1 µM of GAD peptide, only a 30% loss in class II function was observed in 
comparing Priess cells treated with CHX and a control group of cells. Again, CHX 
inhibition was diminished when the dose of GAD peptide was increased. These studies 
are similar to work with murine cells, except for the observed CHX sensitivity of peptide 
presentation by human B cells  [22, 44]. The susceptibility of HSA peptide presentation 
to CHX inhibition  may be due to a requirement for the HSA peptide to be internalized 
and processed by APCs in early endosomes before presentation by class II molecules 
[219].  Yet other peptides including GAD can  directly bind to surface class II molecules 
independent of processing [220]. Studies using protein Ag suggest CHX inhibition of 
class II presentation was somewhat dependent on the source of Ag. Presentation of an 
abundant endogenous SMA, a mutated form of Ig κ, was not effected by treatment of 
cells with CHX (Fig. 15E). Similarly, class II presentation of a high affinity peptide, κ II, 
was also resistant to CHX exposure (Fig. 15F). These studies suggest a selectivity to 
CHX inhibition of class II function. Using peptides at high concentrations or using a high 
affinity ligand (such as κ II), the inhibitory effects of CHX can be overcome.  
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Fig. 15 Inhibition of class II-mediated Ag presentation by CHX. A. CHX decreased 
cellular protein synthesis in a dose dependent manner. Priess and PriessGAD cells were 
grown in L-lysine [4,5-3H] and L-leucine [3,4,5-3H] containing media with increasing 
concentrations of CHX for 6h. Cells were harvested, transferred to 96-well plates, these 
samples were frozen overnight prior to capture of the lysed cell material on filters for 
quantitative analysis of [3H]-incorporation. B. The inhibitory effect of CHX on 
endogenous GAD Ag presentation. PriessGAD cells were incubated with 10 µg/ml CHX 
for 6 h, fixed with paraformaldehyde, then co-cultured with GAD specific T cells. T cell 
activation was measured as described in Materials and Methods. C. CHX treatment 
disrupted HSA epitope presentation. Priess cells were incubated with 0-10 µM HSA 
peptide or protein +/- CHX for 6 h prior to fixation, washing and the addition of HSA 
specific T cells. D. Inhibition of GAD peptide presentation by CHX. Priess cells were 
cultured with 0-10 µM GAD peptide +/- CHX for 6 h prior to fixation, washing and the 
addition of GAD specific T cells. E. The effect of CHX on endogenous SMA Ag 
presentation. Variable numbers of Frev/SMA cells which express SMA, a mutant form of 
Ig κ, were cultured +/- CHX for 6 h before fixation, washing and the Ig κ II specific T cell 
addition. F. The effect of CHX on Ig κ II peptide presentation. Frev cells were incubated 
with 0-10 µM Ig κ II peptide +/- CHX for 6 h before fixed, washed and co-cultured with 
Ig κ II specific T cells. Experiments were repeated at least three times. 
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After confirming functional inhibition of class II upon CHX treatment of APCs, the 
effects of CHX on the expression of key components from the class II pathway were 
addressed. As shown in Fig. 16A, expression of many cellular proteins remained constant 
up to 6 h following CHX treatment. Steady-state protein expression was unchanged by 
CHX treatment for molecules such as class II, class I, endogenous GAD Ag and DM. 
Maintenance of DM expression was also confirmed by flow cytometry (data not shown). 
Similar to VV infection, CHX treatment decreased Ii protein levels in a time dependent 
manner (Fig. 16B). After treatment with 10 µg/ml CHX, 70% of Ii protein remained at 30 
m, 22% remained at 2 h and 10% remained at 6 h. This time course correlated with the 
decreased function of class II molecules (Fig. 15B). Not only total Ii, but also functional 
Ii (DR bound Ii) and residual Ii expression was reduced upon CHX treatment (Fig. 16C). 
Residual Ii may represent a free pool of Ii or Ii associated with class II DP and DQ 
molecules. Consistent with CHX inhibiting at the level of cellular translation, cellular 
mRNA for Ii did not change up to 6 h post CHX treatment. As shown in Fig. 16D, 
mRNAs for CD74, HLA-DRA and ACTA1 all remained constant in CHX treated cells. 
Similar to VV infection, CHX treatment failed to induce DR aggregation (Fig. 16E).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16 Legend see next page. 
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Thus, CHX decreased class II function and Ii protein expression as had been observed 
following VV infection of human B cells. CHX appears to act quickly to halt host protein 
synthesis, possibly explaining why CHX more rapidly disrupts class II function and Ii 
expression. Like VV, CHX blocked Ag and peptide presentation, although some 
selectivity was observed. Thus, at high concentration of some peptides, the effects of 
CHX were overcome. High doses of peptide also overcome VV disruption of class II 
function. Several proteins required for the class II pathway remained constant upon CHX 
treatment, yet a loss of Ii protein expression after CHX treatment of cells, mirrored a loss 
in class II function. In addition, no aggregation of class II or reduction in DM expression 
was observed. Consistent with its activity at the translational level, CHX did not change 
host mRNA expression.  
Fig. 16 CHX rapidly reduced cellular Ii protein levels without changing MHC 
class II expression. A. Class II as well as class I protein expression remained constant 
upon CHX treatment of B cell lines. PriessGAD cells were treated with CHX (10 
μg/ml) for 6 h and lysed for Western blot analysis. Actin protein expression was used 
as a control for sample loading. Densitometric analysis of protein expression is listed 
beside the blots.  Protein abundance at 6 h plus CHX was compared with 0 h samples 
using actin as the endogenous loading control. Data is representative of six 
experiments. B. CHX treatment of APC rapidly reduced Ii protein levels. PriessGAD 
cells were treated with CHX (10 μg/ml), followed by Western blot analysis using an Ii-
specific Ab. The average abundance of Ii steady state protein relative to cellular actin 
after CHX treatment of B cells from three independent studies is shown. C. Reduction 
of functional Ii and residual Ii upon CHX treatment. PriessGAD cells were treated with 
CHX (10 μg/ml) for up to 6 h followed by immunoprecipitation (IP) with DR specific 
Ab-DA6.147. Residual Ii represents Ii protein left in the cell lysates after DA6.147 
pulldown of class II. Cell lysates were resolved on SDS-PAGE, transferred to 
membranes and probed with Ii and DR Abs respectively. The quantification of DR 
bound Ii and residual Ii normalized with DR is listed below the graph. Samples from 0 
h were set as 1. Data shown here are representative from five individual experiments. 
D. CHX treatment of B cells did not change Ii mRNA levels. PriessGAD cells were 
treated with CHX (10 μg/ml) for up to 6 h and analyzed by RT-PCR using CD74, 
HLA-DRA and ACTA1 specific primers. ACTA1 was used as the loading control. 
Data showed were from 28 cycles of amplification. Quantification of CD74 mRNA 
levels after CHX treatment (average from three RT-PCR experiments) is shown. E. DR 
protein expression after CHX treatment. PriessGAD cells were incubated with CHX 
(10 μg/ml) for up to 6 h. Cells were harvested, lysed, mixed with non-reducing SDS 
buffer without boiling, resolved on SDS-PAGE and transferred to membranes, and 
probed with DRαβ Ab-L243, actin Ab and DRα Ab-DA6.147. Representative of six 
experiments are shown. 
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2.3 Comparing the effects of VV infection and CHX treatment on Ag presentation 
and Ii expression 
 
Both VV and CHX negatively influenced class II function and Ii protein expression. 
Kinetically, the inhibition of endogenous GAD presentation was similar upon VV or 
CHX exposure of APCs (data from Fig. 3B vs. Fig. 15B were replotted in Fig. 17A to 
facilitate comparison). However, differences existed between the two agents. For 
example, CHX inhibited Ii expression more rapidly than VV did (Fig. 10A vs. Fig. 16B 
replotted in Fig. 17B). Also, only VV but not CHX reduced CD74 mRNA levels (Fig. 
10E vs. Fig. 16D replotted in Fig. 17C).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To further compare the effects of VV and CHX on the presentation of Ags other than 
endogenous GAD, additional T cell assays were performed. Using HSA protein as shown 
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Fig. 17 Comparison of VV infection 
(MOI=10) and CHX (10 µg/ml) 
treatment of APC in functional 
assays of endogenous GAD 
presentation and Ii expression. A. 
Inhibition of class II presentation of 
endogenous GAD Ag. Data was 
replotted from Fig. 3B and Fig. 15B. 
B. Reduction in Ii protein expression. 
Data was replotted from 
immunoblotting studies from Fig. 
10A and Fig. 16B using actin as an 
endogenous control. C. The effects of 
VV and CHX treatment on B cell 
CD74 mRNA. Data was replotted 
from Fig. 10E and Fig. 16D using 
endogenous controls ACTA1 (for 
CHX treated samples) or HSPA10 
(for VV infected samples). For all 
figure panels, 0h samples were set 
equal 1. Subsequent samples were 
plotted relative to the 0 h samples.  
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in Fig. 18A, exposure of Priess cells to either VV or CHX similarly reduced exogenous 
Ag presentation. Pulsing APCs with higher concentrations of HSA protein partially 
overcame the inhibitory effects of CHX and VV (data not shown).  In contrast to VV 
infection, published studies have shown a reduction in class II mediated Ag presentation 
but not peptide presentation upon murine B cell exposure to CHX  [22, 44]. However, in 
the current studies with human cells, CHX treatments diminished HSA peptide 
presentation to a similar extent to VV (Fig. 18B). GAD peptide presentation on the other 
hand, was more vulnerable to down modulation by VV infection compared with CHX 
treatment (Fig. 18C). Both the HSA protein and peptide must be processed prior to 
presentation by class II, this may account for their enhanced sensitivity to CHX 
treatment. By contrast as indicated above, GAD peptide can directly bind class II. This 
may explain the relative resistance of GAD peptide presentation to CHX treatment. VV 
consistently inhibited the presentation of both HSA and GAD peptides. Thus, while both 
CHX and VV disrupt MHC class II-mediated Ag presentation by B cell lines, differential 
effects of these agents on the presentation of some peptides were observed.    
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Fig. 18 Both VV infection and CHX treatment of human B-LCL decreased MHC 
class II presentation. A. VV or CHX treatment of B cells inhibited exogenous HSA Ag 
presentation.  Priess cells incubated with HSA Ag (1µM) were treated with VV 
(MOI=10) for 14 h or CHX for 6 h prior to cell fixation with paraformaldehyde, then co-
cultured with HSA-specific T cells. T cell activation was measured as described in 
Materials and Methods. B. VV or CHX treatment of B cells inhibited HSA peptide 
presentation. Priess cells were incubated with HSA peptide (1µM) and VV for 14 h or 
CHX for 6 h prior to fixation and analysis of T cell activation. C. VV or CHX treatment 
of B cells inhibited GAD peptide presentation. Priess cells were incubated with GAD 
peptide (1µM) and VV for 14 h or CHX for 6 h before cell fixation, and the addition of 
GAD-specific T cells. T cell activation was evaluated.  For panel A-C, relative responses 
of T cell are shown for APC +/- treatment. For these studies, T cell activation for 
untreated or control samples were set to 100%. Data is representative of at least three 
separate experiments. 
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2.4 Alteration of Ii processing upon VV infection  
The observed differences in the steady state abundance of Ii after VV or CHX treatment, 
suggested that host synthesis inhibition may not be the only factor influencing Ii levels in 
VV treated cells. The proteolytic cleavage of Ii upon transit to endosomal compartments 
also influence Ii steady state abundance in B cells. It has been established that some viral 
proteins, such as human immunodeficiency virus type 2 (HIV-2) and simian 
immunodeficiency virus virion-associated protein Vpx, can interact with Ii and reduce Ii 
expression levels by elevating Ii degradation [221].  Therefore, Ii degradation may also 
contribute to the loss of this class II chaperone in VV or CHX treated cells. To address 
this possibility, B-LCL were exposed to VV or CHX in the presences of various agents 
known to block Ii proteolysis. Drugs such as brefeldin A (BFA), monensin (Mon), 
leupeptin (Leu) and chloroquine (Chl) block Ii maturation and processing at different 
stages, therefore the accumulation of full length and Ii fragments can be assessed in cells 
treated with these agents by Western analysis.  Specifically, BFA blocks protein transport 
from the ER to the Golgi complex by activating the GTPase Arf1p [222], and therefore 
inhibits Ii degradation completely [223]. Monensin is a carboxylic ionophore that traps 
proteins in the Golgi by disturbing Na+ and K+ exchange, thus Ii protein can not transit to 
endosomes like MIIC for degradation [26].  Leupeptin inhibits cysteine and serine 
proteases such as Cat B, Cat L, and Cat S competitively and reversibly in MIIC, 
consequently interrupting the terminal stages of Ii degradation and promoting the 
accumulation of leupeptin-induced peptide or LIP fragment [195, 224]. Chloroquine, a 
lysosomotropic drug, works as a weak base which is retained in acidic compartments, 
increasing the pH of endosomes and lysosomes [225, 226]. Thus chloroquine obstructs 
the early and late stages of Ii degradation by disrupting MIIC acidification [227].  
PriessGAD cells were pretreated with VV (MOI=10) for 2 h followed by the addition of 
BFA (50 ng/ml), Leu (500 μM), Mon (1 μM) or Chl (0.3 mM), and further incubation for 
an additional 12h. Following these treatments, Western analysis was performed with the 
Ii N terminal specific mAb - Pin1.1. For these studies, cells were inoculated with VV 
prior to drug treatments to minimize any effect of these agents on virus infection. For 
CHX treatment, PriessGAD cells were incubated with the above drugs for 1 h followed 
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by CHX (10 µg/ml) treatment for an additional 4 h. The effects of VV and CHX on the 
accumulation of full length Ii and the fragment of LIP are shown in Fig. 19A and B 
respectively. As shown in Fig. 19A, VV treatment of cells decreased full length Ii levels 
to 46% of that observed with control cells.  BFA, Leu, Mon and Chl cell treatments 
resulted in relative accumulation of full length Ii to 158%, 120%, 131% and 123% of 
control treated cells. Leu treatment of APCs as previously reported [195] resulted in Ii 
and LIP accumulation due to inhibition of endosomal-lysosomal proteases including Cat 
S. VV infection decreased the accumulation of full length Ii in BFA and Leu treated 
samples. For VV + BFA group, Ii levels decreased to 50% of BFA treatment alone; while 
for the VV + Leu group: Ii decreased to 60% of Leu treatment alone sample. These 
results suggest that VV did not radically affect the early steps (i.e. before LIP cleavage) 
of Ii processing.  LIP degradation, however, increased dramatically at this later stage of 
VV infection, i.e. only about 10% LIP was detectable after PriessGAD cells were treated 
with Leu and VV compared to those treated with Leu alone. Thus, VV infection may 
influence the late steps (i.e. after LIP cleavage) of Ii processing. Contrary to the 
significant reduction in full length Ii accumulation after BFA and Leu treatment, virus 
infection had significantly less effects on Mon or Chl induced Ii accumulation, i.e. 
cellular Ii levels remained at 90% after Mon or Leu treatment of VV infected cells. A 
recent study showed in addition to fusion at the plasma membrane at neutral pH, VV also 
enters host cells through a low-pH endosomal pathway. Monensin (10 μM), working as 
an endosomal acidification inhibitor, decreases VV entry by more than 70% [78]. Since 
Chl also elevates pH in the lysosomal-endosomal pathway, we inferred Chl may also 
disrupt VV access. When PriessGAD cells were co-incubated with Mon or Chl, we 
observed lower infection efficacies (i.e. about 75%) compared with BFA or Leu treated 
cells (set equal to 100%).  The ability of Mon to decrease VV infection correlated with a 
published report using the same working concentration (i.e. 1 μM) of Mon [78]. By 
contrast, when cells were treated with CHX plus these drugs, a less complicated situation 
was observed. CHX treatment of cells reduced Ii and the LIP fragment equivalently 
independent of cell exposure to BFA, Leu, Mon or Chl (Fig. 19B). The comparable 
reductions in full length Ii by CHX also suggest this drug was similarly able to block Ii 
synthesis even in the presence of BFA, Leu, Mon or Chl treatment.  
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To further study the role of proteolytic degradation in the loss of Ii and Ii LIP fragment in 
cells exposure to VV, studies were carried out focusing on the use of protease inhibitors. 
The reduced levels of LIP in Leu treated cells following VV exposure, raised questions as 
to whether complete inhibition of cellular cysteine proteases was achieved. Thus, an 
additional dose of Leu (i.e. 2×Leu) was added to cells during the incubation as well as the 
irreversible cysteine protease inhibitor-E64. As shown in Fig. 19C, VV infection 
decreased the accumulation of full length Ii by Leu (1×) to about 50% and cellular LIP 
levels to 10% in cells similar to Fig. 19A. For VV infected cells, addition of two doses of 
Leu at 2 and 8 h resulted in higher levels of LIP accumulation confirming that cysteine 
proteases catalyze the late stages of Ii processing in VV infected cells. The use of E64 
also led to the accumulation of Ii LIP fragments in VV infected APCs. Together, these 
studies suggest cysteine proteases function in Ii turnover in control or VV infected cells. 
Yet, blocking of these enzymes required more potent inhibitors during VV infection. 
Studies have suggested that asparagine endopeptidase (AEP) is an acidic protease capable 
of catalyzing the earliest steps in Ii proteolysis [16]. The addition of an AEP inhibitor or 
AENK during VV infection of APCs, slowed Ii processing consistent with a role for AEP 
in Ii proteolysis and further suggested that the early stages of Ii processing were 
conserved during virus infection. To rule out any effect of these Ii processing inhibitors 
on protein synthesis, our [3H]-amino acid incorporation assay was performed. For 
example, PriessGAD cells were cultured with BFA or Leu in the absence or presence of 
CHX. No significant effect on protein synthesis was observed in either BFA or Leu 
treated samples with or without CHX (Fig. 19D).  
To investigate whether serine proteases or the cytoplasmic proteasome play a role in Ii 
processing,  the irreversible serine protease inhibitor-phenylmethyl-sulphonylfluoride 
(PMSF) [228] or proteasome inhibitors-lactacystin (LAC) [229] and epoxomicin (EPO) 
[230] were tested for their effects on Ii steady state levels in cells infected with VV or 
cells treated with CHX. However, no change in Ii abundance was observed upon 
treatment with either of these inhibitors. LIP was not detected. VV and CHX treatment 
decreased Ii levels to about of 50-60% of non-treated samples in the presence or absence 
of these same inhibitors (Fig. 19E and F). The level of viral Ags detected in cells exposed 
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to these inhibitors was similar to cells exposed to VV alone, suggesting these compounds 
did not diminish virus infection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 19 Ii abundance and degradation in cells exposed to VV or CHX. A. Ii 
abundance and LIP accumulation in VV infected B cells. PriessGAD cells were 
incubated +/- VV (MOI=10) for 2 h, then brefeldin A (BFA, 50 ng/ml), leupeptin 
(Leu, 500 μM), monensin (Mon, 1 μM) or chloroquine (Chl, 0.3 mM) were added to 
cells for an additional 12 h. Cells were harvested and analyzed by Western analysis 
using an Ii-specific mAb. VV proteins in infected cells were monitored using a VV 
specific polyclonal Ab. Actin expression levels were used as the sample loading 
control. Full length Ii (31-33 KD) and LIP fragment (21 KD) were detected with the 
PIN 1.1 Ab. Relative abundance of Ii and VV normalized to actin is listed below the 
blots. Control (no treatment) and VV infected alone samples were set equal to 100% 
for Ii and VV respectively. B. Ii and LIP abundance in B cells exposed to CHX. 
PriessGAD cells were incubated with BFA, Leu, Mon or Chl for 1 h then 10 μg/ml 
CHX was added for an additional 4 h followed by Western analysis for Ii or actin.  
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To monitor the degradation of Ii, we employed pulse-chase analysis with [35S]- 
methionine. Here, the proteolysis of Ii was analyzed following VV infection and 
culturing +/- E64. As shown in Fig. 20A and B, the levels of full length Ii dropped to 
53%, 43% and 41% after 2 h, 6 h and 14 h periods respectively. At 2 h and 6 h VV 
infection appeared to slow Ii degradation as detected by the abundance of radio-labeled Ii 
while increased Ii degradation was observed at 14 h. This result was noted in several 
studies by the change in total Ii abundance for control and VV treated samples. E64 
blocked Ii degradation and induced LIP production as expected in uninfected cells. VV 
infection of cells treated with E64 at 2 h and 6 h showed LIP levels less than cells treated 
with E64 alone. By 14 h, following VV and E64 exposure, Ii levels were greatly reduced. 
Equal loading of samples from immunoprecipitates was demonstrated by Coomassie Blue 
staining of gels prior to drying. The increased degradation of Ii at later stages of VV 
infection was verified by flow cytometric analysis. Using an Ii C-terminal specific Ab-
LN2 which detects Ii but not LIP, it was observed that surface full length Ii levels were 
reduced after 14 h VV infection of PriessGAD cells (Fig. 20C). While the majority of Ii 
is found within cells, low levels of Ii transit to the cell surface as shown in Fig. 20C. A 
terminal fragment of Ii processing is called CLIP. Flow cytometry and Ab staining for 
CLIP revealed slightly enhanced levels of this peptide upon VV infection (Fig. 20D). 
Fig. 19 (Cont’) C. Effect of cysteine proteases and AEP on Ii proteolysis within VV 
infection. PriessGAD cells were incubated +/- VV (MOI=10) for 2 h, then Leu (500 
μM), E64 (500 μM) and AENK (1 mg/ml) were added for an additional 12 h. For 
2×Leu samples, an additional dose of Leu was added to cells after 8 h incubation to 
ensure the active form of this inhibitor was present during the extended culturing. 
Cells were harvested and analyzed by Western Blotting. D. Effect of BFA and Leu on 
host protein synthesis. PriessGAD cells were co-incubated with BFA (50 ng/ml) or 
Leu (500 µM) +/- CHX (10 µg/ml) in media containing [3H]-amino acid for 6 h prior 
to harvesting and quantitative analysis of [3H]-amino acid incorporation. E. Effects of 
inhibitors of serine proteases and the proteasome on Ii abundance during VV 
infection. Phenylmethyl-sulphonylfluoride (PMSF, 50 µM), lactacystin (LAC, 250 
nM) and epoxomicin (EPO, 200 nM) were added to PriessGAD cells which had been 
previously infected with VV for 2 h. After an additional 12 h incubation, cells were 
harvested for immunoblotting. F. Effect of inhibitors of serine proteases and the 
proteasome on Ii abundance during CHX treatment. PriessGAD cells were incubated 
with LAC, EPO or PMSF for 1 h followed by the addition of CHX for an additional 4 
h prior to Western analysis for Ii or actin. Data is representative of at least three 
separate experiments. 
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These results were consistent with enhanced degradation of Ii during the later stages of 
VV infection.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20 Ii processing upon VV infection. A. Proteolysis of Ii upon VV and E64 
treatment of B cells. PriessGAD cells pulse radio-labeled with [35S]-methionine were 
cultured in media with excess unlabeled methionine +/- VV and E64 for 0, 2, 6, 14 h. 
Cell lysates were immunoprecipitated with Pin 1.1 and the precipitated proteins 
resolved on SDS-PAGE before Coomassie Blue staining and autoradiography. 
Relative abundance of Ii and LIP fragments is listed below. 0 h and 2 h E64 alone 
samples were set as 100% for Ii and LIP respectively. B. Degradation of Ii +/-VV. 
Data was replotted from the quantification analysis of Ii bands in panel A. C. 
Decreased surface Ii expression upon VV infection. PriessGAD cells were infected 
+/- VV (MOI=10) for 14 h before staining with FITC-LN2 Ab followed by flow 
cytometry. D. Enhancement of surface CLIP levels upon VV infection. PriessGAD 
cells were incubated +/- VV for 14 h before staining cells with FITC-CLIP-Ab 
followed by flow cytometric analysis. For panels C and D: The shaded histogram, 
dark line and dash line represented isotype control, non-infected and infected cells 
respectively. Experiments were repeated at least five times.
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Hence, VV infection appears to alter Ii processing. Our result that an additional dose of 
Leu or the irreversible inhibitor E64 was more potent in blocking LIP degradation 
suggest that a cysteine protease may be induced or elevated to enhance Ii proteolytic 
processing during late stages of VV infection.  
 
2.5 VV infection changed cellular lysosomal protease expression at both the protein 
and mRNA levels 
 
The changes in Ii degradation during virus infection (Fig. 19 & 20), prompted us to look 
at the expression of cathepsins required for Ii and Ag proteolysis. Cathepsins are acidic 
proteases found in the endosomal-lysosomal network, important for processing both Ii 
and Ag [195, 231]. Among the cathepsins tested, Cat S plays a key role in the later stages 
of Ii cleavage in B cells [18, 32]. Cat L mediates Ii processing in cortical thymic 
epithelial cells to regulate positive selection [17, 232]. Cat B and D, on the other hand, 
take a more important role in processing Ag but not Ii in B cells [231, 233]. As shown by 
immunoblotting in Fig. 21A, Cat S levels were greatly reduced, Cat B and L increased 
and Cat D protein levels remained constant after 14 h VV infection. CHX, in contrast 
with VV, did not change the expression of these cathepsins. These results correlated with 
our previous data that only VV but not CHX accelerated LIP degradation (Fig. 19A and 
B). To determine if the same trend occurs at the mRNA level, RT-PCR was performed 
using specific primers. The alterations in CTSS and CTSL (encoding Cat S and L 
respectively) mRNAs were similar to that observed for protein expression, i.e. Cat S 
mRNA decreased while Cat L mRNA increased during VV infection in a time dependent 
manner (Fig. 21B). The mRNAs for CTSB and CTSD (encoding Cat B and D 
respectively), however, both diminished progressively upon VV infection. The 
discrepancy between mRNA and protein expression levels for Cat B and D upon VV 
infection may be due to the relative stability of these proteins even during VV infection. 
Alterations in cathepsins at both the protein and mRNA levels may lead to aberrant Ii and 
Ag processing. Specifically, reduction in Cat S may lead to the decreased Ii degradation 
during the early to mediate stages of infection. The increased Cat L, on the other hand, 
may accelerate Ii degradation during later stages of infection (Fig. 20A and B). 
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The increase in Cat L and the decrease in Cat S upon VV infection were observed at both 
the mRNA and protein levels (Fig. 21). At the same time, LIP degradation was enhanced 
during the late stages of VV infection (Fig. 19 and 20). We proposed that the increased 
levels of cellular Cat L during virus infection could substitute for Cat S to drive the 
terminal stages of Ii processing. The existence of Cat L in B cells is controversial. A 
recent study confirmed Cat L expression in some human B cell lines, while others failed 
to detect this protease [18, 31, 234-238]. Thus, additional studies were carried out to 
confirm Cat L expression in B cells with or without VV infection. CTSL specific primers 
were used to amplify mRNA from PriessGAD B cells as cDNA and sequenced. The 
sequencing results and nucleotide blast software analysis confirmed the presence of 
human CTSL mRNA in B cells (Fig. 22A). Using the ClustalW software, the most 
 
 
 
 
 
 
 
 
 
Fig. 21 VV infection altered protein and mRNA expression of cellular lysosomal 
proteases. A. Protein expression of host cathepsins after VV infection or CHX 
treatment. PriessGAD cells were treated with VV (MOI=10) (left column) or CHX (10 
µg/ml) (right column) and harvested for analysis by Western analysis using cathepsin 
specific Abs. VV proteins were detected to confirm viral infection. Actin expression 
levels were used as the sample loading control.  Relative abundance of each cathepsin 
normalized to actin is listed below the blots. No treated control samples were set equal 
to 100%. B. Alteration in cellular cathepsin mRNAs upon VV infection. PriessGAD 
cells were infected with VV (MOI=10) for up to 14 h. mRNAs were isolated for semi-
quantitative RT-PCR using primers for cathepsins, HSPA10 (encoding HSC70), and the 
viral late gene D8L. Analysis was carried out for multiple cycles of amplification as 
indicated: CTSS (32); CTSB (32); CTSD (32); CTSL (40); HSPA10 (32); and D8L (28). 
Viral D8L gene transcripts were monitored to confirm virus gene expression. Host 
HSPA10 expression was maintained during infection. Data is representative of at least 
three experiments.   
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abundant amplified mRNA sequence in virally infected cells was also identified as 
human CTSL. The predicted proteins derived from these cDNA sequences were further 
validated as human Cat L. Taken with the Western analysis results using Cat L specific 
Ab (Fig. 21A), we concluded Cat L was expressed in human B-LCL and its abundance 
was enhanced upon VV infection. Moreover, in another human B-LCL, Frev, Cat L 
protein was also detected although it was slightly less abundant than in PriessGAD cells. 
Cat L protein increased after VV infection of Frev cells (Fig. 22B). Furthermore, when 
murine B cell tumors were tested, Cat L protein increased in both TA3 and 1153 cells 
during VV infection. Similar to results with PriessGAD cells, Cat D protein levels 
remained constant up to 14 h of VV infection (Fig. 22C). The absolute mRNA levels of 
Cat L or Ctsl in those murine cell lines appeared to either drop a bit (as in 1153) or did 
not change (as in TA3). However, when normalized with Gapdh as the endogenous 
control, Ctsl mRNAs either remained constant or increased in 1153 and TA3 respectively 
(Fig. 22D). CTSL mRNA levels in primary cells-human PBMCs were also measured 
upon in vitro VV infection. As shown in Fig. 22E, CTSL mRNA remained constant in 
these cells upon VV infection up to 14 h.  
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The expression of Ctsl mRNA in APCs upon in vivo VV infection was also studied. Here, 
C57BL/6 mice were i.p. infected with VV (106 pfu/mouse) up to 2 d before harvesting of 
spleens and the isolation of different APC populations. Ctsl mRNA was amplified from 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 22 Cat L expression in human B-LCL, murine B cell tumors and human 
primary PBMCs upon in vitro VV infection. A. Nucleotide blast of amplified 
mRNA from PriessGAD cells using CTSL specific primers. RNA were extracted, 
converted to cDNA, amplified with CTSL specific primers and sequenced. The 
nucleotide blast results confirmed the presence of human CTSL mRNA in human B 
cells. B. Enhanced Cat L protein levels in human B-LCL upon exposure to VV. Frev 
cells were infected with VV (MOI=10) for 14 h before Western analysis. C. Increased 
Cat L protein expression in murine B cell tumors during VV infection. 1153 and TA3 
cells were incubated with VV (MOI=10) for 14 h prior to Western Blotting assays. For 
panels B and C, actin was used as the loading control. VV protein expression was 
probed as evidence of infection. D. Ctsl mRNA expression in murine B cell tumors +/-
VV. Cells were infected as in panel C before RT-PCR analysis. Gapdh was used as the 
endogenous control. Early viral gene E3L was used as a marker of infection. E. CTSL 
mRNA levels in human PBMCs+/-VV. PBMCs were depleted of T cells then infected 
with VV (MOI=5) for 14 h prior to RT-PCR analysis. HSPA10 remained constant 
while viral late gene D8L expression increased. For panels B-E, quantification data for 
Cat L expression normalized to loading controls is listed below corresponding data. 0 
h samples were set as 100%. 
C D E
 
> ref|NM_001912.3|  Homo sapiens cathepsin L1 (CTSL1), transcript 
variant 1, mRNA Length=1731 
 
Score =  329 bits (178),  Expect = 2e-87, Identities = 187/196 (95%), Gaps = 0/196 
(0%), Strand=Plus/Plus 
 
Query  511  TCAGGGTCAGNGNGGTTCTTGTTGGGCTTTTAGNGCTACNGGNGCTCTTGAAGGACANAT  570 
            |||||||||| | |||||||||||||||||||| ||||| || |||||||||||||| || 
Sbjct  742  TCAGGGTCAGTGTGGTTCTTGTTGGGCTTTTAGTGCTACTGGTGCTCTTGAAGGACAGAT  801 
 
Query  571  GTTCCGGAAAACTGGGAGGCTTATCTCACTGAGTGAGCANAATCTGGTANACNGCTCTGG  630 
            ||||||||||||||||||||||||||||||||||||||| ||||||||| || ||||||| 
Sbjct  802  GTTCCGGAAAACTGGGAGGCTTATCTCACTGAGTGAGCAGAATCTGGTAGACTGCTCTGG  861 
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each individual type of APCs using RT-PCR. As shown in Fig. 23A and C, Ctsl mRNA 
increased in a time dependent manner in DCs and macrophages. This enhancement was 
also apparent in a shorter course of VV infection using DCs (Fig. 23D). In primary B 
cells, Ctsl mRNA abundance was lower than in the other populations and seemed not to 
increase during infection (Fig. 23B).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beside cathepsins, the expression of other enzymes contributing to Ag and Ii proteolysis 
was also investigated in cells exposed to VV. The protease, AEP not only initiates Ii 
proteolysis but also participates in Ag processing [31]. A significant reduction in LGMN 
(encoding AEP) mRNA was found during VV infection as shown in Fig. 24. mRNA 
levels for the early endosome marker-early endosome antigen 1 (EEA1) [239], however, 
did not change upon VV infection. EEA1 functions in endosome fusion by linking 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 23 Enhancement of Ctsl mRNA abundance upon in vivo infection of APCs. A. 
Progressive increases in Ctsl mRNA was observed with DCs upon in vivo VV infection. 
C57BL/6 mice were infected before harvesting of spleens and the isolation of DCs as 
described in Fig. 8C. RT-PCR was performed with specific primers. B. Ctsl mRNA in B 
cells detected after in vivo VV infection. B cell mRNA was isolated before RT-PCR was 
performed. C. Enhanced Ctsl mRNA levels in macrophages during in vivo VV infection. 
Macrophage mRNA was isolated prior to RT-PCR analysis. D. Ctsl mRNA abundance 
in DCs up to 24 h of in vivo VV infection. DCs were isolated as in panel A. mRNA 
samples from two mice for each time point were amplified and analyzed side by side. 
For panels A-D, relative quantification (RQ) for each sample is listed below 
corresponding data. RQ of Ctsl mRNA levels was normalized to Gapdh as the 
endogenous control. Ctsl mRNA from non-infected or 0 d/h sample for each APC 
population was set as 1. All other time points were calculated compared with the non-
infected sample. In each time point for panels A-C mRNA was pooled from three mice.  
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phosphatidyl-inositol-3-OH kinase (PI(3)K) and the small GTPase Rab5. EEA1 may also 
help target Rab5-dependent endocytic transport [240].  GILT is required for processing 
Ags containing disulfide bonds [15]. Using a GILT specific Ab, it was observed that 
GILT protein levels remained constant up to 14 h of VV infection or 6 h CHX treatment 
(data not shown).  
  
 
 
 
 
 
 
These studies indicate cellular Cat S decreased while Cat L increased at both protein and 
mRNA levels upon in vitro VV infection of human and murine B cells. In vivo VV 
infection also resulted in enhanced Cat L expression in APCs. Reduction in the levels of 
mRNAs for Cat B, D and AEP upon VV infection may also result in abnormal Ii as well 
as Ag processing and thus contribute to defects in class II protein function and Ag 
presentation. CHX, on the other hand, did not change expression of these enzymes. Yet, 
the disruption of Ii synthesis during CHX treatment of cells may contribute to the defect 
in class II presentation. 
 
2.6 Preservation of class II function by over-expression of Ii upon VV infection 
 
Loss of Ii expression could in part contribute to class II dysfunction, thus we proposed 
enhancement of Ii expression in cells may reduce the inhibition of class II presentation 
observed with VV infection. Three methods to increase intracellular Ii levels were tried, 
i.e. 1) cell fusion to increase the Ii gene copy number; 2) transfection with an Ii-encoding 
plasmid; and 3) using VV as a recombinant vector to express the Ii gene.  The results of 
these studies are presented here.  
 
 
 
 
 
Fig. 24 Expression of LGMN and EEA1 mRNA upon VV infection. cDNAs were 
amplified from 0 and 14 h VV infected  PriessGAD cells by RT-PCR using specific 
primers. HSPA10 was used as the loading control. Early viral gene E3L was detected 
confirming VV infection. Experiments were repeated three times. 
VV (h)  
0       14
LGMN
EEA1
HSPA10
E3L
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2.6.1 Enhancement of cellular Ii expression partially preserved class II function 
during VV infection of cells 
 
Virus induced loss of Ii expression was most apparent in human B lymphoblasts, thus 
initial studies focused on these cells.  Current human or murine B cells lacking Ii are not 
available, yet cell fusion can result in cell lines expressing multiple copies of Ii encoding 
genes. T2DR4DM cells were generated previously [185-187] by fusing human B and T 
lymphoblast cell lines in vitro. T2DR4DM cells express greater levels of Ii protein than a 
B-LCL 7C3DR4 (Fig. 25C). As shown in Fig. 25A, both T2DR4DM cells and 7C3DR4 
cells presented the GAD peptide to T cells specific for this peptide and class II DR4. VV 
infection at MOI 10 disrupted GAD presentation in both cell lines. As in our prior 
studies, viral inhibition of class II function could be partially compensated by adding 
higher peptide concentrations to these assays.  The perturbation of GAD presentation, 
however, was much less severe with T2DR4DM cells which express high levels of Ii 
compared with 7C3DR4 cells which express wild type levels of Ii. Using 1 µM GAD, 
VV infection inhibited GAD presentation 60% in 7C3DR4 cells while blocking only 20% 
of GAD presentation by T2DR4DM cells (Fig. 25B). Similar to our prior results with 
PriessGAD cells (Fig. 10A), alterations in cellular Ii after 6 h of VV infection were not 
observed. The over-expression of Ii in T2DR4DM cells compared with 7C3DR4 cells 
was confirmed by Western analysis using actin as the loading control. Cellular infection 
by VV was confirmed by probing these blots with a VV specific Ab (Fig. 25C). Levels of 
viral protein expression in each cell line were similar. This was important in confirming 
similar amounts of virus likely entered each cell line during the infection period.  
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VV also disrupts class II mediated Ag presentation in non-professional APCs [97]. To 
construct comparable cell lines that differ only in Ii expression, M1DR4, a human 
fibroblastic cell line expressing class II DR4 molecules was transfected with a plasmid 
containing the human genes for Ii p31 and p33 proteins to generate M1DR4Ii cells. The 
heterologous expression of Ii genes was driven by a RSV promoter. The importance of Ii 
in chaperoning of class II was suggested here by the higher expression of surface class II 
DR4 molecules in M1DR4Ii cells compared with M1DR4 cells. About 60% of M1DR4 
cells and 80% of M1DR4Ii cells expressed high levels of surface DR4 as detected by 
flow cytometry after cell selection for a co-transfected plasmid with a drug resistance 
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Fig. 25 Over-expression of Ii partially preserved GAD peptide presentation in 
human lymphoblasts upon VV infection. A. Differential inhibition of GAD peptide 
presentation by VV using lymphoblasts with high and wild type Ii expression. 7C3DR4 
cells and T2DR4DM cells were co-incubated with GAD peptide (0-10 µM) and in some 
samples VV (MOI=10) was added for 6 h before fixation and GAD-specific T cell 
addition. T cell activation was then assessed. B. Relative T cell responses to different 
human lymphoblasts co-incubated with GAD and VV. 7C3DR4 cells and T2DR4DM 
cells were co-cultured with 1 µM GAD peptide +/- VV (MOI=10) for 6 h before 
fixation and T cell addition. Relative T cell proliferation was normalized to the samples 
with no VV, the latter were set to 1. C. Ii protein expression in lymphoblasts. 7C3DR4 
cells and T2DR4DM cells were infected with VV (MOI=10) for 6 h before Western 
Blotting analysis. Ii, actin and VV proteins were probed with corresponding specific 
Abs. Relative abundance of Ii normalized to actin is listed below the data. 7C3DR4 
sample without infection was set as 100%.  
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marker (data not shown). For functional assays, GAD peptide presentation +/- VV was 
tested. Here, M1DR4 cells and M1DR4Ii cells were co-incubated with GAD peptide (0-
10 µM) +/- VV (MOI 0-10) for 6 h. As shown in Fig. 26A, both cell lines could present 
GAD peptide although M1DR4Ii appeared to be more effective and could induce higher 
T cell responses. Increased addition of GAD peptide to each cell type led to higher 
presentation and T cell activation. VV inhibited GAD peptide presentation in a dose 
dependent manner in both cell lines. However, viral inhibition of M1DR4 cells was 
greater than that observed for M1DR4Ii cells. For example, a greater than 75% decrease 
in GAD (5 µM) presentation was detected upon VV (MOI=10) infection of M1DR4 cells. 
Yet under the same conditions, a roughly 40% decrease in GAD presentation was found 
in M1DR4Ii cells exposed to virus. When the T cell responses to 10 µM GAD peptide in 
the presence of VV (MOI = 0-10) were compared, a similar trend was noted. I.e. at same 
concentration of virus, M1DR4Ii cells appeared consistently better as APCs during VV 
exposure (Fig. 26B). However, Ii expression only partially preserved class II-mediated 
Ag presentation, suggesting other mechanisms may contribute to VV-induced class II 
dysfunction. Ii was only expressed in M1DR4Ii cells but not in M1DR4 cells (Fig. 26C). 
Ii levels did not change at 6 h infection with VV at MOI 10. The expression of viral 
proteins in each cell line was comparable, suggesting similar levels of virus entry and 
gene expression for M1DR4 and M1DR4Ii cells.  
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To test if class II function could be preserved by enhancing intracellular Ii expression in 
cells from other species upon VV infection, murine fibroblast cells +/- Ii were used as a 
model. L1DR4 are murine fibroblast cells transduced with the human class II molecule 
DR4. L1DR4 cells were co-transfected plasmids encoding human Ii p31 and p33 forms to 
yield L1DR4Ii cells. GAD peptide presentation, by L1DR4Ii cells was less sensitive to 
virus than L1DR4 cells (Fig. 27A). When relative T cell responses to 1 µM GAD peptide 
were compared, there was a 30% decrease in class II function for L1DR4 cells but no 
reduction in ability of L1DR4Ii cells to present this peptide upon VV infection (Fig. 
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Fig. 26 VV disruption of class II function was greater in a human fibroblast cell 
line lacking Ii. A. GAD peptide presentation upon VV infection of M1DR4 cells and 
M1DR4Ii cells.  M1DR4 cells were transfected with human Ii genes (CD74) yielding 
M1DR4Ii cells. Peptide presentation to T cells was tested using each of these cell lines 
pulsed with GAD peptide (0-10 µM) +/- VV (MOI up to 10) for 6 h. B. Relative T cell 
responses to human fibroblast cells co-cultured with GAD and VV. M1DR4 cells and 
M1DR4Ii cells were incubated with 10 µM GAD peptide +/- VV (MOI up to 10) for 6 
h before fixation and GAD specific T cell addition. Relative T cell proliferation was 
normalized to the VV (MOI=0) sample, with these uninfected cells being set to 1. C. Ii 
protein expression in different fibroblast cells. M1DR4 and M1DR4Ii cells were 
infected with VV (MOI=10) for 6 h prior to Western analysis using specific Abs. VV 
protein levels was probed as evidence of infection. Actin was used as the loading 
control. Relative abundance of Ii normalized to actin is listed below the data. M1DR4Ii 
sample without infection was set as 100%. Data is representative of at least three 
experiments. 
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27B). Only L1DR4Ii but not L1DR4 expressed Ii. Human Ii expressed in these cells 
seemed a little more unstable than observed using human fibroblasts, thus a slight 
reduction (about 24%) in Ii could be observed after 6 h VV infection. The infection of 
these two cell lines were similar as assessed by equal viral protein expression (Fig. 27C). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thus, over-expression of Ii by multiple methods could partially reverse the inhibitory 
effect of VV on class II function. Class II function in both professional and non-
professional APCs was preserved by Ii over-expression upon VV infection. The species 
of host APCs did not appear to matter. These results confirmed the importance of Ii in 
class II-mediated Ag presentation upon VV infection. Notably, this preservation of class 
Ii function was observed at early stages of VV infection prior to viral disruption of Ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 27 Class II dysfunction induced by VV was less severe in murine fibroblast 
cell lines containing Ii. A. Presentation of GAD peptide upon VV infection of L1DR4 
and L1DR4Ii cells.  These cells were co-incubated with GAD peptide (1 µM) +/-VV 
(MOI=10) for 6 h prior to fixation and GAD specific T cell addition. B. Comparison of 
T cell responses to murine fibroblast cells +/- Ii. L1DR4 and L1DR4Ii were co-cultured 
with GAD peptide (1 µM) +/- VV (MOI=10) for 6h. Relative T cell proliferation was 
normalized to uninfected cells which were set to 1. C. Ii protein expression in murine 
fibroblast cells. L1DR4 and L1DR4Ii cells were infected with VV (MOI=10) for 6 h 
prior to Western analysis. Actin remained constant upon VV infection. Relative 
abundance of Ii normalized to actin is listed below the data. L1DR4Ii sample without 
infection was set as 100%. 
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expression. We have postulated at early stages of infection, a viral protein or gene 
product may directly disrupt class II function with the loss of Ii at late stages of infection, 
class II may be even more susceptible to this virus gene. This would be consistent with 
the observed protection of class II by Ii throughout infection. The incomplete 
preservation of class II function by over-expression of Ii upon VV infection also 
suggested that other mechanisms besides Ii reduction may contribute to VV-induced 
disruption of class II function.  
 
2.6.2 Improved class II function in B-LCL infected by recombinant VV encoding Ii  
 
As an alternate method to increase intracellular Ii levels, a recombinant VV encoding the 
cDNA for Ii was developed. To construct a recombinant VV expressing Ii cDNA, the full 
length human Ii (hIi, CD74) cDNA encoding the p31 form of Ii was amplified from 
mRNA of PriessGAD cells. This cDNA was inserted into a transfer vector to add 
proximal EcoRI recognition sites that could be used to excise the cDNA and facilitate 
insertion into another vector. The hIi cDNA with EcoRI recognition sites was ligated into 
the pSC59 vector to yield pSC59-hIi. The pSC59-hIi plasmid could be detected upon 
electrophoresis migrating at the correct size (i.e. about 4700bp) on an agarose gel. Two 
fragments were generated after HindIII cutting of the pSC59-hIi plasmid, one fragment 
was about 4400 bp, while the other was about 300 bp. Detection of the larger fragment 
which migrated above the uncut plasmid, was likely due to the fact that the linear forms 
always migrate slower than circularized form (Fig. 28A). The sequence and orientation of 
the human Ii insert were confirmed by DNA sequencing (data not shown). The 
recombination of pSC59-hIi with VV was performed as described in Material and 
Methods. After three rounds of selection with BUdR, the recombinant VV was harvested, 
titered (about 1×107 pfu/ml) and used to infect CV1 cells. VSC, a recombinant VV 
encoding β-Gal was used as a control virus for these studies. The hIi protein could not be 
readily detected following exposure of CV1 cells to the rVV encoding the human Ii 
cDNA. Even after incubation of CV1 cells for 24 h with the rVV at MOI 10, the 
expression of human Ii in these cells was questionable (Fig. 28B). Another recombinant 
VV expressing the murine Ii cDNA (Cd74) or mIi-VV was therefore tested as a measure 
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to promote mIi expression in cells. Since the homology between human and murine Ii 
protein sequences is about 80%, the specificity of the two Ii Abs: one specific for murine 
(In-1 Ab) and one detecting human Ii (Pin1.1) was tested. As shown in Fig. 28C, Pin1.1 
Ab recognized only human Ii while In-1 bound specifically to murine Ii. Thus, these Abs 
could be used to monitor mouse Ii abundance even in cells expressing the human Ii. 
Murine Ii was detected in cells exposed to the rVV encoding this cDNA (Fig. 28D). 
Therefore, mIi-VV was therefore used in the following biochemical and functional assays 
as a method to increase intracellular Ii. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
To test the effect of mIi-VV on class II function, PriessGAD cells were infected with mIi-
VV, CD4-VV or wild type VV. The ability of these APCs to present endogenous GAD 
Ag to T cells was measured. As shown in Fig. 29A, exposure of PriessGAD cells to each 
virus resulted in diminished GAD presentation. Of the three viruses, CD4-VV disrupted 
GAD presentation comparably to wild type VV. Thus, insertion of a gene into the virus 
did not significantly alter viral infection or its ability to inactivate class II function. mIi-
 
 
 
 
 
Fig. 28 Expression of Ii (CD74) cDNA with a recombinant VV vector. A. The 
treatment of plasmid pSC59-hIi +/- HindIII. 0.5 µg of pSC59-hIi was cut with 20 units 
of HindIII at 37˚C for 3 h. 0.5 µg of uncut and HindIII cut pSC59-hIi were 
electrophoresed on a 1% agarose gel, stained with SYBR® safe DNA gel stain, and 
detected with UV transillumination. DNA markers and corresponding sizes are listed on 
the right. B. Expression of hIi following cell infection with the hIi-VV. CV1 cells were 
uninfected (Cont.) or infected with VSC (recombinant VV expressing β-Gal derived 
from the vector pSC59) or hIi-VV at MOI=10 for 24 h. Western analysis was performed 
using hIi specific Ab Pin1.1. C. Specificity of human Ii Ab Pin1.1 and murine Ii Ab In-
1. Lysates from human B-LCL PriessGAD and murine B cells 1153 were loaded side 
by side on a 10% PAGE gel. Western blots from this gel were probed with Pin1.1 and 
In-1 respectively. D. mIi expression by mIi-VV. CV1 cells were uninfected (Cont.) or 
infected with CD4-VV (recombinant VV encoding human CD4 derived similar to mIi-
VV) or mIi-VV at MOI=10 for 24 h. Western analysis was performed using the mIi 
specific Ab In-1. A series of broad bands were detected with cells exposed only to mIi-
VV, and these proteins displayed a molecular mass close to murine Ii (31 KD). 
Glycosylation of Ii typically results in the appearance of multiple forms of Ii.  
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VV perturbed GAD presentation less severely compared with the other two viruses at 14 
and 24 h after infection. Therefore, expression of Ii via a rVV partially preserved class II 
mediated Ag presentation at late stages of infection. Consistent with these findings, we 
could detect more hIi protein in mIi-VV infected cells compared to cells infected by wild 
type or CD4-VV (see 24 h in Fig. 29B). The cross-recognition of hIi and mIi by Abs was 
ruled out by our studies in Fig. 28C. It is notable that the mIi was expressed behind a 
viral early-late promoter, yet expression of mIi was slow and apparent as a late gene 
product (Fig. 29C). Yet even with delayed expression, the mIi appeared to substitute for 
hIi and preserved hIi abundance during infection. Cellular infection by each VV was 
similar with detection of similar levels of VV protein expression. Equal infection using 
these three viruses was also confirmed by identical E3L mRNA levels in infected 
PriessGAD samples as detected with RT-PCR (data not shown).   
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Fig. 29 Changes in class II function with rVV including mIi-VV. A. Endogenous 
GAD presentation by PriessGAD cells exposed to rVV. PriessGAD cells were infected 
with wild type VV, CD4-VV or mIi-VV (MOI=10) for up to 24 h prior to cell fixation 
and GAD specific T cell addition. T cell proliferation was assessed as described in the 
Material and Methods. B. Relative preservation of hIi following infection with mIi-VV 
but not wild type or CD4-VV. PriessGAD cells were infected with wild type VV, 
CD4-VV or mIi-VV (MOI=10) (marked as WT, CD4 and mIi respectively) for up to 
24 h prior to Western Blotting analysis with hIi, actin and VV Abs. Actin levels 
remained constant up to 24 h infection. C. Expression of mIi during mIi-VV infection. 
PriessGAD cells were infected with mIi-VV (MOI=10) for up to 24 h before Western 
analysis with mIi, actin and VV Abs. VV proteins was probed to confirm cell 
infection. Actin was used as the loading control. 
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Overall, increasing cellular Ii levels both early and late during VV infection, served to 
partially preserve class II function. These results support our prior conclusion that viral 
infection may destabilize class II proteins and that the loss of cellular Ii during later 
stages of infection, further contributes to an overall loss of class II function.  
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Chapter 3 The presentation of VV viral Ag by class II and I molecules 
 
The reduction in cellular Ii expression correlated with the late stages of VV infection, yet 
class II dysfunction and destabilization was observed at the earliest stages of virus 
infection. Thus, we considered mechanisms which might account for the apparent 
reduction in class II Ag presentation at the early stages of virus infection. While prior 
studies suggested VV entered cell by direct fusion at the plasma membrane, more recent 
efforts suggest VV efficiently enters cells by delivery into acidic endosomes [78, 79]. Ag 
and some peptides also enter APCs by endocytosis where proteolytic processing and 
binding to class II molecules take place. Thus, we tested whether VV Ags are processed 
and presented by class II molecules within infected APCs. Prior studies had demonstrated 
VV specific CD4, CD8 T cells and Abs in human vaccinated subjects as well as murine 
models after virus inoculation [83, 91, 241]. The detection of virus specific CD8 and 
CD4 T cells indicates viral Ags are presented by class I and class II molecules. Yet, this 
might take place after the release of virus Ags from dying infected cells. Such an indirect 
pathway, or cross presentation has been reported for VV Ags and MHC class II 
molecules [242]. Here, we attempted to study the direct presentation of viral Ags in the 
context of class II following APC infection. For these studies CD4 T cells specific for 
VV Ags were generated by in vivo murine infection. Cytokine production by CD8 T cells 
isolated from in vivo VV infected mice followed by in vitro restimulation was also 
investigated. The overall goal here was to gain insight into mechanism of VV immune 
evasion while also better understand the pathogenesis of VV infection-induced immunity.  
 
3.1 Primary adaptive immune responses to VV  
 
Primary adaptive immunity is most efficiently initiated after triggering of innate immune 
responses. There is typically a lag phase (about 6 d after pathogen invasion) prior to the 
initiation of primary adaptive immune responses [6]. APCs present processed Ag to T 
cells which can differentiate into effector T cells to induce both cellular and humoral 
immunity. VV-specific CD4 T cells are important for CD8 T cell activation and memory 
[243, 244]. They are also critical for VV specific Ab production [81]. Consequently, the 
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partnership of CD4 T cells and APCs is an essential component in the development of 
VV-induced immunity in both human vaccinees and mouse models.  
 
Our goal was to understand whether virus infected APCs could activate virus-specific 
CD4 T cells and whether viral disruption of class II function interferes with the 
development of cellular immune responses to VV. To test whether virus-specific CD4 T 
cells were elicited during a VV infection, C57BL/6 mice were i.p. infected with 1×106 
pfu VV/mouse for 1, 2 or 7 d before harvesting their lymph nodes and spleens. The CD4 
T cells from these VV-infected animals (termed VV-CD4 T cells) were isolated and co-
cultured in vitro with VV infected primary splenic cells. These splenic cells served as 
APCs and contain predominantly B lymphocytes but also macrophages and DCs. Spleen 
cells were harvested from uninfected C57BL/6 mice, then were irradiated to prevent 
proliferation and in vitro infected by VV (MOI up to 1 for 24 h). Primary APCs are more 
sensitive to VV infection and cell death increased upon exposure to virus at MOI>1. VV-
CD4 T cells were co-cultured with these spleen cells for 3 d. Finally, [3H]-thymidine was 
added to these cultures to detect T cell proliferation in response to the splenic APCs and 
virus. VV-CD4 T cell responses were very low in the first 2 d after in vivo VV infection, 
this is consistent with T cell responses to Ag or other pathogens during a primary 
immune response. However, after 7 d of infection, VV-CD4 T cell responses increased 
dramatically (Fig. 30A). Therefore, 7 d was used as the in vivo infectious period in our 
analysis of primary T cell responses to virus. The viral MOI used for in vitro infection of 
APCs also influenced our detection of VV-CD4 T cell responses. At a MOI of 0.01, the 
dose of viral Ag was too low to induce significant CD4 T cell activation. At a MOI of 
0.1, a measurable T cell response to virus and splenic APCs was observed. Further 
increasing the MOI to 1, however, suppressed CD4 T cell responses. The immunoevasive 
properties of VV may account for this observed suppression at MOI=1, consistent with 
our studies that virus infection diminishes CD4 T cell recognition of protein Ags and 
peptides (Chapter 1 and 2).   
 
To further investigate the responses of VV-CD4 T cells ( from 7 d infected mice) to VV 
viral Ags, primary splenic cells were in vitro infected with VV (MOI=0, 0.01, 0.1, and 1) 
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from 2 to 36 h (Fig. 30B). T cell responses to VV infected cells (MOI=0.01) were barely 
detectable at this low dose of virus. At an infectious MOI 0.1, viral Ags presented by 
splenic APCs induce measurable T cell responses. Notably, the presentation of viral Ags 
resulted in very rapid activation of VV-CD4 T cells, i.e. incubation of spleen cells with 
VV for 2 h was sufficient to induce significant T cell responses. T cell responses to VV 
(MOI=0.1) increased in a time dependent manner. By contrast, VV at MOI=1 induced 
significantly lower T cell responses which appeared to plateau by 6 h post spleen cell 
infection. Again this latter result was similar to our prior findings demonstrating virus 
infection at MOI 1-10 blocked class II presentation of protein Ags such as GAD (Fig. 3). 
Thus, viral suppression of host immunity at VV (MOI=1) likely affects class II 
presentation of viral Ags to CD4 T cells.  
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Fig. 30 See legend next page.  
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The suppression of T cell responses to viral Ag at MOI=1 (Fig. 30), suggested that viral 
infection of APCs at higher MOI could disrupt class II presentation of viral Ags. Our 
prior studies of class II-mediated Ag presentation had shown that the inhibition of class II 
function was less severe with UV-treated virus  [97] and was not observed with heat 
treated virus (Fig. 4B). Therefore, we examined the effects of these two modified forms 
of virus relative to replication competent wild type VV on viral Ag presentation. Splenic 
APCs were exposed to UV treated VV (UV-VV) or heat inactivated VV (HI-VV) at 
MOI=0.1 and 1 with untreated VV serving as a control. As shown in Fig. 31A, UV-VV at 
MOI=0.1 induced T cell responses comparable to untreated VV at same MOI. UV-VV at 
MOI=1 induced higher T cell activation. Again, at MOI=1, viral Ag presentation was 
suppressed by untreated VV. Exposure of APCs to HI-VV induced significant VV-CD4 
T cell responses. At MOI=0.1, HI-VV and untreated VV were similarly presented by 
APCs. Yet, unlike untreated VV, exposing of APCs to a dose of HI-VV (MOI=1) 
measurably enhanced T cell responses (Fig. 31B). This result is consistent with our prior 
data that heat-treatment of VV ablates its ability to inhibit the class II pathway. Data from 
our lab suggested that D8, a late viral membrane protein, could bind to class II molecules 
(P. Li, unpublished). Thus, we reasoned that mutation of the D8L gene within VV might 
thwart the ability of VV to disrupt class II Ag presentation. Experimentally, we tested a 
virus expressing a truncated form of the D8L gene (BSSH) which results in virus 
production of a soluble form of D8. Studies in the literature suggested this virus was 
replication competent and could readily infect cells [177]. Thus, we predicted that 
Fig. 30 Primary CD4 T cell responses to VV. A. Response of VV-CD4 T cells to 
viral Ags presented by splenic APCs. CD4 T cells were harvested at 0, 1, 2, 7 d 
following VV i.p. inoculation of C57BL/6 mice (VV-CD4 T cells). Primary splenic 
cells from uninfected C57BL/6 mice were used as APCs and irradiated followed by in 
vitro infection with VV (MOI=0, 0.01, 0.1, and 1) for 24 h. VV-CD4 T cells from 
virus infected mice and APCs exposed to VV in vitro, were co-cultured for 72 h 
before [3H]-thymidine was added to detect T cell proliferation. B. Time course of 
VV-CD4 T cell responses to in vitro infected APCs. Primary splenic cells from 
uninfected mice were harvested, irradiated, in vitro infected with VV (MOI up to 1) 
for up to 36 h prior to the addition of VV-CD4 T cells harvested from 7 d in vivo 
infected mice. T cell proliferation was monitored by [3H]-thymidine incorporation. 
APC exposure to different viral MOI is indicated. Individual experiments were 
repeated at least five times. 
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exposure of APCs to the BSSH virus might lead to better class II presentation of viral 
Ags and high T cell proliferation than wild type VV. Indeed, when BSSH was tested, 
MOI  of 0.1 and 1 induced higher T cell responses than wild type VV at MOI=0.1 (Fig. 
31C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 31 demonstrated that viral Ag presentation could be observed using modified or 
genetically altered VV, and that in some cases these modified viruses induced higher 
CD4 T cell responses than wild type VV. Thus, we wondered if these modified viruses 
could be used as vaccines to promote stronger immune responses than wild type virus. 
Our rationale is that since these defective VV partially preserve class II presentation, they 
may induce immune responses more effectively than untreated, wild type VV. Thus, 
these defective VV were used to prime mice and compared with untreated, wild type VV 
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Fig. 31 Presentation of UV-, heat-inactivated or D8L truncated VV compared with 
untreated, wild type VV. A. T cell proliferation induced by UV-VV. VV was 
irradiated at 254 nm of UV for 20 m. Splenic cells from uninfected C57BL/6 mice were 
used as APCs and irradiated before incubation with UV-VV and VV at MOI 0.1 or 1 
respectively for up to 24 h. VV primed CD4 T cells (VV-CD4) were isolated from 7 d 
infected mice and added to washed APCs. Proliferation of VV-CD4 T cells was 
monitored as in Fig. 30. B. Presentation of HI-VV. VV was heated at 60°C for 1 h 
before addition to the irradiated APCs for up to 24 h. VV-CD4 T cells were isolated 
and co-cultured with washed APCs for 72 h before [3H]-thymidine addition. C. 
Presentation of BSSH. D8L defective VV (BSSH) or wild type VV were added to 
APCs at MOI=0.1 or 1 for up to 24h prior to the addition of VV-CD4 T cells.  
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in terms of inducing CD4 T cells recognizing viral Ags. After 7 d in vivo inoculation, 
CD4 T cells were isolated from mice primed with either the modified viruses or wild type 
VV. Here, the CD4 T cells were denoted as UV-CD4, HI-CD4 and BSSH-CD4 
respectively according to the corresponding viruses used for in vivo inoculation. When 
the spleens and lymph nodes were harvested from UV-VV or HI-VV primed mice, these 
organs were not swollen or enlarged as typically observed with VV infected mice 
suggesting less induction of lymphocyte proliferation after inoculation. Consistent with 
this, neither UV-CD4 nor HI-CD4 could respond to APCs even after re-stimulation with 
HI-VV at MOI=1 (Fig. 32A and B). HI-VV was used because it induced the highest 
stimulation of CD4 T cells from mice infected with wild type virus (Fig. 31). UV-VV and 
HI-VV can not replicate in cells. This may be one reason why they failed to prime and 
stimulate the proliferation and expansion of CD4 T cells in vivo. When plaque forming 
assays were performed with these two viruses, neither of them could form plaques (data 
not shown). Thus, replication competent VV was required to induce effective CD4 T cell 
responses in vivo. This failure of inactivated VV to promote virus specific T cell 
development in vivo was consistent with several previous studies [206]. However, by 
using some modified methods such as increasing inoculation time, defective VV could be 
used to induce immune response [245, 246]. BSSH, unlike UV-VV and HI-VV, induced 
effective CD4 T cells responses in vivo. The BSSH infected mice had enlarged spleens 
and lymph nodes similar to VV infected mice. The BSSH-CD4 T cell responses were 
measurable after in vitro re-stimulation with HI-VV at MOI=1 although less than wild 
type VV (Fig. 32C). Thus, in vivo priming with BSSH can induce responding CD4 T 
cells. In vitro presentation of BSSH appeared better than wild type VV (Fig. 31C). Thus, 
one would have predicted BSSH would generate a T cell response stronger than wild type 
virus during in vivo infection. Whether BSSH replicates to the same efficiency as VV 
upon animal inoculation is unknown, and could provide one explanation. Still, these 
studies suggest BSSH is a good candidate vaccine. Possibly adding adjuvants to BSSH or 
complete deletion of the D8L gene may help to improve its antigenicity. 
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One of the primary cellular cytokines detected by the T cell proliferation assay used in 
our laboratory is IL-2. To more specifically examine cytokines produced by virus primed 
CD4 T cells, ELISAs were performed. Here, mice were in vivo infected with wild type 
VV or BSSH for 7 d before CD4 T cells (VV-CD4 and BSSH-CD4 T cells) were isolated 
from the animal spleens and lymph nodes. These CD4 T cells were then co-cultured with 
APCs (splenic cells from uninfected mice) that had been incubated with HI-VV (MOI=1, 
24 h). Culture supernatants were harvested and analyzed by ELISA using IFN-γ, TNF-α, 
IL-4 and IL-17 specific Abs. Both VV-CD4 and BSSH-CD4 T cell produced significant 
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Fig. 32 Responses of CD4 T cells isolated from UV-VV, HI-VV or BSSH primed 
mice to in vitro HI-VV treated APCs. A. CD4 responses from UV-VV primed mice.  
C57BL/6 mice were i.p. inoculated with UV-VV (1×106 pfu/mouse) for 7 d before 
lymph nodes and spleens were harvested. CD4 T cells were isolated and co-cultured 
with irradiated APCs pretreated with HI-VV (MOI=0.1 and 1, up to 24 h). After 72 h, 
[3H]-thymidine was added to measure T cell proliferation. B. HI-VV failed to induce 
CD4 responses. Mice were injected with HI-VV (1×106 pfu/mouse) for 7 d before CD4 
isolation. APCs were treated as in panel A and co-cultured with CD4 T cells from HI-
VV or VV inoculated mice. C. CD4 responses after in vivo BSSH infection. Mice were 
infected with BSSH (1×106 pfu/mouse) for 7 d before CD4 T cell harvesting. In parallel 
studies, another set of animals were infected with VV. CD4 T cells from each set of 
mice were isolated and incubated with APCs that had been treated with HI-VV. T cell 
responses were monitored. For all the three panels, the responses of VV primed CD4 T 
cells (VV-CD4) were tested parallel as the positive controls.  
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amount of IFN-γ upon incubation with APCs + HI-VV compared to CD4 T cells cultured 
with APCs alone. BSSH-CD4 T cells secreted slightly more IFN-γ than VV-CD4 in this 
assay (Fig. 33). This result may again support the use of BSSH virus as a vaccine 
candidate. ELISAs for TNF-α, IL-4 or IL-17 failed to detect the production of any of 
these cytokines by CD4 T cells from VV or BSSH inoculated animals under the 
conditions tested (data not shown). Thus, we primarily detected Th1 cytokines, i.e. IL-2 
(assayed by proliferation assay) and IFN-γ (by ELISA) upon in vitro re-stimulation of 
VV or BSSH primed CD4 T cells. Similar results were obtained by using a multi-analyte 
ELISArray kit for mouse Th1 / Th2 / Th17 Cytokines (data not shown). Among the 12 
cytokines we screened, only IL-2 and IFN-γ levels were significantly above background 
(i.e. using CD4 T cells co-cultured with APCs alone as a background control).   
 
 
 
 
 
 
 
 
 
 
 
 
During these studies to analyze VV specific responses of CD4 T cells, we observed that 
the wild type, untreated VV was the best in vivo inducer or activator promoting the 
expansion and development of virus-specific CD4 T cells. The HI-VV at MOI 1 was 
observed to maximally re-stimulate CD4 T cells in vitro, possibly due to its lack of 
immunoevasive properties and its relative preservation of class II function. BSSH, a 
mutant virus, appears to hold promise as a potential vaccine candidate due to its ability to 
induce significant CD4 T cell responses in vivo and could be presented by class II 
molecules in vitro.   
 
 
 
 
 
 
Fig. 33 IFN-γ production by virus specific CD4 T cells upon exposure to HI -VV 
and APCs. APCs were incubated with HI-VV (MOI=1) for 24 h before addition of 
CD4 T cells from VV or BSSH primed mice. After co-cultured for 72 h, culture 
supernatants were harvested and analyzed by ELISA using IFN-γ specific Abs. CD4 T 
cells co-cultured with APCs but no virus were set up as a control (labeled as VV-CD4 
or BSSH-CD4).  
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3.2 Class II presentation of VV peptides  
 
Compared with viral Ags or proteins from intact VV, viral peptides may need less 
intracellular processing and be presented more efficiently. In collaboration with Dr. 
Alessandro Sette (La Jolla Institute for Allergy and Immunology San Diego, CA, USA), 
we examined the ability of class II molecules to bind and present several VV peptides to 
CD4 T cells (listed as Table 3). Peptides were named according to the corresponding 
gene names.  Using co-immunoprecipitation assay, our laboratory has shown that the H3 
and D8 viral proteins can bind to the class II molecules. We proposed that peptides from 
these viral Ags might thus be presented to virus-specific CD4 T cells. Depending on their 
binding affinity for class II, viral peptides could compete with other peptides for class II 
molecules and potentially diminish the presentation of other Ags.  
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Table 3 Viral peptides tested for class II presentation. 
Peptide/ 
Encoding 
Gene 
Name 
VACV-WR 
Protein 
Name 
Time of 
Expression 
Viral Protein 
Function 
Function 
Category Peptide Sequence 
F15L VACWR054 / unknown unknown TPRYIPSTSISSSNI 
E1L VACWR057 late 
poly(A) 
polymerase, large 
subunit 
Genome 
regulation VLTIKAPNVISSKIS 
E9L VACWR065 early DNA polymerase Genome regulation 
PSVFINPISHTSYC
Y 
I1L VACWR070 late virion core DNA binding protein 
Genome 
regulation 
LKAYFTAKINEMV
DE 
L4R VACWR091 late core DNA-binding protein, VP8 
Genome 
regulation 
ISKYAGINILNVYS
P 
J4R VACWR096 early 
DNA-dependent 
RNA polymerase 
subunit rpo22 
Genome 
regulation 
DDDYGEPIIITSYL
Q 
H3L VACWR101 late 
IMV heparin 
binding surface 
protein 
Virion 
structure 
PGVMYAFTTPLISF
F 
D8L VACWR113 late IMV membrane protein 
Virion 
structure 
GEIIRAATTSPARE
N 
D13L VACWR118 late 
rifampicin target 
associates with 
inner surface 
immature virus 
membrane 
Virion 
structure 
PKIFFRPTTITANV
S 
A18R VACWR138 early 
DNA helicase; 
effects elongation 
and termination of 
postreplicative 
viral transcription 
Genome 
regulation 
PKGFYASPSVKTS
LV 
A20R VACWR141 early DNA polymerase processivity factor 
Genome 
regulation 
DNIFIPSVITKSGK
K 
A24R VACWR144 early 
DNA-dependent 
RNA polymerase 
subunit rpo132 
Genome 
regulation 
IHVLTTPGLNHAFS
S 
A28L VACWR151 late IMV protein Virion structure 
FFIVVATAAVCLL
FI 
 
The pool of viral peptides was divided randomly into 3 groups for testing. The peptides at 
various concentrations (from 1-20 μg/ml) were added to the 1153 murine B cell line for 
24 h prior to paraformaldehyde fixation of these APCs. 1153 cells express class II I-Ab 
molecules. Similar to the primary APCs used by Sette and colleagues in their studies to 
identify VV peptides binding class II [81], VV-CD4 T cells (harvested from 7 d VV 
infected mice) were co-cultured with virus peptide treated 1153 cells for 72 h prior to 
measuring T cell proliferation. APCs incubated with VV (MOI 0.1) were set up as the 
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positive control to stimulate virus-specific CD4 T cells. The absolute values of T cell 
proliferation were plotted in Fig. 34A to C. Typically, the 10 to 20 μg/ml of each peptide 
induced the highest response in terms of T cell activation or proliferation. As shown in 
Fig. 34D, the relative response of virus-induced CD4 T cells to each peptide was 
compared following normalization (i.e. VV-CD4 T cells co-cultured with 1153 with no 
peptide or virus addition, set as 1). Those viral peptides that induced responses above 1 
were considered antigenic. Similar to published studies with these peptides, we found 
differences in the relative ability to activate T cells. Based on our results, we concluded 
that J4R, H3L, F15L and L4R peptides displayed the highest relative simulation of T 
cells, followed by I1L, E1L, D8L, D13L, A20R, E9L and A24R derived peptides. Two 
peptides-A18R and A28L appeared unable to activate T cell responses using 1153 cells 
as APCs. Interestingly, peptides from D8L and H3L viral gene products do appear to bind 
class II molecules and activate virus-specific CD4 T cells. In their published study, Sette 
and colleagues directly measured the binding of these viral peptides to class II. While 
binding was observed in their study, using an assay to measure T cell IFN-γ production, 
this group also found not all these peptides can stimulate T cell cytokine secretion [81].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 103
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
1 10 20 1 10 20 1 10 20
Cont. VV F15L E1L E9L
T 
ce
ll 
pr
ol
ife
ra
tio
n 
(×
10
3
cp
m
)
Peptide (µg/ml)
Name
0
5
10
15
20
25
30
35
40
45
1 10 20 1 10 20 1 10 20 1 10 20 1 10 20
Cont. VV I1L L4R J4R H3L D8L
T 
ce
ll 
pr
ol
ife
ra
tio
n 
(×
10
3
cp
m
)
Peptide (µg/ml)
Name
0
10
20
30
40
50
60
70
1 10 20 1 10 20 1 10 20 1 10 20 1 10 20
Cont. VV D13L A18R A20R A24R A28L
T 
ce
ll 
pr
ol
ife
ra
tio
n 
(×
10
3
cp
m
)
Peptide (µg/ml)
Name
0
0.5
1
1.5
2
2.5
3
3.5
1 10 20 1 10 20 1 10 20 1 10 20 1 10 20 1 10 20 1 10 20 1 10 20 1 10 20 1 10 20 1 10 20 1 10 20 1 10 20
F15L E1L E9L I1L L4R J4R H3L D8L D13L A18R A20R A24R A28L
R
el
at
iv
e 
T 
ce
ll 
re
sp
on
se
s
Peptide (µg/ml)
Name
A
B
C
D
T 
ce
ll 
pr
ol
ife
ra
tio
n 
(×
10
3
cp
m
)
T 
ce
ll 
pr
ol
ife
ra
tio
n 
(×
10
3
cp
m
)
T 
ce
ll 
pr
ol
ife
ra
tio
n 
(×
10
3
cp
m
)
T 
ce
ll 
pr
ol
ife
ra
tio
n 
(×
10
3
cp
m
)
T 
ce
ll 
pr
ol
ife
ra
tio
n 
(×
10
3
cp
m
)
T 
ce
ll 
pr
ol
ife
ra
tio
n 
(×
10
3
cp
m
)
R
el
at
iv
e 
T 
ce
ll 
re
sp
on
se
s
R
el
at
iv
e 
T 
ce
ll 
re
sp
on
se
s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 34 Presentation of VV peptides by class II molecules. A. Presentation of F15L, 
E1L and E9L synthetic peptides by class II I-Abon 1153 cells.  Peptides at various 
concentration (1, 10, 20 μg/ml) were added to 1153 cells for 24 h followed by cell 
fixation. VV-CD4 T cells isolated from 7 d in vivo infected mice were co-cultured with 
peptide-treated 1153 for 72 h before measuring T cell proliferation by [3H]-thymidine 
addition. VV-CD4 T cell responses to VV (MOI=0.1) and 1153 were monitored as a 
positive control. B. Presentation of I1L, L4R, J4R, H3L and D8L peptides by 1153 
cells. C. D13L, A18R, A20R, A24R and A28L peptide presentation by I-Ab expressing 
on 1153 cells. For panels B and C, 1153 were incubated with the corresponding 
peptides and treated as described in panel A. D. Relative T cell responses induced by 
these peptides and 1153 APCs. CD4 T cell responses to 1153 cells and each virus-
derived peptide as plotted in panels A-C were normalized. For each set of assays, T cell 
proliferation in response to 1153 cells alone was set equal to 1.
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3.3 The effects of VV infection on class II presentation of a model Ag in vivo  
 
Our prior studies demonstrated that in vitro infection of APCs by VV diminished the 
ability of these cells to present both peptide and proteins to CD4 T cell. This work was 
expanded here to test whether in vivo virus infection could influence the ability of APCs 
to stimulate T cell responses to a protein Ag in a mouse model of induced asthma. We 
selected a murine model of ovalbumin (OVA) induced asthma for these studies which 
were carried out in collaboration with the laboratories of Drs. David Wilkes, Mark 
Kaplan and Randy Brutkiewicz. The asthma model was also selected for these studies as 
the natural route for poxvirus infection is via the respiratory track. Respiratory infectious 
viruses such as respiratory syncytial virus (RSV) and influenza virus may trigger and 
exacerbate asthma [247, 248]. The study of host immune responses to VV in healthy and 
asthmatic animals had not been studied in depth and offered an important model to 
further investigate how VV infection influences host immunity in vivo. OVA induced 
asthmatic mice as well as healthy mice were mock or intratracheally infected with VV for 
4 d, followed by an analysis of virus-induced lung pathology. Histological analysis of 
animal lungs and cytokine analysis of splenocytes from these mice were performed. 
Tissue sections were stained with haematoxylin/eosin (HE) to detect cellularity and 
immune cell infiltration. Mucous production was detected by PAS staining of tissue 
sections and served as a hallmark indictor of asthma. VV infection of mice typically 
results in the activation of T cells producing pro-inflammatory cytokines like IFN-γ (Fig. 
33). Asthma, on the other hand, is mediated by the production of cytokines like IL-4, IL-
5 and IL-13 in the lungs. We speculated that virus infection and pre-existing asthma 
might antagonize each other. Therefore, the inflammation and pathology associated with 
asthma and VV infection might be ameliorated in asthmatic mice challenged with VV 
compared to asthma or infection alone mice. Indeed, VV infection of mice appeared to 
diminish asthma related inflammation as shown by the histological analysis (Fig. 35). In 
control or untreated animal groups, no obvious lesion or PAS+ mucous producing cells 
were observed (Fig. 35A and E).  Asthma alone induced peribronchiolar and perivascular 
infiltrates and bronchus-associated lymphoid tissue (BALT) production (Fig. 35B). Many 
PAS+ cells showed up in mice exposed to asthma only (Fig. 35F).  Mice with VV 
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infection only demonstrated peribronchiolar and perivascular inflammation as well as a 
few PAS+ cells (Fig. 35 C&G). As expected, inflammation in VV-infected asthma mice 
was less severe and in the lungs PAS+ cells were less frequently detected (Fig. 35D and 
H) compared with asthmatic mice alone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The analysis of cytokine production by splenocytes correlated with our histological data. 
Splenocytes including APCs and T cells were in vitro re-stimulated +/- OVA for 72 h 
before ELISA analysis were performed. Among the cytokines we tested, IL-5 and IL-13 
are two important Th2 cytokines induced during asthma. IL-5 plays a role in the 
development, maintenance and activation of eosinophils [249]. IL-13 initiates B cells to 
secrete IgE [249] and induces mucous secretion [250]. As shown in Fig. 36A and B, both 
IL-5 and IL-13 were detected only upon re-stimulation of spleen cells from asthmatic but 
not healthy mice. The production of cytokines in these assays was dependent on OVA 
addition to splenocyte cultures, strongly suggesting that cytokines were secreted by T cell 
recognizing OVA peptides presented by class II molecules on APCs. Viral infection of 
asthmatic mice resulted in reduced IL-5 and IL-13 production during in vitro re-
 
 
 
 
 
 
 
 
 
 
 
Fig. 35 Histochemistry of lungs from mice +/- asthma and/or VV.  Panels A to D 
were lung samples stained with H&E while panels E to H were lung tissue stained with 
PAS. Panels A and E were samples from non-asthmatic, non-VV infected control mice. 
B and F were from asthmatic mice without VV infection. C and G were from VV 
infected healthy mice. D and H were from both asthmatic and VV infected mice. 
Representative images from each group of animals (5 per group) were shown using a 
magnification of 20X. Tissue histopathology was analyzed by Dr. David Wilkes, 
IUSM. 
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stimulation assay. This could reflect with reduced class II OVA Ag presentation upon 
viral infection of the asthmatic mice, which would lead to less T cell activation in vivo. 
Consistent with this, we observed less cytokine production when we attempted to re-
stimulate T cells from these mice in vitro (Fig. 36). The reduction in T cell responses and 
IL-5 and IL-13 secretion may explain the amelioration of the asthmatic condition in these 
mice with VV inoculation (Fig. 35). Induction of asthma alone or VV infection induced 
IFN-γ production in mice. Combining these treatments enhanced T cell IFN-γ production 
synergistically (Fig. 36C). The increased production of IFN-γ in the asthmatic mice upon 
virus infection could promote VV clearance. Indeed, VV titers from animal lung tissue 
were consistently lower in asthmatic mice exposed to virus compared with VV infected 
mice (data not shown). IL-17, another pro-inflammatory cytokine, was produced in both 
asthma alone and asthma + VV groups of mice. Although infection alone did not induce 
IL-17 production in these studies, VV inoculation increased IL-17 expression 
dramatically in the presence of asthma (Fig. 36D). IL-17 appears to trigger inflammation 
in several autoimmune diseases and is associated with asthma [251]. However, our 
histological data (Fig. 35) suggests that this enhanced IL-17 in the combined treatment 
group did not exacerbate asthma. One recent report suggests that IL-17 is partially 
involved in host immunity against VV infection [252]. Thus, enhanced IL-17 production 
may also contribute to the reduced VV titers in the combined treatment group. Together 
these studies suggest virus infection in vivo alters the generation of cytokines secretion 
profile of T cells responsive to a protein Ag, OVA. Future studies will be necessary to 
address whether this is specifically due to changes in class II function upon virus 
infection of resident APCs. But it is known that the level of Ag presentation by APCs can 
shift T cell development from producing Th1 cytokines like IFN-γ to Th2 cytokines like 
IL-4 [253].  
 
 
 
 
 
 
 107
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4 Recall VV specific responses of T cells 
 
Primary adaptive immune responses always contract with the disappearance of Ag. 
However, some Ag-specific T and B cells persist and become the bases for immune 
memory. When the body encounters the same Ag again, the lag period for immune 
responses is shorter and the secondary immune response is greater [6]. Here, we 
examined whether similar T cell responses were observed during secondary challenge of 
animals with VV. Booster immunization of C57BL/6 mice was performed by i.p. 
injection of VV (1×106 pfu/mouse) 3 weeks after a primary inoculation with virus. Since 
re-activation is faster than the primary response, CD4 T cells were isolated 4 d after the 
2nd injection. These CD4 T cells were termed 2×VV-CD4 T cells. 2×VV-CD4 T cells 
were co-cultured with virus incubated APCs (i.e. APCs treated with VV at MOI 0.1 or 
HI-VV at MOI 1 for 24 h). T cell cytokine production was analyzed by ELISA using IL-
2, IFN-γ and IL-17 specific Abs. As in primary responses, only IL-2 and IFN-γ could be 
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Fig. 36 Cytokine production by splenocytes from mice +/- asthma and/or VV 
infection. A. IL-5 production in mice +/- asthma and/or VV infection. Splenocytes were 
harvested and in vitro restimulated +/- OVA (100 μg/ml) for 72 h prior to being 
analyzed with ELISA using IL-5 specific Abs. B, C, D: Quantity of IL-13, IFN-γ and IL-
17 production detected with corresponding Abs for ELISA analysis. Data was averaged 
from five mice in each group. These ELISA analysis were performed by Dr. Gourapura 
Renukaradhya.   
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detected (Fig. 37A and B). IL-17 production was not observed (data not shown). Similar 
to primary responses (Fig. 31), HI-VV stimulated higher amount of IL-2 and IFN-γ 
production than untreated VV. The production of IFN-γ but not IL-17 by 2×VV-CD4 T 
cells was also confirmed by intracellular staining after in vitro polyclonal re-stimulation 
with PMA and ionomycin (done by Norman Yeh at Dr. Mark Kaplan’s laboratory, data 
not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition to CD4 T cells, CD8 T cells also play an important roll in VV specific 
immune memory. To test CD8 T cell function in VV recall responses, CD8 T cells from 
twice inoculated mice (2×VV-CD8 T cells) were isolated with microbeads coated with 
CD8 specific Abs. After in vitro re-stimulation of these T cells with PMA and ionomycin, 
intracellular staining with granzyme B and IL-17 Abs was performed. Granzyme B is a 
caspase like serine protease released by CD8 T cells to lyse infected cell targets [254]. 
Granzyme B is considered a marker to detect cytolytic CD8 T cells. As expected, mice 
infected twice with VV contained a greater percentage of granzyme B expressing CD8 T 
cells (Fig. 38A). These results correlated with previous literatures which had shown that 
VV infection can induce CD8 T cell responses in human [241, 255]. Interestingly, the 
expression of IL-17 was consistently detected in 2×VV-CD8 T cells from infected 
animals (Fig. 38B). IL-17 can be produced by multiple cell types including CD4, CD8, γδ 
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Fig. 37 Cytokines produced by T cells after in vivo VV rechallenge. A. IL-2 
secretion by 2×VV-CD4 T cells. 2×VV-CD4 T cells were isolated from lymph nodes 
and spleens of mice after a 2nd in vivo virus inoculation. 2×VV-CD4 T cells were co-
cultured in vitro with APCs pre-incubated with VV (MOI=0.1) or HI-VV (MOI=1). 
After 72 h incubation, culture supernatants were harvested and analyzed by ELISA 
using IL-2 specific Abs. B. Production of IFN-γ by 2×VV-CD4 T cells. Cell culture 
was same as described in panel A. Supernatants were detected by ELISA using IFN-γ 
specific Abs.  
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and NK T cells [256-259]. IL-17 production by CD8 T cells has been linked to 
pathogenesis in autoimmunity and infection  [256, 260-262]. The induction of IL-17 
expression by CD8 T cells may be one of the mechanisms the host uses to fight VV 
infection. Collaborative studies are underway with Dr. Kaplan and Dr. Brutkiewicz’s 
laboratories to test this hypothesis. 
 
 
 
 
 
 
 
 
 
 
 
 
To further investigate which APC populations could promote T cell IL-17 production, 
CD4 and CD8 T cells were isolated from uninfected mice and activated in vitro under IL-
17 polarizing condition [201] in the presence of various populations of APCs. Splenic 
cells and lymph node cells from untreated C57BL/6 mice were harvested and depleted of 
T cells with CD4 and CD8 Ab coated microbeads to isolate total APCs. Individual APC 
subsets were isolated with CD11c, CD11b and B220 Ab coated microbeads sequentially. 
Splenic CD4 and CD8 T cells were also harvested from uninfected C57BL/6 mice by 
isolation with corresponding Ab coated microbeads. CD4 and CD8 T cells were activated 
in vitro with anti-CD3 and anti-CD28 in the presence of various APC populations (total, 
DCs, B cells and macrophages) and then cultured under conditions to skew these cells for 
differentiation into IL-17 producing T cells for 5 d before intracellular staining with an 
IL-17 specific Ab. For CD4 T cells, B cells followed by DCs were most effective in 
inducing T cell IL-17 production compared with total APCs or macrophages (Fig. 39A). 
For CD8 T cells, DCs appeared to be best while both B cells and macrophages increased 
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Fig. 38 Production of granzyme B and IL-17 by VV-induced CD8 T cells. A. 
Granzyme B expression in 2×VV-CD8 T cells. CD8 T cells were isolated from mice 
after a 2nd inoculation with VV followed by in vitro re-stimulation with PMA and 
ionomycin. Intracellular staining of these cells using granzyme B specific Ab was 
performed 4 h after this re-stimulation. B. IL-17 secretion by 2×VV-CD8 T cells. The 
isolation and re-stimulation CD8 T cells were the same as in panel A. Intracellular 
staining of CD8 T cells was done using an IL-17 specific Ab. In vitro re-stimulation and 
intracellular staining were done by Norman Yeh.  
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T cell IL-17 secretion greater than total APCs did, although the differences are slight 
(Fig. 39B). When APCs from lymph nodes were tested compared with APCs from 
spleen, IL-17 production was much lower for both CD4 and CD8 T cells (data not 
shown). 
 
Taken together, VV inoculation of mice can induce immune memory via activation of 
CD4 and CD8 T cells. The main cytokines produced by these CD4 T cells include IL-2 
and IFN-γ. CD8 T cells, on the other hand, produce granzyme B, IL-17 and IFN-γ (Fig. 
38 and data not shown). In vitro DCs, macrophages and B cells served as APCs to induce 
T cell IL-17 production for both CD4 and CD8 T cells. For activation of IL-17 producing 
CD4 T cells, again each APC type appeared to activate these cells although B cells and 
DCs appeared more potent than macrophages. 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, VV induced both primary and secondary acquired immune responses. 
Inactivated or genetically defective VV could be presented better than wild type VV. This 
may be due to preservation of the class II pathway for Ag presentation upon APC 
exposure to these modified viruses. However, the overall antigenicity of wild type, 
untreated VV was higher than that of the defective VV as demonstrated by the ability of 
wild type, replication competent virus to induce greater numbers of VV-specific T cells 
in vivo. The main cytokines producing by VV specific CD4 T cells were Th1 cytokines 
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Fig. 39 The effect of various APC populations on T cell-induced IL-17 production. 
A. The effect of APC populations on IL-17 secretion by CD4 T cells. CD4 T cells 
isolated from C57BL/6 mice were stimulated with anti-CD3 and anti-CD28 Abs in the 
presence of various APC subsets under conditions to promote IL-17 production for 5 d 
before intracellular staining with an IL-17 specific Ab. B. Differential ability of various 
APC populations to promote IL-17 production by CD8 T cells. CD8 T cells were 
isolated from mouse spleens. Other steps were same as in panel A. In vitro culture and 
intracellular staining were done by Norman Yeh.  
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(IFN-γ and IL-2). Accordingly, VV induced Th1 polarization and antagonized Th2 
cytokine-mediated asthma. A secondary infection induced CD8 T cells to secrete 
granzyme B and IL-17. IL-17 production by CD8 T cells could be enhanced by in vitro 
co-culturing with APCs such as B cells and DCs 
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Chapter 4 Development of humoral immunity to VV membrane proteins 
 
A key goal in our studies of VV and its interaction with host immunity is to generate new 
ideas or approaches for safer vaccines. Immunoevasion represents a major obstacle for 
safe vaccination and the development of protective immunity.  VV-induced disruption of 
class II Ag presentation has been demonstrated and could compromise cellular immune 
responses [96, 97]. The two viral envelope proteins - D8 and H3 bind cell surface 
chondroitin sulfate and heparan sulfate respectively, implicating that these viral Ags 
involved in cell attachment, entry and infection [193, 194].   Using radio-labeled virus, 
we previously observed that D8 and H3 proteins could bind to class II molecules. 
Peptides from these two viral proteins induced CD4 T cell responses (Fig. 34). Thus, 
these two viral proteins are potential targets for amelioration of the current VV vaccine. 
Ab responses to H3 and D8 are detected in humans and mice after VV inoculation [263, 
264]. Here, a polyclonal Ab specific for an H3 epitope (eH3) was demonstrated to be 
effective in blocking VV entry and preservation of class II function during VV infection. 
These results potentially support a role for Ab in protecting immune cell function during 
subsequent VV infections and may offer an alternative for vaccine-induced human 
immunoglobulin (VIG) being used to treat infections in immune compromised 
individuals.  
 
4.1 Expression of viral D8 and H3 mRNAs and proteins in infected B-LCL 
 
To demonstrate that D8L and H3L gene products could be detected in VV infected cells, 
PriessGAD cells were infected with virus (MOI=10) for up to 14 h before Western Blot 
and RT-PCR analysis. As shown in Fig. 40, expression of two viral late gene products 
increased progressively during VV infection. As a viral late gene produce, D8 protein 
was weakly detectable at 2 and 6 h presumably due to its presence in infectious virions 
which enter cells (Fig. 40A). By 8 h, D8 protein was readily detected. H3 protein is also 
considered a viral late Ag and present in virions. H3 protein was detected at a similar 
level at 2 and 6 h, with increased protein expression after 8 h. Differences in mAb 
recognition may account for our ability to more readily detect the H3 vs. the D8 protein 
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in virus infected cells. As expected for a late viral gene, D8 mRNA was just detectable at 
2 h post infection and plateaued by 8 h (Fig. 40B). A similar time course for viral H3L 
late gene mRNA was also observed. In studies of viral early gene product E3L, we noted 
strong expression at 2 h followed by decreased viral mRNA at later times (Fig. 8A). The 
increase in mRNA abundance for D8L and H3L suggest transcription was rapidly 
increased between 2-6 h, which just proceeded a detectable increase in each protein’s 
expression. Thus, both D8L and H3L gene products are readily detected at both early and 
late stages of virus infection, with likely new protein synthesis commencing between 6-8 
h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2 Synthesis of recombinant D8 and H3 proteins  
 
Studies in our laboratory suggested rabbit Abs for H3 and D8 proteins could be generated 
using specific peptides from these viral proteins as immunogens. To confirm that the 
polyclonal rabbit anti-sera raised against an H3 peptide could detect viral H3 Ag, we 
synthesized recombinant H3 protein in vitro. H3 was expressed in E. Coli and purified 
with the QIAexpressionist kit. Recombinant D8 protein was synthesized as well. 
 
 
 
 
 
 
 
 
Fig. 40 Expression of D8L and H3L viral gene products in VV infected B-LCL. A. 
D8 and H3 proteins in VV infected cells. PriessGAD cells were infected with VV 
(MOI=10) for 0-14 h before cell harvesting and lysis for Western analysis using D8 or 
H3 specific Abs. Host GAPDH was detected in samples as the loading control. 
Quantification data from three separate experiments was averaged and plotted. B. 
mRNA from D8L and H3L in VV infected B-LCL. PriessGAD cells were infected as 
described in panel A. Cells were lysed for RT-PCR analysis using D8L or H3L specific 
primers. Host HSPA10 (encoding HSC70) mRNA was used as a loading control. 
Quantification of RT-PCR data was averaged from three individual experiments.  
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Plasmids containing truncated D8L or H3L genes with histidine tag were generously 
provided by Dr. W. Chang (Institute of Molecular Biology, Academia Sinica, Taiwan). 
Bacterial expression of D8 and H3 was confirmed using D8/H3 specific Abs and His-Ab 
(Fig. 41 A and B). The D8/H3 Abs were raised using the viral Ags as immunogens and 
provided by Dr. Chang.  
 
 
 
 
  
 
 
 
 
 
 
4.3 Recognition of the recombinant H3 Ag by Ab generated by a peptide 
immunogen 
 
D8 and H3 proteins can bind to host surface molecules  and may help VV attach or enter 
host cells [193, 194]. Abs of these two viral proteins might therefore be useful in 
blocking viral entry and thus help preserve class II function.  The protective properties of 
Abs specific for poxviruses has been demonstrated in mice, monkeys and humans [91, 
152, 265, 266]. Studies suggest the H3 protein is an immunodominant target of human 
anti-VV Ab, and Abs to H3 can effectively protect against lethal VV infection in mice 
[264]. Often in contrast with whole Ag, vaccines derived from antigenic peptides or 
epitopes induce fewer and/or milder side-effects and may be more readily prepared in the 
laboratory. Thus, two epitopes from H3 protein were conjugated to keyhole limpet 
hemocyanin (KLH) and used to immunize rabbits. One epitope - the H344-61 peptide is 
located in the extracellular domain of the H3 protein and likely exposed on virions. The 
other epitope - the H3244-259 peptide is located in the transmembrane domain of H3. 
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H3
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Fig. 41 In vitro synthesis of D8 and H3. A. Bacterial expression of histidine tagged 
D8 protein was detected with D8 protein specific Ab and His-specific Ab. Bacteria 
were grown with (+) or without (-) IPTG to induce the expression of the recombinant 
viral Ag. In vitro expressed D8 protein was purified in a nickel chromatography 
column, fractionated by SDS-PAGE, transferred to membranes and probed with D8 
protein specific Ab or a His-specific Ab. B. Expression of H3 protein with a histidine-
tag. H3 protein was isolated from bacteria +/- IPTG induction and detected by Western 
analysis with Abs to H3 and Abs to the His-tag. For panels A and B, samples without 
IPTG induction were used as negative controls. 
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Polyclonal Abs specific for these two epitopes were readily detected in the sera of 
immunized rabbits. The H344-61 specific antisera was named as eH3 while the antisera to 
H3244-259 was termed eH3c. Biochemical and functional assays were performed to test the 
specificity and efficacy of these H3 epitope specific Abs in protection of cells from VV 
infection. 
 
First, the specificity binding of eH3 and eH3c to the H3 protein was tested by Western 
analysis and ELISA analysis (Fig. 42). Both eH3 and eH3c recognized viral H3 protein 
but not host cellular proteins in CV1 cells as shown by Western analysis (Fig. 42A). 
These samples were also probed with a set of Abs generated to the H3 and D8 
recombinant proteins as a positive control. ELISA using in vitro synthesized H3 protein 
also demonstrated both rabbit polyclonal Abs to the H3 peptides recognize purified viral 
H3 (Fig. 42B). The affinity of eH3 Ab binding to the H3 protein was higher than that of 
the eH3c Ab based upon the results of these ELISA. Together, these studies confirm that 
anti-sera to H3 peptides recognize the H3 Ag produced in virus infected cells as well as 
purified recombinant H3 protein. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 42 Specific binding of eH3 and eH3c Abs to VV encoded H3 and recombinant 
H3 protein. A. Specific recognition of VV H3 protein by eH3 and eH3c Abs. Equal 
volumes of CV-1 cell lysate and VV purified from CV-1 cells were resolved on SDS-
PAGE followed by immunoblotting with eH3, eH3c or a mixture of Abs to H3/D8 
proteins. An H3 protein specific Ab and a D8 specific Ab were used as controls to 
confirm the migration of H3 protein on electrophoresis. Data is representative of five 
individual experiments. Monomers of H3 protein are marked by * at approximately 35 
KD. A protein at 37 KD was also frequently detected by the H3 Abs and may represent 
a form of viral H3 with increased glycosylation. B. Binding of eH3 and eH3c Abs to 
purified recombinant H3 protein. In vitro synthesized H3 protein was coated on ELISA 
plates followed by the addition of serial diluted eH3 or eH3c Abs. Goat anti rabbit IgG 
Fc-HRP and ABTS were then added sequentially for detection in these ELISA. Data 
shown in panel B was ELISA done by Xiaoping Gu using recombinant H3 produced 
by the author. 
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To further investigate if these two Abs to H3 peptides were functional in blocking virus 
infection, flow cytometry analysis and T cell assays were performed. Vaccinia immune 
globulin or VIG, is a concentrated pooled plasma from recent VV human vaccinees 
potentially purified by serial ethanol precipitation [267]. VIG was used in our analysis as 
a positive control since VIG is known to neutralize VV and block host infection. Pre-
immune sera (PI) harvested from rabbits before immunization with the H344-61 peptide 
was used as a negative control which failed to react with purified virions in ELISA 
(experiments by K. Toomey, not shown). To rule out non-specific binding of the test Ab 
to host cell Fc receptors (FcR), PriessGAD cells are treated +/- a commercial Ab which 
binds and blocks FcR from other Abs. VV association with human B cells in the presence 
of various Abs was tested in vitro. PriessGAD cells were exposed to the fluorescent 
EGFP-VV (MOI=10) in absence or presence of different Abs for 6 h followed by flow 
cytometric analysis to detect the green viral protein produced upon cell infection. 
Infection was calculated as the % of EGFP positive cells among total live cells. This data 
is summarized in Fig. 43A. When infected by EGFP-VV alone without pre-incubation 
with Ab, cellular infection efficacy was around 80%. eH3 Ab blocked VV infection as 
potently as VIG, i.e. only about 10% of the cells contained EGFP when virus was added 
plus these two Abs. eH3c or pre-immune sera (PI), on the other hand, could not protect 
cells from VV infection. The percent cellular infection was similar in the presence or 
absence of the FcR blocker. Ab treatment did not promote or block virus uptake by FcR. 
Next, class II function upon cell incubation with VV and the eH3 or eH3c Abs was tested 
using endogenous GAD as a model Ag. PriessGAD cells were infected with VV 
(MOI=10) +/- various Abs for 6 h. As shown in Fig. 43B, VV infection reduced class II 
mediated-GAD Ag presentation. Pre-incubation of VV with either VIG or eH3 reduced 
VV inhibition of GAD Ag presentation by blocking the ability of the virus to inactivate 
class II molecules. eH3c and PI, however, were both ineffective in protecting class II 
function. Again the FcR blocker did not affect GAD Ag presentation by cells in these 
assays.  
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Thus, we demonstrated here that two viral envelope proteins D8 and H3 were expressed 
in VV infected cells. An Ab specific for the H3 extracellular epitope (eH3) bound to the 
intact H3 protein. This eH3 Ab blocked VV infection of host cells and preserved class II 
function upon exposure to VV.  
 
 
 
 
 
 
 
 
Fig. 43 eH3 Ab reduced VV infection and preserved class II function. A. Reductions 
in VV infection were observed in the presence of the eH3 Ab. PriessGAD cells +/- FcR 
blocker reagent were exposed to EGFP-VV (MOI=10) in the presence of different Abs 
for 6 h before cell fixation and flow cytometric analysis. Methods were described in 
detail in Materials and Methods section. The percent EGFP positive cells were detected 
only for live cells. B. Preservation of class II function by eH3 Ab. PriessGAD cells +/- 
FcR blocker were exposed to VV (MOI=10) +/-Abs for 6 h before GAD specific T cell 
addition. At least three separate experiments were carried out.  
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DISCUSSION AND FUTURE DIRECTION 
 
1. Mechanisms underlying VV disruption of MHC class II function  
 
The goal of this thesis was to investigate the effects of VV infection on APC function and 
the activation of CD4 T cells. Perturbation of MHC class II function may represent an 
important mechanism of VV-induced immunoevasion, which influences the development 
of anti-viral immunity during VV infection. Correlating with previous investigations [94-
96], studies here demonstrated that VV readily infected APCs but not T cells. VV-
induced APC dysfunction and specifically altered class II presentation were demonstrated 
in both primary APCs and immortalized cell lines (Fig. 3). Virus-induced changes in 
class II presentation correlated with the level of cellular infection. Our prior studies [97] 
failed to detect a soluble mediator released from VV infected cells. Also, in blocking VV 
infection of cells using an Ab to viral H3 protein, we found class II presentation was 
preserved (Fig. 43). Thus, virus infection of APCs appears to be directly required for 
virus-induced alterations in class II presentation by these cells. Heat treatment (60˚C, 1 h) 
disrupts VV replication and gene expression, and heat treated virus no longer altered 
class II presentation by APCs (Fig. 4). UV treatment of virus, which blocks early gene 
expression and virus replication, did not ablate the effects of VV on class II presentation 
[97]. Yet, treating cells infected with VV with a viral polymerase inhibitor, AraC did 
partially overcome the loss of class II function at late stages of infection (Fig. 4). AraC 
blocks the expression of viral late gene products [202]. Together these results suggest a 
viral late gene product likely present in infectious virions may be responsible for altering 
class II presentation in APCs.  
 
1.1 Inhibition of host protein synthesis  
 
The precise events leading to virus-induced alterations in the class II pathway remain 
poorly defined. Multiple steps within this pathway may be perturbed by VV following 
virion entry into cells and the transition from early to late stages of virus infection. Yet 
few studies have addressed the temporal changes during VV infection that might 
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influence class II presentation by APCs. Class II dysfunction was observed within 1-2 h 
after VV infection with a progressive decrease in class II presentation as virus infection 
transitioned from early to late stages [97]. In epithelia and some tumor cells, VV 
infection was shown to disrupt host protein synthesis within the first 1-2 h of infection 
[106]. Using the well characterized protein synthesis inhibitor-CHX, it has also been 
demonstrated that inhibition of protein synthesis results in a loss of class II presentation 
[22, 44]. Thus, host protein synthesis inhibition was tested as one possible mechanism by 
which VV might induce class II dysfunction. Class II protein total cellular expression (by 
Western analysis, Fig. 7) and surface expression (by flow cytometric analysis, [97]) did 
not change even after 24 h infection of B cells. Synthesis of new class II subunits was 
detected at both 6-14 h after cell infection (Fig. 10). However, mRNAs encoding class II 
α subunit were found to significantly decrease during both in vitro and in vivo VV 
infection (Fig. 8). The relative long life of class II protein (> 24 h) in human B cell lines 
may account for the sustained presence of class II protein subunits, even as virus 
inhibition of class II gene transcription was observed [215].   
 
Besides class II molecules, several other host mRNAs including ACTA1 (encoding actin) 
and GAPDH decreased in a time dependent manner upon VV infection of APCs (Fig. 8). 
Although reductions in host mRNA appeared to be a general phenomenon upon VV 
infection, some host genes were spared possibly so the virus could exploit these host 
proteins to survive and replicate or due to virus-induced cell stress.  For example, host 
HSPA10 mRNA and corresponding HSC70 protein levels did not decrease with VV 
infection. Thus, this HSC was used as a control for our studies. HSC70 is closely 
structure-related to the stress-induced heat shock protein 70 kD (HSP70), the latter 
increases upon VV infection [268].  
 
1.2 Loss of Ii and destabilization of class II molecules 
 
While screening the expression levels for other components of the class II pathway, the 
relative abundance of an important chaperone for class II, Ii was observed to be 
significantly reduced at both mRNA and protein levels following VV infection of APCs 
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(Fig. 10-12). This reduction in Ii expression was temporally correlated with the later 
stage of virus infection when class II presentation heavily ablated (compared Fig. 3 and 
10). Virus-induced reduction of Ii was a general phenomenon observed using several 
human B-LCL, human PBMCs and murine splenocytes upon both in vitro and in vivo VV 
infection. Levels of functional Ii (class II associated Ii) were diminished along with total 
Ii expression during VV infection (Fig. 13). Ii is important for class II αβ maturation and 
the presentation of endogenous and exogenous Ag as well as peptides. Thus, reductions 
in cellular Ii especially the class II associated Ii during VV infection likely contributes to 
a loss of class II function [22]. Notably, studies with replication-deficient virus also 
revealed decreased Ii expression in infected cells. For example, exposing cells to UV 
irradiated VV lead to both loss of class II function and a reduction in cellular Ii  
(reference [97] and Fig. 10). Viral replication inhibitor-AraC partially preserved class II-
mediated Ag presentation and Ii expression simultaneously (Fig. 4 and 10). Consistent 
with our results, Ii loss induced either by genetic manipulation (antisense 
oligodeoxynucleotides) or inhibitors of protein synthesis (CHX) also significantly reduce 
MHC class II-mediated Ag presentation [20, 22].  
 
On the other hand, enhancement of Ii expression by either transfection or knock-in is 
known to increase the function and folding of some class II alleles [21].  Similarly, we 
observed that over-expression of cellular Ii preserved class II-restricted Ag presentation 
in both professional and non-professional APCs upon VV infection (Fig. 25-27, 29). By 
cell fusion to increase Ii gene copy number or transfection of cells with class II +/- Ii 
plasmids, we demonstrated that higher Ii expression helped preserve class II presentation 
upon exposure to VV (Fig. 25 -27). Notably, we also found that cells transfected with Ii 
have higher surface class II expression and likely more stable class II molecules 
compared to cells without Ii (Fig. 26 and data not shown). Studies have shown Ii 
promotes class II folding and intracellular trafficking [269]. Enhancement of cellular Ii 
level by infection cells with recombinant VV encoding Ii also partially preserved class II 
function (Fig. 29). Together those studies suggest that Ii loss likely contributes in part to 
VV-induced class II dysfunction. 
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Ii chaperones class II from the ER to the endosomal network. Ii deficiency leads to 
misfolding for some class II alleles in the ER [34]. Class II molecules in the absence of Ii 
can associate with ER resident stress proteins such as GRP94, ERP72, GRP78/Bip and 
calnexin [270-272]. These ER chaperones binding to class II molecules could result class 
II accumulation in the ER and induced stress. Stress protein targeted class II molecules 
could also be retrotranslocated to the cytoplasm and degraded by the ubiquitin-
proteasome system [273]. In our proteomics study, we observed that levels of stress 
proteins such as Bip and HSP70 were increased upon VV infection (data not shown). The 
accumulation of class II molecules in the ER also could prevent their transit to 
endosomes and the cell surface, steps required for function. Experiments are ongoing to 
examine class II association with ER stress proteins upon VV infection. Whether ER 
stress is induced during virus infection is unclear but could be linked to accumulation of 
host or viral proteins in this compartment. 
 
Reductions in cellular Ii levels may disrupt class II function by comprising class II 
dimeric structure. Alterations in class II structure with VV infection of cells, are 
consistent with our previous finding that VV destabilizes class II-peptide binding [97]. 
Additionally, when compared the peptides bound with low or high affinity to class II 
molecules, we observed that class II presentation of the low affinity peptide was more 
dramatically reduced by VV infection (Fig. 9). Thus, class II destabilization caused by Ii 
reduction may further compromise the class II pathway in the context of VV infection.  
Early studies demonstrated that Ii processing and expression regulates class II transport 
[274, 275]. Thus, although the steady total and surface class II expression remained 
constant up to 24 h of VV infection, it remains possible that the intracellular distribution 
or routing of class II molecules may be altered in cells exposed to virus. This hypothesis 
could be further tested using confocal or electron microscopy. A previous report 
demonstrated abnormal aggregation for some but not all class II alleles in Ii deficient 
cells [35]. Yet during VV infection, such high molecular mass aggregates of class II DR4 
were not observed (Fig. 14). Another co-factor of the class II pathway chaperoned by Ii, 
DM may be destabilized, retained in the ER or degraded more quickly in the absence of Ii  
[35, 42, 43]. However, here we found no changes in DM protein levels in human B cell 
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lines infected with VV (Fig. 14). The differences between various species (human vs. 
mouse) or cell types (B cells vs. fibroblasts) may lead to this disparity.  
 
Both mRNA and protein Ii expression were diminished upon VV infection, with the 
reduction in mRNA temporally preceding protein loss (Fig. 10). Thus, we concluded that 
inhibition of Ii synthesis was likely the primary cause of reduced cellular Ii levels. 
Decreased [35S]-methonine incorporation into newly synthesized Ii protein upon VV 
infection was consistent with this conclusion. To further investigate the negative effects 
of disrupting host protein synthesis on Ii expression and class II presentation, CHX was 
used. CHX mimicked VV effects on Ii protein expression and class II function (Fig. 15-
18). However, some differences were noted between the negative effects of CHX and 
VV. For example, only VV but not CHX altered Ii mRNA expression. This result was 
consistent with the fact that CHX works at the translational stage to disrupt protein 
synthesis. CHX treatment of cells reduced Ii protein levels much faster than cellular VV 
infection (Fig. 17). Furthermore, the inhibitory effect of CHX on class II peptide 
presentation was more selective than observed with VV infected cells (Fig. 18). In line 
with previous studies  [22, 44], only the presentation of peptides which require 
intracellular processing, could be efficiently inhibited by CHX. While presentation of 
peptides that bind directly to cell surface class II molecules was more resistant to CHX 
treatment. In contrast with CHX, VV infection of cells potently inhibited the presentation 
of all peptides tested (Fig. 9, 18 and data not shown). 
 
These observed differences in the effects of VV and CHX on class II function suggest 
that virus-induced host protein synthesis inhibition not likely the only factor contributing 
to cellular Ii reduction during VV infection. Another pathway potentially contributing to 
Ii loss during VV infection i.e. enhancement of Ii degradation, was also investigated. 
Using the [35S]-methonine pulse-chase assay, we observed decreased degradation of Ii 
during the early stages of VV infection while Ii degradation increased at later stages of 
infection (Fig. 20). Using the cysteine protease inhibitor leupeptin [195], we detected 
reduced expression of the Ii fragment, LIP upon later stages of VV infection (Fig. 19). 
This may suggest faster or more efficient Ii processing. This more rapid degradation of Ii 
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might be due to cellular catabolism or export of Leu, the protease inhibitor, due to virus 
infection. Indeed, VV encodes a cysteine protease I7, important for core protein cleavage 
[276]. Virus derived I7 could bind Leu that otherwise would act on cellular cathespins to 
limit Ii processing. Consistent with this, either increasing the amount of Leu in culture 
media or using an irreversible cysteine protease inhibitor, E64, resulted in increased LIP 
fragment accumulation. These results confirmed that cysteine protease(s) sensitive to Leu 
catalyze the late stages of Ii processing in VV infected cells (Fig. 19). Accelerated LIP 
degradation during the late stages of virus infection was also demonstrated by elevated 
surface CLIP levels on VV infected APCs (Fig. 20). CLIP is a terminal fragment formed 
during Ii degradation by cysteine proteases such as Cat S or Cat L. CHX treatment, by 
contrast, resulted in equally decreased cellular Ii and LIP levels in the presence of Leu 
(Fig. 19). These latter results indicate that disruption of host protein synthesis did not 
directly alter Ii processing.  
 
To further investigate the mechanisms leading to altered Ii processing in virus infected 
cells, the expression of cathepsins as well as other proteases required for Ii processing 
was studied. AEP is a peptidase reported to initiate Ii processing in human B cells [16, 
31]. Decreased AEP mRNA (LGMN) levels were observed upon VV infection (Fig. 24). 
Cat S controls the late stages of LIP processing in many APCs including B cell [32]. 
Upon VV infection, cellular Cat S expression decreased at both the mRNA and protein 
levels (Fig. 21). With reductions in both cellular AEP and Cat S levels, Ii processing was 
expected to slow or halt. Indeed, at early stages of VV infection, Ii processing did slow 
(Fig. 20). Remarkably however, LIP degradation accelerated at late stages of VV 
infection (Fig. 19 and 20). Even after treatment with a 2nd dose of Leu or an irreversible 
cysteine protease inhibitor E64, LIP processing appeared to become faster. These results 
suggested another protease may have been induced or activated to replace Cat S and to 
facilitate Ii processing during late stages of VV infection. In thymic epithelial cells, Cat L 
substitutes for Cat S to proteolyze LIP and promote class II maturation [17, 232]. Both 
Cat L mRNA (CTSL) and mature, proteolytically active form of Cat L increased upon 
VV infection (Fig. 21). This result suggests Cat L may be responsible for the accelerated 
Ii degradation at late stages of VV infection. However, other cellular cysteine proteases 
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and/or viral counterparts like the I7 protease, may also function to speed Ii processing. 
Further screening to map changes in cellular and viral protease expression by Western 
analysis will be required to further address this question. The observed increase in Cat L 
expression was not limited to in vitro VV infection of human B-LCL. Similar results 
were detected upon in vitro and in vivo infection of murine cells (Fig. 22 and 23). The 
explanation for enhanced Cat L expression during VV infection remains to be 
determined. Several possibilities exist. Viral induction of host Cat L may facilitate 
infection, as has been observed for mouse hepatitis virus type 2 and acute respiratory 
syndrome coronavirus [277, 278]. Or VV could use Cat L to promote extracellular matrix 
degradation like tumor cells [279, 280].  Alternatively, elevated Cat L may represent a 
stress response by the host during infection, accelerating processes such as apoptosis [281, 
282]. Correlated with our data that CHX treatment of APCs did not change Ii processing 
(Fig. 19), inhibition of host protein synthesis alone failed to alter cellular Cat S or Cat L 
protein levels at short times of exposure (Fig. 21). 
 
Besides processing of Ii, AEP, Cat S and Cat L are also involved in Ag proteolysis [31, 
283]. Reduced AEP and Cat S may lead to aberrant Ag processing and consequently 
disrupt class II presentation. Even increased Cat L, may not be beneficial for Ag 
proteolysis. Like Ii, these class II-restricted Ags may be degraded faster than they should 
be. Thus, Ag presentation would be down regulated. mRNAs of other proteases mainly 
involved in Ag processing, such as Cat B and D, both decreased upon VV infection (Fig. 
21). The reduction in Cat B and D expression may also contribute to abnormal Ag 
proteolysis. Whether VV-induced changes in cathepsin expression can really influence 
Ag processing remains to be determined. Interestingly, the peptide content of class II was 
altered during cellular infection with an attenuated VV, MVA [284]. Changes in the type 
of peptides as well as their terminal residues were found upon comparing class II DR 
ligands from MVA or uninfected cells. However, not all proteins involved in Ag 
processing are changed by VV. For example, the disulfide bond reductase-GILT protein 
remained constant up to 14 h of VV infection. Remarkably, EEA1 mRNA did not change 
upon VV infection (Fig. 24). EEA1 is an early endosome marker involved in endosome 
fusion and endocytic transport [240]. The recent discovered acidic entry pathway for VV 
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[78] requires endosome.  That’s perhaps the reason for VV to keep EEA1 expression 
constant. 
 
Besides serving a chaperone function in class II pathway, Ii also plays a role in CD1d-
restricted lipid presentation. Ii associates with CD1d, redirects CD1d to endosomes to 
increase CD1d-mediated lipid presentation [285]. CD1d function is also perturbed by VV 
infection of APCs [89, 90]. A reduction in cellular Ii expression during VV infection may 
also influence CD1d presentation. Studies are ongoing to examine whether over-
expression of Ii preserves CD1d function upon VV infection.  
  
Thus, we conclude that VV induced Ii reduction likely contributes to loss of class II 
function during late stages of VV infection. Both a reduction in Ii synthesis and an 
alteration in Ii processing together contribute to the observed loss of cellular Ii protein 
(Fig. 44). Alterations in cellular lysosomal proteases during virus infection may influence 
Ag processing and degradation. This could be further examined in the future. Over-
expression of cellular Ii preserved class II function, confirming the importance of Ii in 
maintaining class II function. Whether viral proteins associate with class II molecules 
during infection, and whether the loss of cellular Ii facilitates these interactions are 
important questions for future studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 44 Mechanisms underlying Ii reduction upon later stages of VV infection. See 
details in the text. 
~Degradation 
Ii reduction
Synthesis 
Ii mRNA Ii protein Cat S Cat L 
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1.3 Viral Ag presentation  
 
Inhibition of class II presentation was detected within 1-2 h of VV infection [97]. Ii 
reduction, however, was not obvious until 6-8 h after VV infection (Fig. 10). Therefore, 
Ii loss likely contributes to class II dysfunction during to the late stage of the virus life 
cycle. Other mechanism(s) that could contribute to the loss of class II function at early 
stages of infection were investigated using both in vitro and in vivo approaches. Our 
published studies revealed destabilization of class II molecules which resulted in 
diminished peptide binding [97]. Consistent with this, we found that peptides which form 
less stable complexes with class II molecules, were more susceptible to VV inhibition 
(Fig. 9). Although not investigated here, competition by VV for other resources required 
by the class II presentation pathway may represent another mechanism, contributing to 
defects in class II function. Thus, the virus might sequester cellular chaperones or 
components of intracellular trafficking which are required by class II molecules. 
 
VV enters the cell by both fusion at neutral and low pH [78, 79]. The latter pathway is 
also the route for internalization and proteolytic processing for exogenous Ag which are 
presented by class II. Thus, viral proteins delivered into the endosomal pathway may be 
readily processed and yield peptides which can be presented by class II molecules for 
recognition by CD4 T cells. VV specific CD4 T cells and Ab have been detected in 
human vaccinated subjects as well as in mouse models, confirming viral proteins are 
processed and likely presented by class II molecules [75, 83, 91, 286], that’s also the 
basis for VV being used as a vaccine. The importance of MHC class II presentation 
during VV infection is also demonstrated by increased lethality of MHC class II deficient 
mice upon VV challenge [83]. Using an in vivo mouse model of VV infection, we 
demonstrated that VV specific CD4 T cells (VV-CD4 T cells) recognize viral peptides 
bound to class II molecules after in vitro infection of APCs by wild type VV or treatment 
of APCs by mutant rVV (Fig. 30-33). These virus specific T cells, VV-CD4 T cells also 
recognized VV derived peptides added to class II+ APCs (Fig. 34). This successful 
induction of VV specific CD4 T cells after in vivo VV inoculation of mice was consistent 
with the detection of virus specific T cells in human vaccinees’ blood samples [287] and 
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primed murine splenic cells [81]. The activation of VV-CD4 T cells by APCs was 
dependent on the in vitro dose and the incubation time of added virus. Treatment of APCs 
for longer incubation times and at low MOI (i.e. MOI=0.1) using wild type VV, induced 
higher CD4 T cell responses. Immunosuppression and disruption of class II function by 
VV were considered as likely reasons for the reduced CD4 T cell responses observed 
after APC exposure to high MOI (i.e. MOI=1) using wild type VV. Inactivation of VV by 
UV or heat resulted in higher CD4 T cell responses compared with untreated replication 
competent VV. Compared with untreated virus, these inactivated viruses disrupt class II 
function less efficiently ([97] and Fig. 4). The greater CD4 T cell responses induced 
using inactivated VV support our hypothesis that viral immunoevasion is responsible for 
the altered class II function at high viral MOI. A recombinant virus BSSH expressing 
truncated D8 (a viral envelope protein that binds to class II), also induced higher CD4 T 
cell responses than wild type VV. These studies with the BSSH rVV suggest that late 
viral protein D8 may play a role in perturbing class II function. However, T cell 
activation by APCs infected with the BSSH virus was still lower than that induced by 
APCs incubated with heat inactivated VV. There are two possible explanations for this 
observation. Truncated D8 may still bind to class II and disrupt presentation more 
severely than heat treated virus. Or heat treated virus likely contains unfolded viral 
proteins which are more easily processed to peptides for presentation by class II, leading 
to stronger T cell activation. When heat inactivated VV was used to immunize mice, no 
VV specific CD4 T cells were detected, suggesting in vivo the inactivated virus was less 
immunogenic (Fig. 32). This inability of heat treated VV to induce VV specific immune 
response was in agreement with several previous studies, showing that heat-inactivated 
VV is ineffective in protecting hosts from orthopoxvirus infection [206].  
 
Class II presentation of synthetic VV peptides was also evaluated and demonstrated a 
hierarchy of CD4 T cells were activated in vivo after virus inoculation (Fig. 34). Similar 
to a published report [81], VV specific CD4 T cells isolated from virus infected mice 
typically targeted viral late gene products, the majority of which are viral structural 
proteins not associated with virulence. While the published study used IFN-γ to monitor 
T cell activation, here T cell IL-2 production was readily detected in response to viral 
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peptide added APCs. Notably, VV epitopes identified using murine T cells here are 
similar to those identified using human T cells [287], indicating conservation of VV 
specific CD4 T cell responses between different mammals. 
 
The main cytokines VV-CD4 T cells produced were Th1 cytokines, IL-2 and IFN-γ (Fig. 
30-33). Similar Th1 cytokine production was observed using wild type or recombinant 
VV infection [288-292]. Interestingly, a study with Ii deficient mice found CD4 T cell 
responses were biased towards Th1 differentiation and Th1 cytokine production [293]. 
Thus, VV-induced Ii reduction may in part contribute to this Th1 polarization. Using 
recombinant VV encoding IL-2 (rVV-IL2), IL-2’s function in VV infection has been 
studied. IL-2, working together with IFN-γ, increases VV clearance by activation of NK 
and CD4 T cells in both immunocompetent and immunodeficient mice [151, 294]. 
Induction of local immunity and chemotaxis by rVV-IL2 has been reported [295]. This 
immunostimulatory function of IL-2 has been extensively used in infection and cancer 
research.  
 
The importance of IFN-γ in host immunity to VV is demonstrated by the increased 
susceptibility to virus infection in IFN-γ receptor deficient mice compared to wild type 
mice [296]. It has been long established that VV infection induces IFN-γ production in 
CD4 T cells [288]. IFN-γ activates cellular PKR; 2’-5’ oligoadenylate synthetase (OAS); 
and inducible nitric oxide synthase (INOS) to fight against virus infection [297]. On the 
other hand, VV has evolved several mechanisms to block IFN-γ action.  VV produces a 
decoy receptor to disrupt IFN-γ anti-viral function [52]. Deletion of the viral gene B8R 
which encodes the decoy IFN-γ receptor, significantly reduces VV virulence [298]. 
Blocking of the B8R encoded decoy receptor by a murine IFN-γ mimetic helped 
C57BL/6 mice survive a lethal VV challenge [299]. VV also encodes a phosphatase, 
VH1. VH1 inactivates signal transducers and activators of transcription (Stat) 1, an 
important component within the IFN-γ signal transduction pathway [300]. The viral gene 
E3L produces ds-RNA binding proteins to prevent IFN-induced PKR activation [60]. The 
E3L gene product also counteracts OAS activation [61]. The K3L viral gene product 
blocks PCR activation by mimicking its substrate eIF-2a [62]. PKR- induced host mRNA 
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translation inhibition and OAS-mediated host RNA degradation are therefore blocked by 
VV. This may favor infected cell survival and offer an environment for VV replication. 
As for IL-2, IFN-γ has been tested as a therapeutic for infection and cancer.  
 
Another potential role for Th1 cytokines is to antagonize Th2 cytokine responses [301]. 
Th2 cytokines are mainly involved in allergy and parasite infection. A previous study 
showed that increased apoptosis of Th1 cells led to Th2 predominance in atopic diseases 
[302]. Thus, we proposed that VV infection would antagonize a Th2-mediated allergic 
disease. Indeed, using an OVA-induced asthmatic mouse model, we observed 
significantly decreased inflammation in mice co-infected with VV compared to 
uninfected mice (Fig. 35). The observed allergic airway inflammation reductions in the 
eosinophilic inflammatory infiltrate and mucus production with VV infection of 
asthmatic mice may be due to the decreased IL-5 and IL-13 production respectively (Fig. 
36). Although atopic dermatitis has long been established as a contraindication for VV 
vaccination [48], these studies using an asthma model suggest VV inoculation or 
immunization may not be detrimental in patients with airway allergic diseases. In fact, 
the amelioration of pre-existing asthma suggests that exposure to some viruses or rVV 
might be useful as a treatment for asthma. These studies also suggest that VV or related 
attenuated viruses could be considered as a vaccine for individuals with airway allergic 
diseases. Additional research is required using mouse models before testing VV as a 
prevention and/or treatment for asthma in humans. 
 
Th2 cytokine production was greatly reduced in animals with asthma that had been co-
infected with VV. However, expression of pro-inflammatory cytokines, IFN-γ and IL-17 
was significantly enhanced in the VV infected asthmatic mice compared to healthy 
animals exposed to VV alone (Fig. 36). Although not severe, inflammation and mucosal 
production could be observed in mice inoculated with VV alone. In animals treated to 
induce asthma, these small abnormal lesions were not observed upon VV inoculation 
(Fig. 35). In addition, Th2 cytokines antagonize Th1 cytokine-mediated anti-VV 
responses [303], thus, the reduction of Th2 cytokine production in VV infected asthmatic 
mice may also help VV clearance.  Accordingly, VV titers in the lungs of inoculated 
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mice were lower in the asthmatic mice compared with healthy animals challenged with 
virus. The enhanced VV clearance was likely due to the increased IFN-γ production. IL-
17, also a pro-inflammatory cytokine could not be detected in mice exposed to VV alone. 
Pre-existing asthma dramatically increased IL-17 expression (Fig. 36). IL-17 may play 
important roles in inflammation and pathogenesis during asthma via recruitment of 
neutrophils [251]. Since the asthmatic lesions were mitigated upon VV infection, we 
would propose here IL-17 production was not detrimental to animals. IL-17 may decrease 
OVA-induced bronchial eosinophilia by reducing IL-5 levels [304]. The role played by 
IL-17 in OVA-induced asthma model may depend on the timing of events such as virus 
challenge. The OVA mediated asthma model involves Ag priming (by i.p.) followed with 
Ag boost (by i.n. or inhalation) to induce allergic sensitization. Before the OVA 
inhalation boost, IL-17 promotes bronchial neutrophilic influx. During inhalation, 
however, IL-17 becomes an asthma inhibitor through blocking IL-5 expression [304]. In 
our model VV was administered after OVA inhalation, thus, VV-induced IL-17 
production in asthma progression, should be inhibitory. Thus amelioration of asthma was 
observed (Fig. 35). Besides mediating autoimmunity, IL-17 is also involved in protective 
immunity against various infections caused by bacteria, viruses, and fungi [252, 257, 262, 
305-307]. We proposed that similar to a Gram negative bacterium Klebsiella pneumoniae 
infected mouse model [308], IL-17 was involved in clearance of VV from the lung. 
Correlating with our results on IL-17 and VV, a recent study supports a role for IL-17 in 
VV clearance [252]. Here the authors demonstrate the reduced virulence of recombinant 
VV encoding murine IL-17 compared to wild type VV. However, using a different 
vaccinia viral vector with a leader sequence, an earlier report drew the opposite 
conclusion that a recombinant VV expressing murine IL-17 was more virulent than wild 
type VV [154].  More detailed comparisons of these two different murine IL-17 
expressing VV are required before a conclusion can be drawn. Nevertheless, more recent 
literature [252] showed that IL-17-deficient mice were more susceptible to wild type VV 
infection than control mice. This result suggests IL-17 may function in protection against 
viruses. Interestingly, IFN-γ and IL-17 do not act independently. IL-17 induces IFN-γ 
production [307]. On the other hand, IFN-γ limits IL-17 production to contain 
inflammation [309]. Some studies also suggest T cells producing IL-17 are plastic and 
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can shift to produce IFN-γ [310]. Thus, we conclude that IFN-γ and IL-17 might work 
together to increase VV clearance in an asthma plus VV infection model.  
 
The diminished Th2 cytokines may promote asthma mitigation and cellular immunity 
against VV, as well as decreasing VV specific humoral immunity. The titration of VV 
specific Abs would address this possibility. Besides secreting cytokines, Th1 cells also 
induce the production of IgG2b and IgG2c Abs while Th2 cells elicit the secretion of 
IgG1 and IgE Abs [311, 312]. These Th-related Ab isotypes have important implications 
in autoimmunity as well as infectious diseases. One essential mechanism by which Ab 
help to clear pathogens is via activation of complement system to lyse the infected cells. 
Thus Ab production, Ab isotype switching as well as complement activation are 
potentially interesting future directions that could be pursued in this virus-asthma model.  
 
Besides the antagonism between two types of Th cytokines, VV infection may block 
asthma development by directly disrupting a residual OVA Ag presentation by APCs.   
Using splenocytes taken from asthmatic mice +/- VV infection as APCs and CD4 T cells 
isolated from those mice as responders, class II presentation of OVA in the presence or 
absence of VV could be tested using Ag presentation assays. The presentation of OVA 
and/or VV by APCs from healthy mice to treated/control CD4 T cells could be tested in 
parallel. OVA presentation by class I could also be tested using CD8 T cells and assays to 
monitor cytokine production. Such studies would directly investigate the function of 
APCs and T cells from asthmatic mice in the context of a virus infection. 
 
The profile of cytokines produced by CD4 T cells from twice inoculated mice (2×VV) 
were similar to those secreted by CD4 T cells after the primary exposure to VV. The 
main cytokines secreted by the 2×VV-CD4 T cells were IL-2 and IFN-γ (Fig. 37). Also 
as in primary response, no detectable IL-17 was produced by 2×VV-CD4 T cells. 
Investigations using CD8 T cells from mice inoculated twice with virus (2×VV-CD8 T 
cells) revealed significant granzyme B and IL-17 production (Fig. 38). Granzyme B is a 
marker for CD8 T cell activation. Although first discovered in activated memory CD4+ T 
cells, IL-17 is produced by CD8+ memory T cells after stimulation [313]. IL-17 
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producing by CD8 T cells is important for immune defenses against Klebsiella 
pneumoniae infection [256, 260-262]. A recent report demonstrated IL-17 producing 
CD8 T cells protected naïve recipients from lethal influenza A infection [10]. We inferred 
IL-17 expressing in CD8 T cells might also play a role in VV specific T cell recall 
responses. IL-17 is repressed by Th1 cytokines [314], perhaps limiting the amount of IL-
17 detected in the present study. 
 
IL-17 exerts its pro-inflammatory function mainly by expansion and recruitment of 
myeloid lineages (monocytes and neutrophils) with the production of growth factors 
(such as granulocyte colony-stimulating factor) and CXC chemokines respectively. It also 
activates T cell responses through the induction of the co-stimulatory molecule 
intercellular adhesion molecule (ICAM). Other IL-17 linked mechanisms regulating 
immunity include enhancement of the local inflammatory environment by expression of  
IL-6 and PGE2 [251]. Damaging inflammation is the basis for IL-17 mediated 
autoimmune diseases. Yet this cytokine also promotes the destruction of invading 
pathogens like the Gram negative bacterium Klebsiella pneumoniae and possibly viruses. 
The role IL-17 plays in cancer progression may depend on the angiogenic activity of IL-
17 and tumor immunogenicity. For example, IL-17 promotes tumor growth by enhancing 
angiogenesis in a murine fibrosarcoma model [315]. While this cytokine also inhibits 
murine hematopoietic tumors by increasing cytotoxic T cell generation [316]. By adding 
different APC populations to in vitro polarized IL-17 producing CD4 and CD8 T cells, 
we detected the abilities of these cells to promote IL-17 production (Fig. 39). B cells 
followed by DCs, were better at promoting CD4 T cell IL-17 production. For CD8 T 
cells, DCs were most effective among the three types of APCs. We inferred that the IL-
17 promoting ability of APCs could be used to control production of this cytokine in vivo. 
As for autoimmunity or certain cancers, IL-17 production could be decreased focally by 
blocking the activity of distinct APC type. For other cancers or infections, IL-17 
production may be enhanced by activation of specific APC type. Thus, IL-17 production 
could be manipulated to regulate disease and inflammation. 
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In summary, we conclude that VV-derived peptides are presented by class II molecules. 
Yet the efficiency of even viral Ag presentation may be reduced due to virus-induced 
changes in the class II pathway. Whether viral peptides compete to fill the class II ligand 
binding groove and act as competitive inhibitors remains possible. Yet the observed 
reduction in viral Ag presentation suggests the virus may have evolved other mechanisms 
to regulate class II function such as manipulating cellular Ii levels. Class II presentation 
of VV epitopes correlated temporally with the inhibition of exogenous or self Ag 
presentation (Compare Fig. 3 and 30). This was interesting as it suggests very rapid 
proteolysis of viral proteins to yield peptides for class II, again supporting virus entry into 
endosomes containing class II. Notably, heat treated virus was also processed and 
presented by class II again likely due to endocytic uptake of the virus. However, heat 
inactivated VV failed to induce VV specific CD4 T cell activation and proliferation in 
vivo. By contrast, animal inoculation with infectious, replicating VV lead to the 
development of VV specific CD4 T cells which secrete cytokines IL-2 and IFN-γ. These 
Th1 type cytokines are important in further mobilizing host defenses to virus infection as 
well as potentially antagonizing Th2 mediated diseases such as asthma. Consistent with 
the induction of Th1 cytokines in response to virus, in animals with induced asthma VV 
intra-tracheal inoculation significantly ameliorates bronchial eosinophilia inflammation 
and mucosal secretion by abrogating IL-5 and IL-13 expression respectively. IL-17 was 
also detected in spleen cells after VV infection of asthmatic animals. VV clearance was 
slightly improved in asthmatic mice compared with mice infected with VV only. IFN-γ 
together with IL-17 may be important in viral clearance. Interestingly, IL-17 secretion 
was detected in CD8 T cells after virus inoculation, suggesting a role for these cells in 
viral clearance or associated inflammation.  
 
2. Candidate viral genes linked to VV-induced class II dysfunction 
 
To define potential viral or host gene products which may be important in disrupting 
class II presentation pathways, it is important to consider the biology of this virus. Using 
virus infected Hela cells, it was demonstrated that the expression of VV genes is 
programmed and divided into at least three stages. Viral proteins involved in the early 
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stages of transcription are synthesized late in infection and packaged in the virions. Early 
gene transcription initiates within 20 m of infection and peaks at 1.5 h. Early mRNAs are 
translated into growth factor such as secreted epidermal growth factor-like protein 
(encoded by C11R), immunoevasive molecules such as soluble IFN-γ receptor-like 
protein (encoded by B8R), as well as enzymes and factors for DNA replication such as 
DNA polymerase (encoded by E9L) or intermediate gene transcription such as capping 
enzyme (encoded by D1R) and VITF 1 (vaccinia virus intermediate transcription factor 1, 
encoded by E4L). Intermediate transcription starts 1 h after infection and peaks at 2 h 
which products are required for late gene expression such as VLTF 1 (vaccinia virus late 
transcription factor 1, encoded by G8R). The transcription of late genes begins about 2 h 
of infection and continues to increase [1]. Some of the late gene products are structural 
proteins including envelope proteins (such as D8 and H3, encoded by D8L and H3L 
respectively) and core proteins (such as P4a, encoded by A10L).  Late genes also encode 
factors or enzymes for early transcription such as VETF (vaccinia virus early 
transcription factor, encoded by A7L and D6R) and RAP94 (a 94 KD viral polypeptide 
which associate with RNA polymerase, encoded by H4L). Viral DNA replication occurs 
1-2 h after infection and is essential for intermediate and late gene transcription [1, 317].  
 
Using UV irradiated VV, we demonstrated that virus replication is not essential for 
disruption of class II presentation [97]. Similar results were obtained with the virus 
specific DNA polymerase inhibitor AraC (Fig. 4). These suggest a possible role for viral 
late proteins in regulating class II presentation. Consistent with this, viral early genes 
B1R and H5R likely do not play a role in disrupting the class II pathway (Fig. 5). At later 
times of infection, AraC treatment of cells could partially preserve class II function, 
supporting a role for viral late gene product(s) in VV disruption of class II presentation. 
Indeed, the products of two late viral genes, D8L and H3L bind to class II molecules (P. 
Li, data not shown). VV encoding truncated D8L partially preserved class II presentation 
(Fig. 31). Thus, future studies should explore the role of these two viral genes in both in 
vitro and in vivo experiments for their immunosuppressive properties.  If class II function 
could be preserved by a deficiency in either of these two genes, this again would support 
hypothesis that specific viral proteins contribute to VV-induced class II dysfunction. 
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Using I-Ab restricted VV specific CD4 T cells from C57BL/6 mice, peptides derived 
from 13 different viral proteins were identified as immunodominant in mice (Table 3 and 
[81]). Most of these peptides are derived from late gene products. Peptides derived from 
D8 and H3 proteins are included among these immunogenic epitopes.  Using CD4 T cells 
derived from vaccinees’ PBMCs, viral genomic wide screening of peptides that could 
induced human VV specific CD4 T cell response, was carried out [287]. Similar to those 
viral peptides that could induce murine CD4 T cell responses, immunodominate peptides 
from virion structural proteins expressed during late stage of VV infection were 
recognized by human CD4 T cells. For instance, the six epitopes most frequently 
recognized by human CD4 T cells include products of A3L (encoding p4b precursor of 
core protein 4b) and A10L (encoding core proteins), D13L, H3L, L4R and WR148 
(encoding an inclusion-forming protein). It has also been demonstrated that A24R and 
D1R (mRNA capping enzyme large subunit) could be presented by class II DR1 to 
human CD4 T cells [318]. Gene products of I1L, A20R and A28L have also been 
proposed as candidates yielding epitopes which might bind class II DR1 based on 
predictive algorithms [319]. Thus, there may be considerable overlap between human and 
murine CD4 T cell specificity for VV proteins. Whether the presentation of these viral 
peptides influences class II presentation of other non-viral Ag has yet to be tested. It 
might also be informative to examine class II presentation using rVV lacking some of 
these immunodominant viral Ags.  
 
3. H3 peptide specific Ab in the preservation of class II function upon VV infection 
 
Circulating Abs can exert immune function by inactivating the inoculum and reducing 
pathogen transmission. Several studies have shown the importance of Ab for immunity 
against VV infection [91, 152]. Passive immunization by transferring Abs is efficient in 
protecting a host from poxvirus including VV infection [265, 266]. Administration of 
sera from vaccinees (VIG) has been successful in treating VV infection and preventing 
additional complications. However, since routine smallpox vaccination has been stopped 
after eradication of smallpox, the supply of VIG is limited. One goal is to find an 
alternative for VIG. H3, an envelope protein involved in viral entry, has been tested as an 
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immunogen. One paper demonstrated that recombinant H3 could be recognized by 
vaccinees’ sera [287], indicating H3 specific Ab was induced after vaccination.  Another 
paper showed that mice passively immunized with anti-H3 protein sera survive a lethal 
VV challenge [264]. Notably, Ab to H3 protein appears to be an important component of 
VIG [320]. Using a peptide located within the extracelluar domain of H3 to immunize 
rabbits, Ab to H3 was generated. As expected, this Ab to H3 (eH3) is effective in 
blocking VV infection and preservation of class II function (Fig. 43). Specific host cell 
receptors for VV have not been identified, yet virion binding to the cell surface appears to 
precede virus endocytosis and fusion [78]. The eH3 Ab may block viral entry by 
disrupting H3 binding to host cell surface heparin sulfate.  
 
Our data suggests that Ab to a single epitopes within the viral H3 protein can block VV 
infection and consequently maintain class II function in APCs. Potentially peptide 
specific Ab could be used as an alterative for VIG. Ongoing experiments in our lab are 
testing the protective effect of Ab to H3 in an i.n. VV mouse model. Here, H3 peptides 
are being tested as immunogens to induce active immunity against VV in a mouse model. 
Whether this peptide will induce protective or virus neutralizing Abs in mice remains to 
be determined. It may be possible to enhance immunity by coupling H3 peptides that 
induce T cell responses and Ab production.  
 
4. Design of attenuated VV  
 
The ultimate aim for viral research is to design effective vaccine or therapeutics. For VV, 
a safer vaccine is essential for protection of immunodeficient patients and hypersensitive 
individuals from poxvirus-induced pathogenesis. Since VV has been used as a vector to 
express foreign genes from tumor antigens and pathogens, an improved VV vaccine may 
have broad implications.  Both innate and adaptive immunity are important for VV 
clearance. Yet VV has evolved several mechanisms to evade host immunity. To design 
an improved attenuated VV, the focus must be on increasing host immunity while 
reducing viral factors which disrupt host defenses. Ideas on such improved vaccine 
strategies are offered here. 
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4.1 Enhancement of host immunity  
 
In this thesis, we observed a reduction in Ii expression correlated with the late stages of 
virus infection and class II dysfunction. Over-expression of Ii partially preserved class II 
function. Recombinant VV encoding Ii (mIi-VV) inhibited class II function less severely 
than wild type VV (Fig. 29). Thus, we propose Ii encoding rVV could be used as an 
attenuated VV to preserve class II function. This recombinant virus must be tested in vivo 
in a mouse infection model to determine whether enhanced cellular and humoral 
immunity can be induced. In the long term, Ii encoding rVV may be useful for promoting 
defenses in some immunodeficient individuals.  
 
VV infection induces Th1 cytokine production. Studies suggest expression of IL-2 by VV 
(rVV-IL2) may be useful in boosting host vaccination. For example, rVV-IL2 inoculation 
helped to inhibit SIV/HIV progression by promoting the induction of mucosal as well as 
systemic humoral and cellular immunity [321]. This recombinant virus also deterred head 
and neck carcinoma growth by increasing cellular immunity [322]. Notably, co-
expression of mucin-1 (MUC-1) and IL-2 by a recombinant virus led to metastatic breast 
tumour regression in advanced stage patients [323]. Recombinant VV encoding IFN-γ 
(rVV-IFNγ) has also been shown to have improved potency in infection and cancer 
therapy. rVV-IFNγ blocked infection of cells and mice by various viruses including VV 
itself [324, 325]. rVV-IFNγ inoculation inhibits murine breast cancer [326]. Engineering 
recombinant VV to express cytokines and Ii may offer a novel vaccine vector.  
 
4.2 Reduction of virulent genes 
 
As another approach to design better VV-based vaccine, one could try deletion of 
virulence or immune suppressive factors. D8, a viral envelope protein that binds cell 
surface chondroitin sulfate [194] also appears to bind class II molecules (data not shown). 
VV with a truncated D8L gene (BSSH virus) induced higher VV specific CD4 T cell 
responses than wild type VV (Fig. 31), suggesting this modified virus was less 
suppressive. However, when BSSH was used to prime mice, CD4 T cell responses were 
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not as robust as those observed with wild type VV (Fig. 32). Thus, further analysis of the 
key domains within D8 and their role in blocking class II function is needed. 
Alternatively, addition of an adjuvant may be needed to increase the antigenicity of 
BSSH. Another envelope protein, H3 was also found to bind to class II molecules (P. Li, 
data not shown). Thus, VV with mutations in the H3L gene should also be tested to see if 
this restores class II presentation during virus infection.  
 
Inactivation of VV by either UV irradiation or heat, led to improvements in class II 
molecule presentation compared with replication-competent VV, likely due to reduced 
immune suppression by the modified viruses (Fig. 31). However, these modified viruses 
failed to induce VV specific CD4 T cells in vivo (Fig. 32). The observation that 
inactivated VV provides little to no protection against orthopoxvirus infection, has been 
confirmed in several studies [206]. However, the antigencity of these inactivated VV 
could be increased by several methods. It has been demonstrated that multiple 
inoculations of heat inactivated VV protects rabbits from lethal challenge using rabbitpox 
by inducing host production of neutralizing Ab [245]. VV inactivated by strictly 
controlled UV irradiation can induce humoral immunity in rabbits and monkeys [246]. 
VV inactivated by antimicrobial nanoemulsion of soybean oil and detergent is effective 
in inducing both humoral and cellular immunity against VV [327]. Thus, by applying 
multiple inoculation [245], carefully controlling UV exposure [246] or using different 
methods to modify virus [327], improved non-replicating vaccines could be achieved.  
 
Taken together, VV may disrupt class II presentation by reduction of Ii at late stages of 
infection.  At early times of virus infection, destabilization of class II molecules and 
possibly competitive binding of class II to viral Ag may contribute to class II 
dysfunction. Other possibilities may also explain the early stages of VV-induced class II 
dysfunction (Fig. 45). The results here have implications in terms of our understanding of 
both VV pathogenesis and host immune responses to poxvirus infection. Finally, these 
studies may offer new insights into the design of attenuated vaccines in the future.  
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Fig. 45 The effects of VV on class II-mediated Ag presentation. 
Late stagesEarly stages
1. Viral Ag/peptide competition 
for class II?
2. Viral Ag/peptide binding to 
class II molecules?
3. Disruption of class II 
association with rafts?
4. Changing in class II sorting?
Ii reduction
1. Synthesis inhibited by 
reduction of Ii at both protein 
and mRNA levels.
2. Degradation altered by 
regulation of  cathepsin S 
and L.
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